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ABSTRACT 
End stage renal disease (ESRD) is associated with several physiological and metabolic changes 
which together cause poor health and impair patients’ quality of life. Anaemia is one of the 
most common metabolic consequences of renal failure and is highly prevalent among ESRD 
patients. Renal anaemia has a significant negative impact not only on patients’ health outcomes 
but also poses a heavy economic burden on the health system due to the high cost of treatment.  
Interactions between nutrition, anaemia status or/and response to anaemia therapies have been 
suggested. This programme of work aimed to investigate anaemia and nutritional status 
(including body composition) among haemodialysis (HD) patients and to study how nutrition 
status and body composition modify patients’ anaemia status and their response to the hormone 
erythropoietin (EPO). The first two sections of this project were cross-sectional studies 
conducted to characterise the health status of patients. Firstly, health outcomes were compared 
between the UK (n = 101) and Tanzanian (n = 96) HD patients after which a more in depth 
study was conducted in Tanzania only (n = 77). These are presented in chapter 2 and 3 
respectively. Both studies showed that Tanzanian HD patients had increased risk of low 
haemoglobin (Hb) levels, inadequate nutrition and inflammation. The findings showed that 
body fat and muscle mass were significantly and positively associated with Hb and EPO 
response. These investigations were then extended to the UK via recruitment and assessment 
of a cohort of UK adults HD patients on EPO treatment (n = 41). The UK study was conducted 
longitudinally and included additional markers of anaemia and nutritional status to further 
assess the relationship previously observed and in an attempt to uncover the mechanisms 
involved. The findings showed that longitudinally, body fat, significantly and positively 
influenced Hb concentration independent of EPO type and gender. Equally, there was a positive 
association between leptin hormone and Hb concentrations, suggesting a potential link and 
possible mechanism for the observed association between body fat and Hb levels. Finally, 
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building on this work, an exercise intervention of low intensity (walking + intradialytic 
resistance training) was adopted and conducted as a randomized controlled pilot and feasibility 
study. The aims were to investigate if such an intervention was feasible and acceptable to 
patients and staff and capable of inducing favourable changes in patients’ body composition 
(body fat and muscle), and if so, how any such changes would modify patients response to EPO 
and their Hb status. The eight week study was unable to achieve significant changes in body 
composition or iron markers. However, there was a slight improvement in exercise 
performance and lower body strength assessed through the sit to stand test.  To our knowledge, 
the low intensity exercise protocol used, combining walking + intradialytic resistance training, 
has not been previously tested in the dialysis setting and offers an acceptable intervention for 
further research.   
This programme of work has demonstrated that good nutrition helps improve the EPO response 
and Hb levels of HD patients. A flexible and low intensity exercise programme involving 
walking and intradialytic resistance training is feasible and practical in the presence of a 
physiotherapist. However eight weeks of low intensity exercise is not sufficient to induce 
changes in body composition or EPO response in HD patients but may help improve their 
physical functioning and so warrants further investigation as a more cost effective alternative 
to cycle-based interventions. 
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CHAPTER 1 
1. INTRODUCTION AND LITERATURE REVIEW  
1.1. General introduction and relevance of the thesis 
Chronic kidney disease (CKD) is the condition describing a gradual loss of kidney function or 
kidney damage over time (persisting for three or more months)1. The disease is asymptomatic 
in its early stages and often coexists with other conditions such as diabetes and hypertension 
which are also known to be common primary causes of CKD1,2. 
Several other metabolic complications such as protein energy malnutrition (PEM)3, metabolic 
acidosis4, anaemia4, mineral and bone disorders (MBD)5, inflammatory syndrome and 
cardiovascular diseases6 also evolve during the course of the disease process and tend to 
become more severe as the disease progresses to end stage renal disease (ESRD)7. At this end 
stage, the kidneys have a very limited function such that a renal replacement therapy such as 
dialysis or kidney transplant is required to sustain the individual’s life8. 
The disease prevalence is escalating both in developed and developing countries concomitantly 
with the increasing prevalence of diabetes and hypertension9. This poses a high economic 
burden due to the increased care demand and the range of treatments that ESRD patients require 
to survive10. The burden is particularly overwhelming in developing countries including those 
of sub-Saharan region due to limited treatment resources (expertise in renal care and finances), 
often leading to suboptimal care and increased mortality risk11. 
Management of ESRD requires a holistic approach within which nutritional management plays 
as important a role as renal replacement and pharmacological therapies. Whilst the discipline 
of nutrition and dietetics is widely developed and specialized in developed countries like the 
UK, this is not the case in developing countries of the sub-Saharan region. The region has 
limited nephrology services in general, and specifically few professionals working in renal 
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nutrition/dietetics. All patient care services including nutrition management are entrusted to a 
few nephrologists and specialized nurses who are often overwhelmed with work load, 
potentially compromising the quality of care delivered.   
Acknowledging the gap in the renal nutritional services in the region, the high risk of 
malnutrition and its association with poor treatment outcome, this thesis presents findings from 
research work conducted to investigate the nutritional status of ESRD patients on 
haemodialysis in one of the countries in the Sub-Saharan region (Tanzania) and identifies the 
areas of inadequacy and recommendations for improvements. Further research work involved 
comparing the nutritional status and other treatment outcome indicators of Tanzanian 
haemodialysis (HD) patients and those in one hospital in the South East UK in order to identify 
possible areas for action and examples of best practice which could be implemented in 
Tanzania. For example, it is not uncommon for haemodialysis patients to persistently exhibit 
low response to anaemia management therapies (Erythropoietin (EPO) hypo responsiveness) 
despite them being on an appropriate dosage. To try and explain this phenomenon, studies in 
dialysis patients including the initial stages of this research work have suggested a role for 
nutritional status, including body composition, on the response to anaemia management 
therapies12,13. As a result, the final study in this programme of work aimed to investigate these 
relationships in more detail via a prospective design and to investigate whether it is possible to 
improve body composition in dialysis patients through a low cost and low intensity exercise 
programme, which would be applicable to a developing country setting, and, if so, whether this 
can mediate the outcomes of anaemia management.  
The findings add to the body of knowledge on the role of nutrition and body composition in 
patients’ response to anaemia management therapies and help improve responses to the 
therapies specifically in low resource settings. This is particularly important considering the 
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negative implication of EPO hypo responsiveness to the patients’ overall health and high cost 
of both EPO and iron therapies.  
1.2. Overview of chronic kidney disease (CKD) 
1.2.1 Definition, sign, symptoms and diagnosis of CKD  
1.2.1.1. Definition of Chronic Kidney Disease (CKD) 
The kidneys play an important homeostatic role in regulating volume and solute concentration 
in the extracellular fluid; regulating electrolytes and minerals including sodium, potassium and 
calcium; regulating body pH; excretion of water soluble metabolic waste products through 
urine and production of the hormones erythropoietin (responsible for red blood cell synthesis) 
and renin (responsible for the control of sodium, water and blood pressure). The kidneys 
perform these roles through the functional units which are tubular in structure (nephrons) and 
abundantly available in each kidney (about 1 million). These nephrons are surrounded by a 
network of capillaries which supply blood to the Bowmans Capsule ready to be filtered through 
ultrafiltration process and then to return reabsorbed substances back to the circulation (see 
Figure 1:1). 
 
Figure 1:1:Cross-sectional diagram of the kidney and nephron showing glomerular filtration process 
  Source: Kidney Precision Medicine Project, KPMP 2018, an initiative of National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) 
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CKD normally occurs as a result of a disease or an injury to the glomerular or tubular structure 
within the nephron which causes a progressive deterioration of the kidneys until they can no 
longer maintain their homeostatic function.   
CKD is therefore defined according to the presence of kidney damage and the level of kidney 
function (i.e. glomerular filtration rate, GFR). The current criteria of kidney damage described 
in the 2012 Kidney Disease Initiative Global Outcome (KDIGO) guideline1, are presented in 
Table 1:1.  
Table 1:1: The new criteria for CKD (either of the following present for > 3 months) according to the 
2012 KDIGO guideline 
Markers of kidney damage  
(one or more) 
Albuminuria (AER 30mg/24 hours); ACR ≥ 3 mg/mmol  
Urine sediment abnormalities 
Electrolyte and other abnormalities due to tubular disorders 
Abnormalities detected by histology 
Structural abnormalities detected by imaging 
Histology of kidney transplantation  
Decrease in GFR GFR < 60 ml/min/1.73m2  
AER, Albumin excretion rate; CKD, Chronic kidney disease; GFR, glomerular filtration rate; ACR, Albumin to 
creatinine ratio 
This updated definition criteria was endorsed by the NKF-K/DOQI US commentary in 
201414. 
1.2.1.2. Signs, Symptoms and Diagnosis of Chronic Kidney Disease 
Because CKD develops  over a long period of time, it is typically asymptomatic at its early 
stage and  as a result, often  referred to as a ‘silent killer’15,16.  Nevertheless, the disease can be 
detected by routine laboratory measurements.  Early detection and treatment will often help 
prevent or delay adverse health outcomes. 
The ability of the kidney nephrons to perform their physiological role (see section 1.2.1.1) 
declines with disease progression and as a result a person may experience excess body fluid 
accumulation and is likely to show signs of oedema on limbs and/or stomach or even the face. 
They may also experience fatigue, nausea/vomiting, and may have a poor appetite and a 
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metallic taste in the mouth (uraemia) due to the build-up of uraemic toxins. They are also likely 
to experience itching sensations due to phosphate retention; and may feel confused15,17. 
Diagnosis of the disease is generally achieved by blood tests to estimate GFR and urine tests 
to measure the amount of albumin excreted by the kidneys16. As described earlier, lower GFR 
(< 60 ml/min/1.73m3), albuminuria (> 30mg/24 hours) and /or other evidence of structural 
abnormalities of the kidneys observed for ≥ 3 months is diagnostic of CKD1 and differentiate 
it from acute kidney injury which is a rapid onset condition17. 
Further tests such as ultrasound or kidney biopsy may be performed to ascertain the underlying 
cause of the disease18. 
1.2.1.2.1. Blood and urine tests 
Because blood urea and creatinine are metabolic waste products  normally excreted and 
regulated by the kidneys, as the  kidney function declines,  these compounds will  not be 
effectively  excreted and subsequently accumulate in the blood19. Abnormally high values of 
urea and creatinine measured in the blood or urine therefore indicate the presence of the 
disease20. 
Kidney damage in CKD will often cause leakage of protein and red blood cells from the blood 
stream through the Bowmans Capsule and into the urine. A urine dipstick test that changes 
colour in the presence of albumin can be used to check for albuminuria. Alternatively, urine 
albumin-to-creatinine ratio (UACR) can be used, which is a test that measures and compares 
the relative amounts of albumin and creatinine in the urine sample.  
Urine Albumin (mg/dL) / Urine Creatinine (g/dL) = UACR in mg/g 
UACR estimates how much albumin would pass into the urine over 24 hours and a result of 
>30mg/g may signify the presence of kidney disease. In this case, the test will normally be 
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repeated once or twice to confirm the results. The level of protein in the urine will reflect the 
severity of the disease1,21. 
1.2.1.2.2. Clinical examination 
Hypertension and oedema are important clinical features of kidney disease. Hypertension can 
be both an aetiological factor and a consequence of CKD22 as discussed later (section 1.2.3.2). 
Persistent high blood pressure, particularly if it is uncontrolled, could be an indicative of kidney 
disease and such patients need to be repeatedly screened for kidney damage. Patients should 
particularly pay attention to headaches and visual disturbances as these usually occur when 
blood pressure rises23,24. Oedema (fluid retention and swelling) will be noticed particularly in 
the lower legs, feet and less often in the face and hands. This indicates the accumulation of 
fluid in the tissues and may indicate protein leakage from the kidneys. However, it should be 
noted that there are other causes of oedema that are not related to kidney disease,  e.g. 
malnutrition, liver disease and cancer, that may also cause fluid retention in the abdomen 
(ascites)25. Importantly, this accumulation of fluid will mask weight loss and so identifying and 
quantifying the extent of oedema is an important part of nutritional assessment. 
1.2.2 Estimation of glomerular filtration rate and disease stages 
1.2.2.1 Estimation of Glomerular filtration rate (eGFR) 
Since GFR cannot be easily measured in clinical practice it is normally estimated from 
prediction equations that take into account serum creatinine concentration, and other variables 
like: age, gender, race and body size depending on the equation used 26. GFR estimation 
equations are presented in table 1:2. 
The MDRD equation 27-29 has four variables (serum creatinine, age, race, sex) and was 
developed from the Modification of Diet in Renal Disease (MDRD) study. The equation has 
been widely used to estimate glomerular filtration rate of CKD patients in both clinics and 
epidemiological studies 30,31.   
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Table 1:2: Different equations for estimation of glomerular filtration rate: MDRD, CKD-EPI Cr, 
CKD-EPI Cy, as presented by KDIGO 20131 and Levey et al.27 
Gender Serum 
creatinine 
Serum 
Cystatin C 
GFR estimation equation  
MDRD study equation27 
    175 X SCr-1.154 X age-0.203 X 1.212 (if black) X 
0.742 (if female) 
CKD – EPI Creatinine equation
1 
Female ≤ 0.7 mg/dl  
(≤ 62μmol/l) 
 144 X (SCr/0.7)-0.329 X 0.993Age [ X 1.159 if 
black] 
Female > 0.7 mg/dl  
(> 62μmol/l 
 144 X (SCr/0.7)-1.209 X 0.993Age [ X 1.159 if 
black] 
Male ≤ 0.9mg/dl 
 (≤ 80μmol/l) 
 144 X (SCr/0.9)-0.411 X 0.993Age [ X 1.159 if 
black] 
Male > 0.9mg/dl  
(> 80μmol/l) 
 144 X (SCr/0.7)-0.209 X 0.993Age [ X 1.159 if 
black] 
CKD-EPI Cystatin C equation1 
Female/Male  ≤ 0.8mg/l 133 X  (SCysC/0.8)-0.499 X 0.996Age  [ X 0.932 
if female] 
Female/Male  > 0.8mg/l 133 X  (SCysC/0.8)-1.328 X 0.996Age  [ X 0.932 
if female] 
MDRD; Modification of diet in renal disease, CKD-EPI; Chronic kidney disease – Epidemiological 
Collaborative equation; sCr, serum creatinine; SCysC; serum cysteine C 
The MDRD equation was recommended by the 2002 NKF-K/DOQI guidelines for the 
estimation of glomerular filtration in adults. However, since the MDRD equation was 
developed in people with CKD, it was suggested to be biased, and that it underestimates GFR 
at higher levels32. This led to development of a new GFR estimation equation, the 2009 CKD-
Epidemiological Collaboration (CKD-EPI) equation. Like the MDRD equation, the CKD-EPI 
also included age, race, sex and serum creatinine but it differs from MDRD equation by 
applying statistical linear spline on the serum creatinine to account for a weak association 
between creatinine and GFR at lower vs higher creatinine levels33.  
The KDIGO 2012 Clinical guideline1 therefore recommends using CKD-EPI instead of MDRD 
for the estimation of glomerular filtration. In addition, whenever cystatin C has been measured, 
the guideline recommends to include cysteine in the CKD-EPI equations34 to estimate GFR 
and use this as a confirmatory test, particularly in patients with eGFRCr of 45-59ml/min/1.73m
2 
but with no markers of kidney damage.  The K/DOQI commentary group is in agreement with 
all the KDIGO recommendations on GFR estimation14. 
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1.2.2.2 Stages of chronic kidney disease (CKD) 
CKD is classified into different stages depicting the extent to which the kidneys have lost their 
function, as traditionally reflected by the GFR. The KDIGO 2012 guideline1 suggests the 
staging should also consider the cause of the disease (including the presence or absence of 
systemic disease and the location within the kidney) in addition to GFR level and albuminuria 
measures. However, addition of the “cause” in the CKD staging was challenged by the K/DOQI 
commentary14 because, whilst some specific causes can be related to faster CKD progression 
rate or other health outcomes, there are currently no accurate methods to quantify risk based 
on disease aetiology and therefore has the potential to limit understanding and clinical practice. 
The 2012 KDIGO clinical practice guidelines classified CKD into five stages based on the 
GFR and three stages based on albuminuria measures as presented in Table 1:3.  
Table 1:3: CKD stages based on Glomerular filtration rate and Albuminuria measures  
GFR based classification 
Stages GFR(ml/min/1.73m2) Description terms 
G1 ≥ 90 Normal kidney function 
G2 60 – 89 Mildly decreased kidney function† 
G3a 45 – 59 Mildly to moderately decreased kidney function 
G3b 30 – 44 Moderately to severely decreased kidney function 
G4 15 – 29 Severe decreased kidney function 
G5 < 15 End stage kidney failure 
Albuminuria categories 
Stages AER (mg/24 hours) ACR (mg/mmol) Description terms 
A1 < 30 < 3 Normal to mildly decreased kidney function 
A2 30 – 300 3 – 30 Moderately increased kidney function† 
A3 > 300 > 30 Severely increased kidney function# 
GFR, glomerular filtration rate; AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; †relative to 
adult level; #including nephrotic syndrome (albumin excretion usually > 2200mg/24 hrs [ACR > 220mg/mmol]) 
 
1.2.3 Aetiology of CKD 
The causes and risk factors for CKD are varied and their contribution to the disease aetiology 
varies across regions. While non-communicable diseases (NCDs) such as diabetes and 
hypertension remain the most common cause of CKD in developed and most developing 
countries2, in low-and middle income countries like sub-Saharan Africa, there are several 
additional potential etiological factors such as infectious diseases and toxic chemical 
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exposure35. Poor sanitation and environmental pollution due to unplanned infrastructure and 
overcrowding in rapid urbanisation in low income countries exacerbate the problem36,37. In 
rural areas, extreme poverty and agricultural based activities are also likely to expose people 
to other risk factors like water contamination, snake bites, heavy metals and agrochemicals2,35. 
The use of herbal medication has also contributed significantly to ESRD onset in developing 
countries35. All these may also interact with common urban factors such as NCDs to increase 
the risk of CKD in these regions38. The regional differences in the magnitude of CKD burden 
for the two major causes of ESRD, diabetes and hypertension, are presented in the following 
sections.  
1.2.3.1 Diabetic nephropathy  
Diabetic nephropathy (DN) is a significant global cause of CKD and ESRD, accounting for  30 
– 50% of all CKD cases and affecting about 285 million (6.4%) adults worldwide39.  In the 
UK, 27% of  renal failure is caused by DN40. Its contribution is reported to be even higher in 
the United States (45%) and other developed countries like Hong Kong (50%), the Republic of 
Korea (48%), New Zealand (47%), Japan (44%), Canada (38%) and Australia (37%) but lower 
in other developed countries like France (23%), Belgium (22%), the Netherlands (19%), Italy 
(18%), Norway (18%) and Russia (16%)41. There is also trend towards a greater aetiological 
contribution of diabetes to ESRD development in the developing countries42 ranking first in 
Bangladesh43 and accounting for 24% of ESRD cases in South Africa41. 
DN is the syndrome characterized by the presence of proteinuria, diabetic glomerular lesions 
and loss of glomerular filtration rate (GFR) among people with diabetes. Initially, a patient will 
present with microalbuminuria (albuminuria persistently at 30 – 299mg/24 hours), a stage 
called incipient nephropathy. If not treated, about 80% of patients with type 1 diabetes will 
have progressively increasing urine albumin excretion to a level of ≥ 300mg/24 hours within 
10 – 15 years, a condition called overt nephropathy. The GFR of patients with overt 
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nephropathy declines at a rate of 2 – 20ml/minute/year and ESRD develops in 50% of them 
within 10 years and up to 75% over a 20 year period44. Patients with Type 2 diabetes, on the 
other hand, are more likely to be found with overt nephropathy at the same time that their 
diabetes is diagnosed45. Although historically DN in type 2 diabetic patients was considered a 
‘benign’ condition as compared with in type 1 diabetes, it has subsequently been recognised 
that  type 2 diabetes is the most frequent cause of CKD, the clinical and public health 
significance of which will only increase as the  prevalence of Type 2 increases worldwide46. 
Also, with the development of type 2 diabetes at a younger age, sufferers are likely to  live 
longer with diabetes and therefore a higher proportion may develop DN and ESRD47. 
However, not all people with diabetes will develop DN and even so, the progression rate is 
modified by other risk factors like hypertension, glycaemic control, dyslipidaemia and 
smoking48,49.  In addition, genetic profile50, age and race have also been shown to influence the 
development of DN. People of Black and Hispanic ethnicity51, and patients with a family 
history of DN have a greater risk of developing the condition52.   
1.2.3.2 Hypertension (HT) 
Hypertension (HT) is identified as a sustained blood pressure higher than 140/90mmHg53,54. 
Normally, there are no signs or symptoms of hypertension and therefore patients may be 
unaware that they have the condition.  
HT is a leading cause of ESRD in countries like South Africa55 and  accounts for over a third 
of all cases in Pakistan (39.6%)43. It is the second leading cause of ESRD in the United States 
41 and the fourth (accounting for 7%  incident RRT cases in 2015) in the UK preceded by 
diabetes, glomerulonephritis and uncertain aetiology40.  
The relationship between CKD and hypertension is multidirectional, with raised blood pressure 
being both a cause and a consequence of CKD56.  When the arterial pressure is above 
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160mmHg or when the auto-regulatory mechanism is weakened as a result of conditions like 
renal disease, diabetes and high protein intake, capillary pressure will increase with the increase 
in BP. The effect of this increase in BP will extend to  the kidney vasculature causing  
mechanical stretch of the glomerular capillaries and mesangial cells, which will then induce a 
repair response through the actions of  fibrogenic cytokines and angiotensin II57. The repeated 
damage and repair of these tissues can result in glomerulosclerosis which can also be worsened 
by other factors like proteinuria as in the case of diabetic nephropathy58.   In a large health 
screening registry, individuals with baseline BP close to 180/100mmHg were about 15 times 
more likely to develop ESRD than individuals with baseline BP of 110/70mmHg59.  
1.2.4 CKD epidemiology and patients’ profile 
CKD has become a public health problem with rising global incidence and prevalence. The 
disease has nearly doubled as a cause of mortality and was reported to be the 18th highest cause 
of death worldwide in 201060. According to the Lancet series on CKD (2012)61, more than 10% 
of people aged 20 years and above are said to have any level of CKD worldwide and the 
prevalence is expected to increase even further as a result of the global increases in the 
prevalence of diabetes mellitus, hypertension, obesity, and aging2,9. However, the incidence 
and prevalence of ESRD differ substantially across countries and regions. More than 80% of 
all patients receiving treatment for ESRD are estimated to be in affluent countries like North 
America, Japan and Europe which have large elderly populations and universal access to health 
care62. 
Whilst lower rates  of CKD are reported in poor countries, particularly those in sub-Saharan 
Africa, this may be due in part to an absence of reliable and validated measures of kidney 
function35 and a lack of access to renal replacement therapy (RRT), impacting the accuracy of 
the figures reported63,64. In fact, it is estimated that, by 2020, the burden of diabetes and 
cardiovascular diseases will have increased by 130% in Africa, with concomitant increases in 
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the incidence of CKD and ESRD.  Therefore by 2030 more than 70% of patients with ESRD 
will be residing in developing countries11. 
The demographic profile of people with CKD and ESRD also varies widely worldwide and 
between ethnic groups. In the USA,  CKD progresses to ESRD at younger ages in African 
American and Hispanic population compared to Caucasians (mean age 57 and 58 years vs 63 
years respectively)65. In the UK, mean age of HD patients in 2015 was 64.4 years40; contrasting 
with mean ages in India of 51 years66, China 50 years and Japan 62 years67. In Africa, the 
average age of patients on HD patients is lower compared to other parts of the world. Even in 
South Africa (the most developed country of Africa), the mean age of patients on renal 
replacement therapy in 2012 was 48.9 years68 potentially indicating that people progress to 
ESRD at a younger age or that older people have poorer access to dialysis.  
ESRD has both economic and socio-psychological effects on communities as patients are often 
chronically depressed, unemployed and in need of financial and social support11,69. Patients 
undergo significant lifestyle changes including dietary modification, continuous medication 
and attendance at the treatment facilities (often thrice weekly for haemodialysis patients) which 
bring a sense of losing freedom and losing control of one’s own life70. Moreover, dialysis 
treatment may have an impact on body image causing patients to perceive themselves as 
unattractive due to procedures performed to create dialysis access points (e.g. fistula or neck 
line). This lowers patients’ self-esteem and may impact on their dressing style and social 
relations71.  
Such changes can cause anxiety and depression as patients struggle to cope and adjust and 
consequently their quality of life (QoL) may be diminished, with wider implications for the 
family and social relationships70,72,73. Unfortunately, depressed patients also have poor 
compliance to the treatment and therapies and consequently have worse survival74.  
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In countries where there is no national health service, renal replacement therapies required by 
ESRD patients confer an unaffordable financial load, the burden of which is proportionally 
greater in poorer countries75. Limitations of medical facilities, human resources and financial 
constraints result in patients only receiving partial treatment and rehabilitation, with the 
majority of patients who start dialysis discontinuing their therapy when financial resources run 
out within the first year, risking early mortality due to uremic complications10.  In situations 
where access to dialysis and transplantation services may be limited or unavailable, the final 
consequence of progressive CKD is always death.  
1.2.5 Management of patients with ESRD 
1.2.5.1 Renal replacement therapy (RRT) 
Renal replacement therapy is a life time treatment that patients with renal failure receive to 
sustain their lives. The treatment setting for people with ESRD varies considerably across the 
world, being influenced by factors such as disease severity and the health system of the 
region76. In the UK, whilst the majority of mild to moderate CKD cases might be managed in 
primary care settings, ESRD cases requiring RRT are usually managed in a secondary care 
setting77. 
There are currently three RRT choices available for ESRD patients in the UK (peritoneal 
dialysis, haemodialysis and transplantation) and patients are normally  given an opportunity to 
choose their preferred modality78. To optimize care, decisions regarding the choice of modality 
would usually be made by involving patients, families and the health care team, considering 
the risks and benefits of the therapy for the individual patient.  A final choice is conservative 
management where the patient would be medically managed to control their symptoms as long 
as possible without dialysis. 
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The 19th UK renal registry report79 shows that among the 941 per million population (pmp) 
patients receiving RRT in 2015, transplant was the most common RRT modality (501pmp), 
followed by HD (384pmp) with PD was the least prevalent (55pmp)(see figure 1:2). 
 
Figure 1:2: Proportion of ESRD patients receiving different treatment modalities in the UK in 201579:  
CAPD= Continuous Ambulatory Peritoneal Dialysis; APD= Automated Peritoneal Dialysis; HD=Haemodialysis 
 
This report shows that there has been an increase in the usage of HD and transplantation (1.3% 
and 4.8% respectively) between  2011 and 2015 but a fall in the proportion receiving  PD over 
the same period (-2.1% pmp)79. This PhD research project involved patients receiving 
haemodialysis treatment and so for this reason only HD therapy will be discussed in this 
introduction. 
1.2.5.1.1 Haemodialysis (HD) 
Haemodialysis (HD) is the process of filtering the blood to remove waste products and excess 
fluid which build up in the body when the kidney function is reduced. The HD machine gains 
access to the blood stream through a central venous catheter (CVCs) or arterio-venous fistulae. 
The dialysate fluid is then introduced into the dialyser to precipitate the removal of solute from 
the blood (figure 1:3)80. In the UK, HD can be provided through renal units located in the main 
hospital or at satellite units which are normally located nearer to patients’ homes. The NICE 
guideline encourages treatment to be performed by patients at their own homes if possible81.   
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Figure 1:3: Hemodialysis process. During hemodialysis, the anterior blood is pumped through a filter, called a 
dialyzer and the filtered blood (venous) return to the body. 
                              Source:  NIH-NIDDK 82 and web resources 
HD machines are expensive and need to be operated by highly trained nurses or technicians 
rendering this form of therapy expensive. The treatment is also time consuming as the patient 
usually spends four hours connected to the machine for three days every week. Considering 
the additional time spent by patients travelling to and from their dialysis unit three times a 
week, the treatment can be daunting and have a major impact on their quality of life83. 
To reduce this burden, home dialysis is an alternative option for some patients who are stable, 
have a conducive environment and have appropriate support at their homes84. However, in 
reality home HD accounts for a small (7.9%) proportion of all patients receiving RRT in the 
UK compared to those receiving dialysis in centres (39.0%)79. As well as a high patient, staff 
and financial burden, HD is also associated with numerous complications, particularly during 
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the HD initiation period. These are most commonly related to vascular access (e.g. poor flow, 
infection on the access site)  and hypotensive disorders85. 
1.3 Metabolic dysregulation in chronic kidney disease (CKD) and end stage 
renal disease (ESRD) 
The reduced ability to excrete nitrogenous metabolic waste by the failed kidney, leads to an 
accumulation of potentially toxic metabolites in the serum, such as urea, p-cresol and creatinine 
(collectively called uraemic toxins in a condition called uraemia)86. Uraemia is known to play 
a role in the pathogenesis of the disorders of CKD and other functional changes including 
protein energy wasting (PEW) and metabolic acidosis. Kidney failure will also cause poor 
mineral and electrolytes homeostasis, fluid accumulation, reduced production of hormones 
such as 1, 25-dihydroxyvitamin D3, renin, and EPO. For this reason ESRD patients are at 
increased risk of developing anaemia and EPO resistance87,88, vascular calcification89, vitamin 
D deficiency and skeletal muscle dysfunction with a reduction in exercise tolerance90,91. 
Uraemia has also been linked with inflammation, oxidative stress conditions and 
cardiovascular diseases6,92. Complications of CKD notably affect all organ systems and are 
linked with a decline in health related quality of life (HRQoL) and increased mortality. This 
thesis focuses on the interplay between protein energy malnutrition/wasting, inflammation and 
anaemia in ESRD. 
1.3.1 Malnutrition and inflammation in end stage renal disease (ESRD)  
ESRD is accompanied by adverse changes in nutrition and body composition particularly 
among dialysis patients3,93. Similarly, inflammation is also a common feature in ESRD 
attributed to accumulation of toxic metabolites94,95 and other dialysis related factors96,97. 
1.3.1.1 Protein energy wasting (PEW) as a consequence of undernutrition 
Uraemic syndrome causes a decline in appetite (due to taste alterations and nausea)98-100, 
impaired food utilization and assimilation101, and consequently a progressive decline in dietary 
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intake101,102. Uraemia has also been shown to affect the composition of a patient’s gut 
microbiome and so may interfere with the absorption of nutrients such as fatty acids86. With 
prolonged dietary inadequacy the body’s production and sensitivity to insulin is also likely to 
decline with a subsequent  increase in glycogenesis and fatty acid mobilization103,104. If 
persistent, this will cause a loss of visceral protein, decreased plasma protein synthesis 
(hypoalbuminemia) and increased liver fat infiltration due to lipolysis105. Figure 1:4 
summarizes the aetiology of PEW in CKD.  
Undernutrition is not the only aetiological factor for PEW in ESRD patients. Increased resting 
energy expenditure (REE) attributed to the dialysis itself, comorbidities and persistent 
inflammation106 could also contribute in the pathogenesis of PEW in this patient group. Indeed 
PEW was observed to be more prevalent among dialysis patients within the highest tertile as 
compared to the lower tertile of REE107.   
 
Figure 1:4: A conceptual model for aetiology of Protein energy wasting (PEW) in CKD and direct clinical 
implications. 
Source:  Carrero et al.(2013)108  
1.3.1.2 Metabolic acidosis and Protein energy wasting 
Metabolic acidosis is another metabolic change which occurs with CKD progression and it is 
characterized by an increase in the body concentration of hydrogen ion with a concomitant 
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reduction in blood bicarbonate (HCO3). The condition is recognised to play a significant role  
in the acceleration of protein catabolism, causing negative nitrogen balance and muscle loss109; 
and a reduction in protein synthesis109-111. Patients with renal failure are prone to metabolic 
acidosis due to the reduced ability to excrete excess hydrogen ions into the urine and to reabsorb 
bicarbonate ions4. Haemodialysis patients are particularly at risk if they have inadequate 
bicarbonate in the dialysate or inadequate dialysis, gastrointestinal loss of bicarbonate or high 
protein intakes112,113. The type of diets consumed by patients also have a significant impact on 
the onset of metabolic acidosis as metabolism of high protein foods results in production of 
acids whereas fruits and vegetables provide alkali4. High intradialytic weight gain in this 
patient groups has also been associated with an increased risk of developing metabolic 
acidosis114.  
Metabolic acidosis is a predictor of CKD progression (independent of baseline estimated GFR, 
demographic, socioeconomic and other clinical factors)115 and mortality116. 
Analysis of data from the DaVita database which involved prevalent ESRD patients treated 
with PD and HD117, showed a 15 – 35% in increase in the risk of mortality for patients with 
bicarbonate levels < 22mEq/L whereas analysis of data from the DOPPS study (involving a 
randomly selected sample of HD patients from France, UK, Japan, Germany, Italy, Spain and 
USA)118 showed an increase of up to 48% in mortality risk among patients with pre-dialysis 
serum bicarbonate < 18mEq/L or ≥ 27mEq/L (analysed in a midweek session). Subsequently, 
the same DOPPS study found the best patient survival was associated with bicarbonate levels 
in the range 18 – 21 mEq/L. 
Correction of metabolic acidosis (through supplementation with oral sodium bicarbonate) was 
found to restore albumin status and concentration of essential amino acids111  and improve 
muscle strength in patients with mild metabolic acidosis119. 
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1.3.1.3 Inflammation and PEW 
 Inflammation has also been linked with PEW through a reduction of appetite120 and  a reduced 
synthesis and half-life of albumin107 and  is associated with increased insulin resistance, an 
increase in muscle loss121,122, and increased energy expenditure123. 
Recognising the multiple nutritional and metabolic alterations that occur with the progression 
of CKD, the International Society of Renal Nutrition and Metabolism (ISRNM)108, have 
presented their consensus on the aetiology of PEW as shown in figure 1:4. It also highlights 
the consequences of PEW including the increased risk of infectious disease, cardiovascular and 
frailty among patients. 
In summary, as illustrated by the ISRNM108, PEW is the consequence of multiple mechanisms 
inherent to CKD, including undernutrition, systemic inflammation, comorbidities, hormonal 
derangements, the dialysis procedure, and other disorders of uremic toxicity. Whilst PEW may 
increase patients’ risk of infection, CVD, frailty, and depression, these complications may also 
increase the extent of PEW. 
1.3.1.4 Assessment of PEW in ESRD 
Serum albumin along with prealbumin are the common and convenient markers of protein 
energy malnutrition for both research studies124,125 and clinical practice. However, the use of 
serum albumin levels as a marker of nutritional status among dialysis patients has long been 
questioned due to the marker being also an acute phase reactant which is downregulated in 
response to systemic inflammation126,127. Although albumin synthesis decreases with dietary 
protein intake in nephrotic patients128, conditions such as hepatic and inflammatory disorders 
also cause albumin breakdown and a decline in its synthesis129. Moreover, the association 
between hypoalbuminemia and high rate of mortality among ESRD patients was found to be 
dependent on systemic inflammation130. For this reason, the UKRA131 considers a low serum 
albumin to be a strong predictor of increased mortality and morbidity rather than an indication 
20 
 
of nutritional status. However, no single marker can be adequately used to diagnose PEW and 
comprehensive examination requires multiple complementary measurements132. Serum 
albumin therefore continues to serve as a potential screening tool for malnutrition that helps to 
highlight individuals requiring further investigation, using additional measures of body 
composition133. The European Best Practice Guideline(EBPG)134 and K/DOQI135 recommend 
the serum albumin levels be kept above 40g/l and prealbumin level above 0.3g/l.  
Other methods recommended by the UKRA131 to be used in assessing undernutrition include: 
Actual Body Weight (ABW) (< 85% of Ideal Body Weight (IBW)), reduction in oedema free 
body weight (of 5% or more in 3 months or 10% or more in 6 months), Body Mass Index (BMI) 
(<20kg/m2) and Subjective Global Assessment (SGA) (B/C on 3 point scale or 1-5 on 7 point 
scale). SGA is a screening tool that helps identify individuals at risk for malnutrition based on 
the physical, clinical examination and changes in dietary intake136. 
The EBPG134 and K/DOQI135 also highlighted a number of tools, that in addition to serum 
albumin, they can also  be used in the diagnosis of malnutrition. These include: dietary 
assessment, anthropometry, normalized protein nitrogen appearance (nPNA), serum 
prealbumin, cholesterol and techniques of body composition analysis such as bio impedance, 
dual X-ray absorptiometry and near-infrared reactance.   
1.3.1.5 Management of PEW in ESRD 
Because of the possible multiple causes of PEW in ESRD, efficient management of the 
condition will also involve multiple approaches that reflect its aetiology. 
Adequate diet plays an important role in ensuring optimal nutrient supply and minimizing the 
risk of malnutrition in this group of patients. Protein restriction (≤ 0.6 g/kg/d) has been used as 
a means of disease management before the development of haemodialysis, and was reported to 
be beneficial in controlling metabolic disarrangement including metabolic acidosis137, CKD-
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MBD138, attenuating insulin resistance, reducing oxidative stress139 and even assisting in 
delaying the progression of kidney failure in those with moderate renal insufficiency140-143. For 
this reason, it was suggested that protein intakes of 0.6g/kg/d can adequately meet the 
nutritional requirement of non-dialysis patients144 but  the UKRA recommends a protein intake 
of at least 0.75g/kg of ideal body weight per day for patients with CKD stage 4-5 not on 
dialysis. If a lower protein diet (<0.6g/kg/d) is desirable to prevent uraemia, evidence shows 
that it is important that adequate energy (30–35 kcal/kg/day) intake is ensured to prevent 
PEW145,146. 
However, the MDRD study, which is the largest RCT investigating the role of protein intake 
in disease progression, returned controversial findings when it failed to show an advantage of 
a low protein diet139,143.  Further analysis of MDRD data actually showed a link between protein 
restriction and poor indices of nutritional status147. A very low protein diet (0.28 g/kg/d) was 
also found to increase mortality risk among ESRD patients, even when supplemented with a 
mixture of essential keto acids and amino acids (0.28 g/kg/d)148.  Moreover, the problems of 
uraemic anorexia and the impaired gastrointestinal absorption and utilization of ingested 
protein which occur with disease advancement are of concern when considering the utility of 
a low protein diet in this population149.  
Compared to renal patients who are not yet on dialysis, dietary protein requirement of patients 
on maintenance dialysis is high due to the increased protein catabolism and nutrients lost with 
the treatment, which aggravates PEW146. Both the UKRA131 and NKF K ⁄ DOQI135 clinical 
practice guidelines therefore recommend protein intakes of not less than 1.2g protein ⁄ kg ⁄ day 
for stable dialysis patients with at least half of that being of high biological value (i.e. from 
animal sources). EBPG guidelines suggested that a slightly lower threshold of 1.1g/kg/d would 
still be sufficient150. With regards to energy intake,  NKF-K/DOQI135 and UKRA131 
recommend intakes of 30–35 kcal/kg/day for all patients depending upon age and physical 
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activity. A wider recommended range (30 - 40 kcal/kg/day) was proposed by EBPG 
guidelines150. 
Other notable strategies are those that help to control uraemia such as increasing dialysis 
adequacy by either dialysing for longer or more frequently151. Renal units will measure the urea 
reduction ratio (URR) (with the aim of achieving >65% reduction between pre and post dialysis 
urea measurements) and Kt/V, a measure of dialyser clearance of urea relative to total body 
water (>1.2) to asses dialysis adequacy. 
1.3.2 Anaemia in end stage renal disease 
1.3.2.1 Mechanism of anaemia development in ESRD 
Pathogenesis of anaemia in CKD patients is multifactorial, however insufficient production of 
erythropoietin (EPO) hormone from the failing kidneys is reported to be the most important 
factor87. This is because the hormone is required to promote the process of red blood cell 
production known as erythropoiesis. Erythropoiesis is a complex processes that involves 
proliferation and maturation of erythroid-lineage committed cells (erythroid burst and colony 
forming units) into morphologically distinct erythroid precursors (the bone marrow (BM) 
erythroblasts) that undergo progressive differentiation and nucleation up to the stage of 
reticulocytes and mature red cells152-154. 
Apart from EPO, iron is also required in erythropoiesis, particularly in the differentiation stage 
i.e. in the early steps of erythroid differentiation to produce cytochromes and enzymes and 
during terminal differentiation where globin and haem synthesis are coordinated to produce 
haemoglobin 155,156. Iron deficiency is therefore another factor in the aetiology of anaemia in 
CKD patients. Figure 1:5 provides a schematic presentation of renal anaemia pathogenesis157.  
Anaemia prevalence increases with disease progression, affecting 17.4% and 53.4% of stage 3 
and 5 patients respectively within a USA cohort (2007 – 2010)158. 
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The UK renal registry also showed lower prevalence of anaemia among stage 3 CKD patients 
(14.3% F, 20.4%M) than in stage 5 CKD (61.2%F, 81.5%M) patients159.  
 
Figure 1:5: Schematic presentation of mechanisms underlying development of renal anaemia. Black and grey 
arrows represent normal physiology (black for iron and grey for regulatory processes). Coloured arrows 
represents the effects of CKD (blue for activation, red for inhibition effects). Iron and EPO are crucial in red 
blood cell production in bone marrow. Iron availability (dietary iron and microphages iron from senescent red 
blood cell) is controlled by the hepcidin hormone from the liver (iron is downregulated by the increase of the 
hormone). Hepcidin level is controlled by several feedback loops including the level of iron and EPO. In ESRD 
patients, hepcidin level is highly elevated presumably due to reduced renal clearance and inflammation, causing 
iron-restricted erythropoiesis. CKD also inhibits EPO production by the kidney; may also cause uremic induced 
inhibition of erythropoiesis; shortened red blood cell life span and increased blood loss.  
 Source: Babitt and Lin, (2012)157.  
 
Anaemia has been linked with increased risk of cardiovascular disease, reduced tolerance to 
exercise, cognitive impairment, reduced quality of life (tiredness, lethargy, and reduced 
appetite), increased hospitalization rate and increased mortality160. 
1.3.2.2 Iron deficiency in CKD 
There are multiple reasons for iron deficiency in patients with CKD and ESRD. Insufficient 
intake of iron rich food due to poor appetite (secondary to uraemia) and stringent dietary 
restriction (e.g. reduced red meat reduces haem iron intake, reduced fruit and vegetable reduces 
vitamin C intake which can reduce non-haem iron absorption), may exacerbate iron deficiency 
in these patients161.  
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Uraemia and inflammation are therefore also thought to be contributory factors in the aetiology 
of iron deficiency anaemia in CKD patients162,163. The uptake of iron by intestinal epithelial 
cells and iron recycling from macrophages is facilitated by a membrane transporter called 
Ferroportin164. This membrane transporter tends to be bound and degraded (downregulated) by 
hepcidin hormone, resulting in reduced iron absorption by the intestine and iron accumulation 
within the reticuloendothelial system164-166. Hepcidin hormone is normally regulated according 
to the level of circulatory and iron stores by a negative feedback loop. Iron availability increases 
hepcidin expression, thus limiting further iron absorption, while iron deficiency and hypoxia 
inhibit hepcidin expression thus increasing iron availability167-169. However, hepcidin 
expression is also found to be induced by inflammation, suggested to be body’s defence 
mechanism to fight infection and cancer hence limiting iron availability169,170. 
Another factor that might contribute to iron deficiency in ESRD patients is the recurrent blood 
loss associated with the dialysis therapy. Patients are estimated to lose approximately 1-3g of 
iron per year due to retention of blood in dialysis lines and clotted dialyzers, frequent blood 
draws, and a higher propensity toward gastrointestinal bleeding171. Inadequate dialysis can also 
cause low clearance and hence greater accumulation of uraemic toxins, production of pro-
inflammatory cytokines and consequently impaired erythropoiesis172,173. 
1.3.2.3 Assessment and diagnosis of anaemia in CKD 
The UKRA clinical practice guideline on anaemia of CKD174 and NICE175 suggest that 
haemoglobin (Hb) be routinely measured (at least twice a year for non-dialysis and every 4 
weeks depending on Hb concentration or/its rate of change for dialysis patients) to screen for 
anaemia. Hb levels less than 110g/l warrant further investigation to derive a correct diagnosis 
and management plan. The 2006 KDOQI176 guidelines have grouped the Hb thresholds 
according to gender, i.e. Hb concentration <135 g/l for adult males and <120 g/L for adult 
females indicates further diagnostic tests should be performed. This recommendation is 
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endorsed by the European Renal Best Practice (ERBP) working group177 although they 
considered age and reduced the male cut off value to Hb <132 g/L for men >70 years. The new 
2012 KDIGO guidelines have similar recommendations for the Hb threshold in females but 
slightly lower for males (<130g/L).178 
Other evaluation tests, in addition to Hb concentration, include: full blood counts, serum 
ferritin to assess iron stores, absolute reticulocyte count and tests to determine iron status (% 
hypochromic red blood cells (%HRC), reticulocyte Hb (CHr) and % Transferrin saturation 
(%TSAT).  UKRA179 defines ‘iron replete’ as adult patients having %HRC < 6%, CHr > 
29pg/cell, ferritin > 100μg/l and %TSAT >20%. Low ferritin (<100μg/l) is an indication of 
iron deficiency anaemia, nevertheless, normal or high ferritin (≥100μg/l) should not be deemed 
to conclusively indicate a patient is  iron replete without investigation as the marker could be 
raised as a result of infection or inflammation.  
1.3.2.4 Treatment and management therapies for anaemia in ESRD 
1.3.2.4.1 Erythropoietin (EPO) therapy 
Because insufficient EPO production from the failing kidneys has been found to be the main 
cause of anaemia in CKD patients87, the use of recombinant human erythropoietin (rHuEPO) 
has been central to treatment. The use of EPO have also helped to manage anaemia, reducing 
the need for blood transfusions and improving patients’ quality of life. UKRA174 and 
K/DIGO177 both recommend treatment with EPO for all patients with anaemia of CKD who 
are likely to benefit in terms of quality of life and physical function. 
The K/DIGO177 guidelines also suggest that all CKD stage 5 patients start the therapy when 
Hb levels are between 90 – 100g/l in order to prevent their Hb concentration falling below 
90g/l. However, the two guidelines recommend such therapy to only be initiated once other 
possible causes of anaemia e.g. iron deficiency and inflammation have been ruled out or 
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corrected. The decision on the choice of EPO is normally based on efficacy, safety, cost and 
its local availability. 
The dose is individualized depending on the patients Hb concentration, target level, the 
observed rate of increase in Hb, body weight and clinical circumstances. Frequency of 
administration is based on the disease stage, treatment setting, efficacy, patient’s tolerance and 
preference and the type of EPO used. For HD patients EPO can be administered either 
intravenously or subcutaneously with an initial dose of short–acting EPO given thrice weekly 
for maximal efficacy180. The starting dose is often 20 to 50 IU per kilogram body weight 3 
times a week followed by a weekly maintenance dose of 3 x 20 IU/kg if the increase in Hb is 
inadequate178. In England, prescription follows the recommendation of The British National 
Formulary (BNF) and NICE guidelines which direct that, for adult HD patients, an initial dose 
of Epoietin-Alfa (Eprex®) equal to 50 units/kg is given 3 times weekly. The dose is normally 
adjusted according to response in increments of 25 units/kg, 3 times weekly at intervals of at 
least 4 weeks. For maintenance, usually a total of 75–300 units/kg weekly (as a single dose or 
in divided doses) is advised.  
The initial dose of EPO normally prescribed in Tanzania is 4000 IU, 3 times a week3.The 
frequency is normally decreased to twice a week when Hb concentration rise to 110-120g/l and 
once a week when Hb is 120- 130g/l. EPO is stopped when Hb level reach 130g/l.    
1.3.2.4.2 Iron therapies 
Because of the need for iron for erythropoiesis152,154, iron therapy is also paramount for anaemia 
management170. Iron can be administered via the oral, intramuscular or intravenous (IV) route. 
Studies on the effect of oral (Ferrous sulphate) versus IV iron (Iron sucrose) administration in 
raising haematological indices (Hb, Ferritin and TSAT levels) in pre-dialysis patients give 
mixed results. Whilst the two routes were reported to be equally effective in a report from the 
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REVOKE study authored by Agarwal et al181, the FIND-CKD trial182,  a longer, multicentre 
trial involving a larger sample size, found that  IV iron (Ferric carboxymaltose) surpassed the 
oral iron (Ferrous sulphate) in the achievement of treatment targets and delaying/reducing the 
need for other anaemia management including EPO. It is worth noting that these two trials used 
different IV iron formulations and that the audit by Hofman et al.183 suggested an increased 
effectiveness of Ferric carboxymaltose compared to iron sucrose. Furthermore, the dosage of 
oral iron was lower in FIND-CKD trial (100mg twice a day) compared to REVOKE trial 
(325mg three times a day) which may contribute to the differences seen.   
On the other hand, for dialysis patients (both PD and HD), there is strong evidence supporting 
the efficiency of IV iron supplementation over oral iron in achieving Hb targets, maintaining 
iron stores and reducing EPO doses184-186 possibly due to poor intestinal absorption of oral iron 
caused by increased circulating hepcidin (see  section 1.3.2.1). Patients treated with IV iron 
were also found to have significantly higher levels of Hb (mean difference 9.0 g/l), TSAT, and 
ferritin as compared to those supplemented with oral iron187. In addition to raised Hb levels185, 
EPO dose was also found to be reduced with IV iron.  For this reason, IV is the first line 
therapeutic option for correcting iron deficiency in HD patients.  
However, there have been concerns regarding the use of IV iron, in particular, high doses of 
IV iron have been linked with an increase in the risk of infection, oxidative stress, vascular 
calcification and atherothrombosis188,189. Contrasting results were produced by the recent 
multicentre randomised study “the Proactive IV Iron Therapy in Haemodialysis patients 
(PIVOTAL)”190 trial that assessed the efficiency and safety of high-dose (400mg of iron 
sucrose/month) compared to low-dose IV iron (0 – 400 mg iron sucrose/month) administration 
among HD patients. In this study, the high-dose regimen was superior in lowering EPO dose 
to the low-dose regimen. Moreover, the risk of death or major nonfatal cardiovascular events  
was lower in the high-dose group than in the low-dose group.  The rate of hospitalization for 
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any cause and for infection were not different between the two treatment groups. However, the 
thrombosis affecting vascular access was more common in high-dose (24.0%) compared to 
low-dose (20.8%) IV iron recipients. The findings from this add to the evidence base and will 
help inform developments in CKD-anaemia treatment guidelines in order to optimise treatment 
outcome. 
Currently a the treatment follows standard guidelines where-by patients are normally started 
with the initial (corrective) IV iron dose, commonly prescribed as 500 - 1000mg given as a 
single or divided doses depending on the preparations. This dose is then followed by 
maintenance dose of 50 – 100mg weekly or fortnightly depending on the ferritin level175,178,191.  
In the UK, the BNF (February 2016, section 9.1.1.2) outlines four options for parenteral iron 
preparations. These are: Iron dextran (CosmoFer®), Iron sucrose (Venofer®), Ferric 
carboxymaltose (Ferinject®) and Iron isomaltoside 1000 (Monofer®).   
UKRA guidelines179, and similarly the ERBP in their position statement in the 2012 KDIGO 
guideline177, recommend that adult patients on EPO management therapies maintain their Hb 
concentration between 100 and 120g/l and that dose review and adjustment be made when the 
Hb is < 105 or >115g/l and/or ferritin is > 500μg/l. The 2012 KDIGO178 clinical practice 
guideline for anaemia in CKD suggests the same lower threshold (100g/l) but recommends a 
slightly lower upper cut off, specifically that there should be a treatment review when the Hb 
is >110g/l. The recommended target for iron storage (ferritin) is 200 – 500 ng/ml and for TSAT 
≥ 20% and IV iron dosage should be reviewed when ferritin reaches 500ng/ml and discontinued 
when it is ≥800ng/ml, unless the Hb is below the desirable level. This guideline was endorsed 
by the KDOQI192.  
Tanzanian clinics use Hb levels (< 110g/l) as an indication for iron prescription (100mg of Iron 
sucrose (Venofer®) for 5 to 8 consecutive HD sessions) to achieve a desirable level of Hb 
(>110g/l). The same dose is normally repeatedly prescribed when a patient’s Hb level declines 
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below 110g/l or fails to reach their Hb target while ruling out other causes of low Hb including 
helminthic infestations and bacterial infections which are common in these patients. However, 
the attainment of the optimal dose also depends on financial ability of the patient as patients 
are required to pay for their prescriptionsa.  
1.3.2.5 Erythropoietin (EPO) hormone hypo responsiveness in ESRD 
Despite EPO being an important therapy in the management of anaemia of CKD about 5-10% 
of patients exhibit an inadequate response to the therapy193. These patients fail to achieve or 
maintain the target Hb levels despite the correct dose of EPO194. EPO resistance has been 
associated with poor clinical outcomes, increased cardiovascular morbidity, disease 
progression and all-cause mortality195,196. Iron deficiency (absolute iron deficiency) and/or 
insufficient iron bioavailability (functional iron deficiency) is named as the  major limiting 
factor for the effectiveness of EPO in HD patients, due to iron’s involvement in erythropoiesis 
as described in section 1.3.2.1 155,156.   
Inflammation is also acknowledged to contribute to poor response to EPO therapy. Pro-
inflammatory cytokines like interferon-gamma (IFN-γ), tumour necrosis factor alpha (TNF-α), 
interleukin 1 (IL-1) and inter-leukin 6 (IL-6) can induce resistance of erythroid progenitor cell 
to EPO or promote increase of hepcidin, hence impairing the release of stored iron into the 
reticuloendothelial system 197,198.  
Studies have also indicated that malnutrition might contribute to poor EPO responsiveness 199; 
200, possibly due to the association between malnutrition and inflammation201, with stringent 
dietary restrictions also reducing iron availability for erythropoiesis hence EPO 
hyporesponsiveness.  
                                                          
a Personal communication with Dr. Pascal Ruggajo (Nephrologist and Lecturer at Muhimbili University of 
Health and Allied Health in Tanzania) on 21st February 2016 
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Another factor suggested to influence EPO responsiveness is secondary hyperparathyroidism. 
This may be due to its inhibitory effect on early erythroid precursors and its negative effect on 
bone marrow cellularity and it has been linked with the development of bone marrow fibrosis 
202. Intervention to suppress PTH has been shown to improve anaemia in CKD patients 203,204. 
High levels of alkaline phosphatase have also been associated with CKD anaemia and EPO 
hypo-responsiveness 205,206. 
Inadequate dialysis may also impair EPO response due to accumulation of uremic toxins which 
can further inhibit production of EPO and erythropoesis. Gaweda et al.207 indeed found an 
association between Kt/V, as a measure of dialysis adequacy, and erythropoietin response. 
1.4 The interplay between nutrition status, body composition, inflammation 
and anaemia in ESRD 
The multifactorial pathogenesis of malnutrition in ESRD is discussed in section 1.3.1.1 where 
the involvement of uremic toxicity, poor dietary intake, increased energy requirement, 
hormonal derangement and disturbances in protein and energy metabolism were suggested.  
As previously explained, protein energy malnutrition/wasting and inflammation are both 
common conditions affecting ESRD patients. Furthermore, the two conditions are closely 
related as inflammatory responses can significantly increase the risk of malnutrition. In the 
inflammatory state, energy requirement tends to increase due to the increased resting energy 
expenditure (REE)208. Inflammation is also known to reduce albumin by impairing synthesis 
and reducing its half-life thus contributing to muscle loss. 209-211 and this can occur independent 
of inadequate nutrition 212.  Several studies have indeed shown muscle protein loss with 
increases in circulatory IL-6 213. It is also suggested that pro-inflammatory cytokines can act 
on the central nervous system to decrease appetite214 contributing to poor nutrition.  
Similarly, over nutrition (resulting in obesity), despite being shown to increase the survival 
advantage of HD patients215, may have detrimental effects dependent on the pattern of regional 
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fat deposition and subsequent metabolic implications. Abdominal fat increases the expression 
of pro-inflammatory cytokines and observational studies have linked it with inflammation in 
CKD patients 216,217 
It not uncommon for the two conditions to occur simultaneously in dialysis patients, a condition 
called Malnutrition-Inflammation complex syndrome (MICS)218 and in fact many features that 
indicate the presence of PEW (e.g. hypoalbuminemia) can also be induced by the presence of 
inflammation219. 
1.4.1 Nutritional status (including body composition) and anaemia in ESRD 
Nutrition (with or without inflammation) has a significant role to play in patients’ overall 
quality of life and treatment outcomes, including the anaemia status of ESRD patients.  
As already noted, ESRD patients face enormous dietary restrictions that limit intakes of fruits 
and vegetables, potentially causing low consumption of important micronutrients like vitamin 
C which promotes iron absorption. Dietary iron intake is also limited among these patients as 
they are continuously restricted to control their dietary sodium, potassium, phosphorus, dietary 
fat and cholesterol220. Moreover, uraemic patients have reduced appetite and researchers have 
reported this to be associated with lower haemoglobin levels and increased EPO requirement 
221. 
Body composition has increasingly been reported to play a role in iron status and erythropoietin 
hormone (EPO) response, whereby increased body weight and even obesity (BMI > 30kg/m2) 
have been found to be protective among dialysis patients. do Sameiro-Faria et al.12 observed 
greater resistance to EPO among underweight patients (BMI <20 kg/m2), presenting with 
functional iron deficiency and a high degree of inflammation compared to those with BMI ≥ 
20 kg/m2. The same study found a decrease in adiponectin and EPO doses and an increase in 
transferrin and lymphocyte counts with an increase in BMI even at ≥ 30kg/m2 BMI level and 
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showed that BMI, along with albumin and soluble transferrin receptor (sTfR), were 
independent predictors of the EPO dose required to achieve target haemoglobin levels. Kotanko 
et al.13 found a significantly higher weekly dose of EPO among African-American HD patients 
with lower tertiles of subcutaneous adipose tissues (SAT) and total adipose tissue (TAT) and, 
in females only, for those with lower tertiles of muscle mass (MM). They hypothesized that 
this could be a reflection of low uremic toxin load and large urea distribution volume in larger 
patients. This is because larger dialysis patients have smaller relative mass of high metabolic 
rate organs (HMRO) (and thus waste product producing) per unit of weight or BMI, such that 
their large muscle and fat volume act as a large distribution volume. Guinsburg et al.222 also 
found erythropoietin response index (ERI), (weekly weight adjusted dose of EPO (U/kg/week) 
divided by haemoglobin concentration (g/dL)), which is an index of EPO resistance, to be 
inversely correlated with both lean tissue index (LTI, lean tissue mass/ height2) and fat tissue 
index (FTI, fat tissue mass/ height2) even after controlling for other variables known to relate 
to ERI. This author concluded that the observed protective effect might be a reflection of better 
nutritional status or in patients with high FTI, it may reflect a reduced distribution volume of 
haemoglobin due to lower percentage of water in fat tissues. However, it is also possible for 
the association observed to be a mathematical artefact since body weight makes up the 
denominator for ERI calculation, therefore it is not surprising for ERI to be negatively 
correlated with fat mass (a component of total body weight). This calls for more investigation 
to ascertain how body composition actually influences EPO response.   
The protective effect of high BMI and fat is believed to be a result of leptin hormone as this 
hormone increases with an increase in BMI223 and fat mass in ESRD patients 224. In vitro studies 
have shown that leptin can induce proliferation, differentiation and activation of 
haematopoietic cells225. This was also demonstrated in human studies including those of renal 
patients whereby leptin was suggested to help stimulate erythropoiesis226,227 and to be 
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predictive of EPO sensitivity228 . Moreover, leptin was found to be positively associated with 
haemoglobin levels in ESRD patients229. However, a contradictory association was found in 
the in vitro study by Ching et al.,230 which showed an increase in hepcidin expression in the 
hepatoma cells incubated with leptin, suggesting that leptin could have negative effect on iron 
metabolism. The contradictory observation may suggest that the erythropoietic role of leptin 
may be dependent on other factors such as availability of iron.  
1.4.2 The role of iron in muscle metabolism and function 
The previous sections have highlighted the role of iron in red blood cell (RBC) production 
and specifically its role as an  essential part of haemoglobin (a protein in RBC) which confers 
the oxygen carrying and transportation potential155,156.   
However, in addition to RBC production, iron forms an essential part of myoglobin. Myoglobin 
is the heme containing protein group that is developed in red muscle in response to 
mitochondrial demand for oxygen231. It binds to oxygen and transports it from RBC to the 
mitochondrial organelles of the muscle cell. Unlike haemoglobin that supplies oxygen to all 
parts of the body, myoglobin is active within muscle groups only and therefore helps to 
maintain oxygen supply to muscles during periods of oxygen deprivation232.   
Because of these broad applications of iron, mineral deficiency in this population group is 
therefore linked with not only the onset of anaemia and its related consequences like fatigue, 
and reduced exercise endurance but is also associated with other adverse effects like cardiac 
dysfunction233 and restless legs syndrome234 which are suggested to be consequences of 
insufficient generation of cellular energy and oxygen shortage in myogloblin in the heart and 
skeletal muscles235. 
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1.5 Interventions for improving nutritional status and body composition in 
end stage renal disease 
Multiple approaches are potentially effective in preserving muscle and preventing malnutrition. 
Providing adequate dialysis therapy is among the strategies suggested as this will hopefully 
reduce uremic toxin accumulation and hence mitigate the effect of uraemic toxicity. Studies on 
haemodialysis have shown an increase in protein intake as dialysis dose (measured as Kt/V) 
increased 236 a relationship that remains at least until a desirable Kt/V is achieved237,238. Hakim 
et al.239also found a significant improvement in nutritional indices (i.e. serum albumin and 
protein creatinine ration (PCR)) among Hd patients whose Kt/V increased to above 1.21 
compared to those whose Kt/V was below 0.86. 
As previously discussed (see section 1.3.1), metabolic acidosis and inflammation play a 
significant role in the development of muscle wasting. Correction of metabolic acidosis is 
therefore also found to help manage PEW and studies have shown improvements in nutritional 
status with oral bicarbonate supplementation240. Efforts made to minimize and treat uremic 
inflammation, such as through dialysis prescription, e.g. short dialysis241 or 
hemodiafiltration242 compared to conventional HD, have the potential to counteract the 
inflammation induced PEW.  These may remove the requirement for overly restrictive diets in 
maintenance dialysis patients leading to improved nutritional status. 
Controlling the  metabolic disorders which occur alongside  ESRD, such as diabetes mellitus, 
is also important in preserving muscle mass.243 Nutritional supplementation through the 
gastrointestinal route and even the parenteral route during dialysis (for patients who cannot 
tolerate oral or enteral administration) have been shown to improve the nutritional status of 
patients with overt PEW.244Anabolic steroids stimulate muscle protein synthesis by inducing 
mRNA expression of androgen receptors in the skeletal muscles and increasing the intracellular 
pool of amino acids from protein degradation.245,246 Improvement in indices of nutritional status 
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was indeed seen among haemodialysis patients intervened with nandrolone decanoate which is 
an androgen and anabolic steroid medication247.  
Studies have shown that physical activity amongst dialysis patients may be very limited 248,249 
and this has been recognised to increase the risk of muscle wasting as a consequence of “muscle 
disuse”250,251. Exercise interventions, particularly resistance training, have the potential to 
tackle this and have been shown to promote muscle growth, muscle mass and even to increase 
muscle strength252,253. Furthermore, intradialytic exercise is thought to counter-act muscle 
protein catabolism254. The topic of exercise intervention in dialysis patients is further explained 
in section 1.5.1. 
1.5.1 Exercise intervention in end stage renal disease   
ESRD patients particularly, those on maintenance dialysis, have poor physical functioning and 
low levels of activity and this has been shown to compromise their quality of life and survival 
255-258. NKF-K/DOQI259 has therefore recommended that dialysis patients be “counselled and 
regularly encouraged to increase their level of physical activities”.  
Different exercise modalities have been studied to date in particular those conducted during 
dialysis sessions (intradialytic) or between two dialysis sessions (inter dialytic)260,261 and these 
have indeed been shown to be beneficial not only for the physical performance262 of dialysis 
patients but also for their overall quality of life263. Intradialytic exercises, in particular aerobic 
exercises, have been shown to improve blood circulation in the body and through the dialysis 
circuit hence improving dialysis clearance264, vascular health265, heart rate variability266 and 
inflammation status267.  
The benefits of exercise (resistance training) also extend to improving body 
composition251,268,269. In one study269, 79 HD patients participated in lower extremity resistance 
exercise intradialytic training using ankle weight for twelve weeks three times a week. 
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However, in addition to exercise, these patients were also supplemented with an anabolic 
steroid (nandrolone decanoate) and the effects on muscles were only observed when these 
interventions were combined.  Kopple et al.268, on the other hand, showed the beneficial effect 
of exercise alone. In their study, an increase in lean body mass, muscle mRNA and muscle 
IGF-1 protein were observed among HD patients randomized to intradialytic 
strength/resistance training when compared to those who did not exercise. Muscle benefits of 
exercise was also reported in another intra-dialytic exercise programme by  Kirkman et al.251 
in which 23 HD and 9 non-HD patients were randomized to progressive resistance exercise 
training (PRET), consisting of thrice-weekly high-intensity leg press exercises (three sets of 
eight to ten repetitions at 80% of their predicted one-repetition maximum i.e. the maximum 
weight that can be lifted one time with proper technique), vs. control (sham) therapy, consisting 
of low-intensity lower body stretching activities using ultra-light resistance bands for 12 weeks. 
After this intervention period, the PRET group showed a significant increase in thigh muscle 
volume and knee extensor strength for both HD and non-HD patients.  
The haematological benefit of an exercise intervention was also proposed in a study by 
Reboredo Mde et al.270 . In this study, a statistically significant improvement in the Hb 
concentration of patients with ESRD was observed following 12 weeks of 30 minutes of 
intradialytic aerobic exercise on a cycle ergometer performed three times a week. The author 
suggested this increase in Hb might be a result of an increase in the Kt/V that was also evident 
after intervention period. 
The in-centre exercise programmes (intradialytic and inter dialytic), although widely utilized 
in studies, do come with challenges, most often organisational and cost issues related to the 
required equipment and personnel. The additional visits to the clinics (for inter dialytic 
exercises programme) would be expected to be a barrier to patients’ acceptability and 
compliance to the programmes.  Researchers have therefore also attempted to investigate the 
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benefits and acceptability of easy to implement home exercise programmes for dialysis 
patients. Among the documented home based exercise programmes is that by Manfredini et 
al271 which is a simple, personalized, low-intensity, home-based walking programme (20 
minutes walking at low to moderate speed every second day). This programme was tested in a 
6 months multicentre, randomized clinical trial (EXCITE study) and was found to improve 
physical performance and quality of life compared to a control group.  
Nevertheless, how the exercise training should be performed (intradialytic or inter dialytic, 
daily or other frequency, in which settings, for what duration and at what intensity) is still open 
to debate and there are currently no standard exercise recommendations for this patient group. 
In a randomized control trial by Orcy et al.253 an exercise intervention approach that combined 
resistance and aerobic exercise proved to be better in improving functional performance than 
either of the exercise modalities alone. Based on this literature, in the last stage of this research 
project, we proposed and tested a combined resistance and aerobic exercise programme, 
specifically utilizing a simple and flexible home based aerobic exercise (walking) as opposed 
to the conventional ergonomic bikes that are expensive and practically more difficult to 
arrange.  
1.6 Introduction summary and thesis rationale 
Anaemia is highly prevalent among ESRD patients, primarily owing to the inability of the 
failed kidney to produce erythropoietin hormone compounded by impaired iron metabolism. 
In addition, there are numerous other factors that contribute to the onset and prognosis of renal 
anaemia, such as dialysis indequacy, inflammation and nutritional status (including the more 
recently reported impact of body composition). The situation is particularly of concern for 
those on haemodialysis due to the increased risk of blood loss in the dialysis circuit.  
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To treat the condition, patients are on continuous anaemia management therapies which include 
iron supplementation and injectable erythropoietin hormone.  Nevertheless, there is a notably 
high rate of hypo responsiveness as patients fail to reach their haemoglobin targets despite EPO 
treatment. This is also the case for haemodialysis patients in Tanzania where clinical reports 
have persistently indicated low haemoglobin levels amongst patients, with implications for 
their quality of life and survival. 
Factors that have been identified to modify responsiveness to EPO treatment (mentioned 
earlier) are not likely to uniformly affect all patients across the globe or between developed 
and developing regions as their significance could be mediated in part by socio-economic 
factors including the availability of resources (finance and expertise).  
In particular we do not know what specific factors are contributing to the situation among 
Tanzanian patients as there are no published reports on this subject. This project therefore 
investigated the association between marker of iron status and the suggested contributory 
factors for renal anaemia with a focus on nutritional factors (including body composition), in 
order to make recommendations for potential interventions to improve anaemia management 
among this patient group. Currently, renal nutrition services are limited in Tanzania. We 
anticipate that this work will help raise awareness of the significant role of nutrition in patients 
care whilst also providing practical strategies to optimise their management.  
The final stage of this project investigated the feasibility of a low intensity intradialytic 
resistance exercise combined with a home based flexible walking programme. It investigated 
whether such a programme is beneficial in improving body composition and ultimately 
haemoglobin levels of HD patients.  
If patients are supported to maintain optimal nutritional status and improve their response to 
anaemia treatments, this confers long term benefits for patients and the health care system in 
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general. There is potential to optimise patients’ treatment, reduce the quantity of anaemia 
therapies required to reach clinical targets, reduce hospitalization rate and improve their quality 
of life. This will in turn help to reduce the burden to the health care system by reducing  the 
costs associated with treatment and hospitalization.  
1.7 Aims of the thesis 
i. To investigate and characterize the nutritional status and other treatment outcomes of 
adult HD patients in Tanzania and that of UK and make comparison between the two 
settings and with recommended standards. 
ii. To study the association between markers of anaemia, nutritional status and  
inflammation among HD patients on erythropoietin maintenance therapy.  
iii. To test the acceptability of a low intensity exercise intervention (combining aerobic and 
anaerobic exercise) and assess its impact on different components of body composition, 
dialysis adequacy and inflammatory status and patients’ response to EPO among 
haemodialysis patients on erythropoietin maintenance therapy.  
1.8 Project Hypothesis 
We hypothesized that patients with better nutritional status (in particular higher muscle mass) 
would have a better response to anaemia treatment as illustrated by greater attainment of 
desirable Hb levels among HD patients. 
We also hypothesized that low impact exercise combining walking and resistance training 
would  help improve physical functioning, increase muscle mass and facilitate better responses 
to anaemia treatment among HD patients. 
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CHAPTER 2 
2 A CROSS-SECTIONAL STUDY OF NUTRITIONAL 
STATUS AND BIOCHEMISTRY PROFILE OF 
TANZANIAN VERSUS UK HAEMODIALYSIS PATIENTS 
2.1 Introduction and rationale of the study 
Chronic Kidney Disease (CKD) prevalence is escalating both in developed and developing 
countries and is increasingly recognised as a global health problem. A meta-analysis by Hill et 
al272 found a global general CKD (stage 1-5) prevalence of 13.4% and for stage 3-5 of 10.6%. 
The author also showed regional prevalence of CKD and table 2:1 presents data for CKD stage 
3-5. CKD epidemiological data for developing countries is still scarce and of limited quality 
and there is limited access to health care services in these region. The available prevalence data 
might well be underestimated.  
Table 2:1: Results from a meta-analysis showing the proportion of people with CKD (3-5) in different 
countries selected as regional representatives.  
Region #Number of participants †Prevalence % (C.I) 
S. Africa, Senegal, Congo 1202 7.60 (6.10, 9.10) 
India, Bangladesh 12,752 6.76 (3.68, 9.85) 
Iran 20,867 11.68 (4.5, 18.84) 
China, Taiwan, Mongolia 62,062 10.06 (6.63, 13.49) 
Japan, S.Korea, Oceania 298,00 11.73 (5.36, 18.10) 
Australia 896,941 8.14 (4.48, 11.79) 
USA and Canada 1,319,003 14.44 (8.52, 20.36) 
Europe 2,169,183 11,86 (9.93, 13.79) 
Adapted from a study by Hill et al.272 ; 
#
Number of people included in the analysis from named countries; 
†
Percentage (Confidence interval) of those found with CKD (3 - 5) 
Nevertheless, another meta-analysis by Kaze et al.273 showed the overall prevalence of CKD 
in Africa to be 15.8% (4.6% for stage 3-5). In this study, the author found regional differences 
in overall CKD prevalence where-by Western Africa had the greatest disease burden (19.8%), 
followed by central Africa (16.0%), Eastern (14.4%), Southern (10.4%) and the lowest 
prevalence was in Northern Africa (6.1%).  The CKD prevalence in the Eastern Africa region, 
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where Tanzania is located, seems to hold a significant position in both, the global and African 
context. Indeed, the available studies in Tanzania indicate the CKD prevalence in the country 
ranges from 7%38 to 13.6%274. 
CKD represents a significant clinical and public health challenge and this is of concern 
particularly in Tanzania and other developing countries due to limited health facilities for 
dialysis and transplant technologies and the high cost associated with the treatment75. The 
country has only eight haemodialysis units and 10 nephrologists with a general population of 
approximately 50 million people. The treatments are costly: the cost for one dialysis session in 
Tanzania is about 179 US dollars. This means a person undergoing the recommended three 
times weekly HD sessions needs around 537 US dollars for the dialysis alone per week, 
excluding other related cost such as transport and medications. According to the Tanzanian 
Employment and Earning Survey of 2013, the average monthly wages were $147.79 and 
$340.67 for employees from private and public sectors respectively98,275. The high relative cost 
of treatment and therapies is likely to cause the majority of patients who start dialysis to 
discontinue the therapy or to experience inadequate therapy, so increasing the risk for early 
mortality due to uremic complications, comorbidities and malnutrition10. 
2.1.1 Nutrition in management of dialysis patients 
Malnutrition including muscle wasting is a common problem and of concern particularly 
among patients on dialysis3,93 owing to metabolic changes associated with uremic syndrome 
98,100,221, dietary restriction and protein losses on treatment276. The pathophysiology of PEW is 
described in section 1.3.1.  Malnutrition has been associated with poor treatment outcomes and 
increased mortality among ESRD and HD patients130,277. For this reason, it is of paramount 
importance for nutritional management to be provided in conjunction with dialysis for optimal 
treatment outcomes and to maximise patients’ quality of life. Dialysis patients need to have 
adequate energy (30 – 40Kcal/ kg/day) and protein (at least 1.2g/kg/day) intake, 131,135 and a 
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balanced intake of fruits and vegetable to supply them with important nutrients, minerals and 
dietary fibre whilst avoiding excess potassium. Optimal dietary practices and nutritional 
interventions have been found to improve the nutritional status278, uremic symptoms279, bone 
health 280 and haematological status 281,282 of HD patients.   
Nevertheless, the need to limit dietary phosphate and potassium is likely to compromise the 
food intake of these patients, increasing the risk of nutritional inadequacy283. Expert input from 
renal nutrition professionals/dietitians is therefore highly desirable to help patients meet their 
nutritional needs whilst maintaining their blood biochemistry within acceptable ranges.  
Based on practical experience there has been a consensus that there should be approximately 1 
registered renal dietitian per 100 maintenance dialysis patients, and that the ratio should not 
exceed 1:150284. A patient would expect to have a consultation with a dietitian in the pre-
dialysis (low clearance) period and immediately after starting dialysis, with frequent follow 
ups to assess the adequacy of the diet and ensure adequate nutrition. This does not happen in 
Tanzania. Currently there is no renal trained dietitian/nutritionist and few 
nephrologists/physicians, with those that are employed on the units already overburdened with 
other clinical roles and unlikely to have the time or expertise to provide comprehensive dietary 
advice and monitoring to HD patients. Although there are no nutritional data specific for renal 
patients, the undernutrition prevalence reported among young children (14%), adolescents 
(18%) and women of reproductive age (10%) in the country, as presented by USAID285 might 
give us an indication of what the situation is likely to be for those with renal disease.    
It is unfortunate that Tanzania, like many other African countries, lacks national registries to 
record the incidence, prevalence and general care and treatment outcomes of patients with renal 
failure. Such information is crucial not only for the evaluation of care practices and health 
outcomes of patients, but also for planning intervention programmes to improve patient care.  
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Set against this socio-economic and clinical background, this cross-sectional study observed 
the nutritional status and biochemical profile among adults with CKD and on HD in selected 
renal units in Tanzania and compared these, firstly with recommended standards and secondly 
with the  practices in a renal unit in the south of England.  
Table 2:2 represents the recommended standards for some of the study parameters taken from 
different available clinical practice guidelines. These were used as reference standards for 
comparison with the observed values from the study. 
Table 2:2: Recommended levels of the biochemical parameters in renal patients on haemodialysis and 
their reference sources  
Parameter 
(pre dialysis serum) 
Recommended  
Value/ranges 
Guideline sourced  
Albumin (g/l) 40286 EBPG on Nutrition: Guideline 2.1(F) 
Adj calcium (mmol/l) 2.2 – 2.5174 UKRA,CKD-MBD Guideline 2.2 
Sodium (mmo/l) 135 - 145287 NKF, Hyponatremia - web resources 
Phosphate (mmol/l) 1.1 – 1.7174 UKRA, Clinical guideline on 
Haemodialysis: Guideline 6.5 
Potassium (mmol/l) 4.0 – 6.0174 UKRA, Clinical guideline on 
Haemodialysis: Guideline 6.4 
Haemoglobin(g/l) 100 -120174 UKRA, Clinical guideline on 
Haemodialysis: Guideline 6.8 
EBPG = European Best Practice Guidelines on Haemodialysis; UKRA = U.K Renal association; CKD-MBD = Chronic 
Kidney Disease-Mineral bone disorders 
 
2.2 Aim and objectives 
2.2.1 Aim 
To characterise the nutritional status and biochemical profile of Tanzanian adults with CKD 
treated with haemodialysis and to compare these with recommended standards and with data 
from HD patients treated in the South of England. 
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2.2.2 Specific Objectives 
i. To develop a data collection proforma which incorporates the most relevant nutritional 
and biochemical parameters and indices of dialysis adequacy as well as demographic 
data. 
ii. To obtain permission from clinical leads at renal centres and relevant research 
committees in Tanzania and UK to conduct the study  
iii. To extract data on care, nutritional indices and health outcomes from retrospective 
records of HD patients in two selected renal units in Tanzania and records from satellite 
HD patients in a renal unit in the South of England.  
iv. To analyse and compare nutritional indices and treatment outcomes to recommended 
standards.  
v. To compare nutritional indices and measures of treatment outcome between patients 
managed in Tanzania and in the UK. 
2.3 Study design and methodology 
This study utilised data that were retrospectively extracted from patients’ clinical records at 
three time points, across three clinical settings in two countries. In the UK, this study was 
classified as an audit since no new data were collected apart from those in clinic records and 
for this reason, ethical approval was not required. In contrast, the Tanzanian clinic classified 
the study a research and therefore, the study went through the local ethics review process.  
2.3.1 Ethical considerations 
The study protocol was submitted to the clinics involved for review and approval. The study 
received approval from both Tanzanian clinics and the UK (See appendix 2 and 3 for Tz ethics 
certificate and UK approval letter respectively).  For confidentiality, clinical ID numbers or 
file numbers (for Tz) were used instead of names for patients’ identification.  
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2.3.2 Participants and recruitment strategy 
The study involved patients who had been receiving HD for at least six months in two dialysis 
clinics in Tanzania (Access and Muhimbili) and eight satellite units associated with one renal 
unit in the South of England (Queen Alexandra hospital) (assumed to be representative of UK 
HD management).  
For Tanzania (Tz), all patients that were receiving HD at the Access (n=45) and Muhimbili 
(n=51) renal units at the time of study were eligible for inclusion into the study.  
At the point of the study, 506 patients were receiving HD across the eight different satellite 
units of Queen Alexandra Hospital. A list of all satellite patients was obtained and every 5th 
patient in the list was selected to make up a desired sample size of 100 (comparable with the 
Tanzanian sample size). The total study sample were therefore 197 HD patients, chosen on the 
basis of time and resources. However, availability of data varied across different parameters, 
hence a total sample below 197 was returned for most parameters, with the Tz sample 
consistently having more missing data for the parameters investigated. 
2.3.3 Data collection 
Biochemical results were extracted for three consecutive months (over the preceding six month 
period) and were recorded from individual files retrieved from hospital databases. The 
proforma included the following biochemistry values that measure kidney function and 
treatment outcome: pre and post-dialysis serum creatinine and urea; pre-dialysis albumin, C-
reactive protein (C-RP), parathyroid hormone (PTH), bicarbonate, adjusted calcium, sodium, 
potassium, phosphate, haemoglobin (Hb). As standard procedure (to minimize confounding 
effect of patients’ hydration status) for both clinics, blood samples for monthly tests were 
drawn and analysed on the mid dialysis day of the week (i.e Wednesdays for those dialysing 
Monday, Wednesday and Friday;  and Thursdays for those dialysing Tuesday ,Thursday and 
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Saturday). Body mass index (BMI) was also recorded as a measure of nutritional status. 
Demographic data included age, sex, date of starting dialysis, eGFR and dialysis hours per 
week. The proforma used is presented in Appendix 4. 
2.3.4 Data management and analysis  
Data were entered into an Excel sheet at the point of collection and transferred to IBM® SPSS 
version 22 for analysis.  
Data were assessed for normality and descriptive statistics were performed. Data were then 
presented as percentages, means (SD) or medians (25th, 75th percentile) as appropriate. As data 
were not normally distributed, Friedman’s test was used to investigate differences in 
parameters across three time points and Mann Whitney U test for the differences between two 
settings at each time point. Chi-squared analysis was performed to assess the association 
between categorical variables, for example HD setting (Tz vs UK) and achievement of 
recommendations (above recommendations/ meeting recommendations/ below 
recommendations) for each of the parameters at measurement time point 3.  
Non-parametric data were transformed using the two-step transformation method described by 
Templeton288 to allow application of parametric statistics. The “mixed between-within subject” 
ANOVA also called split-plot ANOVA (SPANOVA) was then performed to study the 
combined effect of time and HD settings. SPANOVA was also used to study the effect of HD 
setting and gender on each parameter at measurement time point 3. 
Level of significance was set at p≤0.05 in all analyses.  
2.4 Results 
2.4.1 Demographic characteristics 
The study involved 197 patients (TZ, n = 96 and UK, n = 101). Male patients outnumbered 
female in both settings as seen in Figure 2:1. More than 60% of all patients were male.  
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                                         Figure 2:1: Distribution of study participants according to gender in the two HD settings 
The age of UK patients ranged from 26 to 89 years with a median (25th, 75th percentile) of 68 
(57, 78) years. There was no significant age difference between female participants (median 
(25th, 75th percentiles) = 68 (60, 78) years) or male (median (25th, 75th percentiles) = 68 (55, 
78) years), p = 0.7.  Unfortunately, the ages of Tz participants was not routinely recorded and 
so no cross-country age comparison could be made. At the time of this study all Tz participants 
were reported to be receiving a standard of 12 hours of dialysis per week whilst haemodialysis 
hours for UK participants ranged from 8 to 13 hours per week with a median (25th, 75th 
percentile) of 12 (12, 12).  
2.4.2 Comparison of biochemical parameters of Tanzanian and UK HD patients 
with recommended standards  
In this study, only eight parameters were available for direct comparison between UK and Tz 
counterparts. These were serum creatinine, urea, albumin, calcium, sodium, potassium, 
phosphate and iron, all of which were recorded at three time points. There are no recommended 
standards for serum creatinine or urea as these are measured and routinely monitored pre- and 
post-dialysis as a marker of dialysis clearance rather than for making comparisons with 
standards. 
2.4.2.1 Gender effect on studied biochemical parameters 
Descriptive statistics showed that the gender imbalance occurred irrespective of setting 
(figure 2:2). Split-plot ANOVA (SPANOVA) was then conducted to study if there was any 
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gender effect on each of the studies parameter across the three time points on a sample 
combining both UK and TZ patients. Results showed that there was no gender effect for any 
of the parameters except for serum creatinine and urea. Males had significantly higher urea 
and creatinine levels (figure 2:2(a) and (b) respectively). This was independent of time point. 
 
Figure 2:2: Split-plot ANOVA analysis results showing the effect of gender (male, n = 123; female, n = 74) 
across three time point measurements (month 1, month 2, month 3) on mean pre-dialysis (a) Urea, (b) 
Creatinine, (c) Albumin and (d) Phosphate levels. Two settings (Tz and UK) combined; The dotted lines show 
the recommended ranges for parameters according to the UK Renal Association guideline and European Best 
Practice Guideline on Nutrition; Error bar represent 95% Confidence Interval  
 
  
 
(d) Phosphate (c) Albumin 
(a) Urea 
                 
(b) Creatinine 
                                                                                                                                   
 
….RECOMMENDED RANGE 
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Figure 2:3: Split-plot ANOVA analysis results showing the effect of gender (male, n = 123; female, n = 74) 
across three time point measurements (month 1, month 2 and month 3) on mean pre-dialysis (a) Sodium, (b) 
Calcium, (c) Potassium and (d) Haemoglobin levels; Two settings (Tz and UK) combined; The dotted lines are 
the recommended ranges for parameters according to the UK Renal Association guideline and European Best 
Practice Guideline on Nutrition; Error bars represent 95% Confidence interval. 
2.4.3 The summary of biochemical parameter values at three time points and 
their comparison with recommended standards 
The median scores for most parameters, except for albumin and haemoglobin concentrations, 
were found to be within the recommended levels at all three measurement time points (table 
2:3). Haemoglobin concentration were significantly below the safe level for Tz HD patients at 
all three time points where as albumin levels were significantly lower than the required level 
for participants in both settings at all three time points (table 2:3).  
 
 
 
 
 
 
 
 
  
 
(b) Calcium 
(c) Potassium 
(a) Sodium 
….RECOMMENDED RANGE 
(d) Haemoglobin 
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Table 2:3: A summary of pre-dialysis biochemistry measures for U.K and Tz HD patients at three time points (month 1, month 2 and month 3) 
  Tanzania U.K   
Time 
point 
Parameter n median 25th , 75th  
percentile 
N median 25th , 75th  
Percentile 
Recommended 
range/value 
Source 
Mth 
1 
Creatinine (mmol/l) 78 797.1 578.0, 1078.3 98 664.0 500.2, 804.5 N.A  
Urea (mmol/l) 76 17.8 13.3, 22.3 98 16.4 12.3, 20.7 N.A  
Albumin (g/l) 59 39.0** 35.3, 41.9 98 32.5*** 29.2, 35.3 40 EBPG on Nutrition286 
Adj calcium (mmol/l) 72 2.2 2.1, 2.4 97 2.3 2.2, 2.4 2.2 – 2.5 UKRA, CKD-MBD guideline174 
Sodium (mmo/l) 78 135.0 132, 139 98 137 135, 139 135 – 145 NKF, Hyponatremia, web resources287 
Phosphate (mmol/l) 74 1.4 1, 1.8 98 1.5 12, 1.7 1.1 – 1.7 UKRA, Clinical guideline on HD114 
Potassium (mmol/l) 76 5.2 4.5, 6.0 97 4.9 4.4, 5.4 4.0 – 6.0 UKRA, Clinical guideline on HD114 
Haemoglobin(g/l) 78 82.0*** 75.7, 106.0 98 113.0 103, 121.3 100 - 120 UKRA, Clinical guideline on HD114 
BMI (kg/m2) N.A   101 26.2 23.1, 30.4 ≥ 23 EBPG on Nutrition286 
C-RP (mg/l) N.A   83 8 4, 27 < 5 NKF-KDOQI289 
Mth 
2 
Creatinine (mmol/l) 82 893.5 626.5, 1108.1 98 631.0 512.0, 794.3   
Urea (mmol/l) 81 18.5 13.3, 24.5 98 16.8 13.6, 20.1   
Albumin (g/l) 64 38.0*** 33.0, 40.8 98 32.5*** 29.0, 35.3   
Adj calcium (mmol/l) 75 2.1 2.0, 2.3 97 2.3 2.2, 2.5   
Sodium (mmo/l) 81 137.0 134.0, 139.0 98 136.0 134.0, 139.0   
Phosphate (mmol/l) 78 1.5 1.0, 2 98 1.5 1.2, 1.8   
Potassium (mmol/l) 80 5.2 4.5, 5.6 98 4.8 4.2, 5.3   
Haemoglobin(g/l) 87 81.2*** 68.0, 101.0 98 111.0 104.8, 120.3   
BMI (kg/m2) N.A   101 26 23, 30.5   
C-RP (mg/l) N.A   90 11.5 4, 20.3   
Mth 
3 
Creatinine (mmol/l) 87 860.0 637.0, 1201.0 98 662.5 526.8, 788.3   
Urea (mmol/l) 83 17.5 12.3, 24.6 98 16.6 13.6, 20.1   
Albumin (g/l) 67 37.0** 35.0, 41.0 98 33.0*** 29.0, 35.3   
Adj calcium (mmol/l) 79 2.2 2.0, 2.3 97 2.3 2.2, 2.5   
Sodium (mmo/l) 84 136.0 133.0, 139.0 98 136.5 135.0, 139.0   
Phosphate (mmol/l) 77 1.4 0.9, 1.9 98 1.5 1.2, 2   
Potassium (mmol/l) 83 4.7 4.1, 5.5 98 4.8 4.2, 5.2   
Haemoglobin(g/l) 92 81.1*** 69.9, 101.0 98 111.0 104.8, 121.0   
 BMI (kg/m2) N.A   101 23 23, 30.2   
 C-RP (mg/l) N.A   95 9 4, 21   
***significance difference between patients score and recommended value, P < 0.001,**significance at P < 0.01. One sample Wilcoxon signed rank test; N.A, data or value not available; 
EBPG = European Best Practice Guidelines on Haemodialysis; UKRA = U.K Renal association; CKD-MBD = Chronic Kidney Disease-Mineral bone disorders; NKF, National Kidney  
Foundation; HD, Haemodialysis; KDOQI = Kidney Disease Outcome Quality Initiative 
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2.4.4 The combined effect of time and HD settings – The mixed between and 
within analysis  
The split-plot ANOVA (SPANOVA) was conducted to study the combined effect of HD setting 
(Tz Vs UK) and time (at three time points) on the biochemical parameters. Results showed that 
there was a small but significant difference in urea and creatinine levels between the two HD 
settings, specifically that Tz HD patients presented with higher levels of urea and creatinine 
than their U.K counterparts (figure 2:6(a & b)).  
 
Figure 2:4: The combined effect of measurement time and HD setting for mean (a) urea and (b) creatinine 
levels according to SPANOVA analysis. Error bars represent confidence intervals 
There was no time or time-setting interaction effect on urea level but on creatinine a significant 
time effect was observed. The levels increased from time point 1 to time point 3. 
There was also a significant effect of HD setting on albumin (figure 2:7(a)) and potassium 
(figure 2:7(c)) levels, Tz HD patients had higher levels compared to UK patients.  There was 
no effect of time nor a time-setting interaction effect on albumin levels but a significant time 
effect on potassium (F (2,165) = 9.16, p=<0.001, partial ƞ2 =0.10) the levels decreased from 
time point 1 to 3. There was also a significant time-setting interaction effect F (2,165) = 4.5, 
p=<0.001, partial ƞ2 =0.012) on potassium. 
(b) Creatinine 
                                                                                                                                   
 
(a) Urea 
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There was no significant effect of HD setting on phosphate (figure 2:7(b)) or sodium (figure 
2:7(d)) levels. No time or time-setting interaction effects on phosphate levels were observed. 
Figure 2:5: The combined effect of measurement time and HD setting for mean (a) Albumin, (b) Phosphate, (c) 
Potassium and (d) Sodium levels according to SPANOVA analysis. Error bars represent confidence intervals 
 
However, a significant effect of time was seen although the direction of this effect was unclear 
(F (2,164) =4 .83, p=0.009, partial ƞ2 =0.06). There was also a significant time-setting 
interaction effect (F (2,164) = 6.43, p=0.002, partial ƞ2 =0.07). 
 
(a) Albumin  
 
(c) Potassium  
           
(b) Phosphate  
(d) Sodium 
     Recommended range 
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Figure 2:6: The combined effect of measurement time and HD setting for mean (a) Calcium, (b) Haemoglobin 
levels according to SPANOVA analysis. Error bars represent confidence intervals 
 
A significant effect of HD setting on calcium (figure 2:8(a)) and haemoglobin (figure 2:8(b)) 
levels was observed. There was no time or time-setting interaction effect on calcium levels. 
Similarly, the measurement time point had no significant effect on the haemoglobin levels, 
however there seem to be a significant time-setting interaction effect on haemoglobin levels 
(F(2, 170) = 19.404), p < 0.001, partial ƞ2 = 0.186). 
2.4.5 Proportion of patients within, below and above recommended standards 
by settings for time point 3 measurements 
Because there was no significant difference on parameters across three time points, data on 
time point three were used for subsequent analysis. Data were categorised into either below, 
within or above recommendation then statistical comparison was carried out between Tanzania 
and UK HD patients. 
2.4.5.1 Serum albumin 
When serum albumin levels were grouped according to recommended standards (within and 
below recommendations) and by setting, a high proportion of participants in each setting had 
(a) Calcium 
(b) Haemoglobin 
      Recommended range 
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albumin levels below recommendations. However, Tz participants were significantly better off 
as compared to their UK counterparts (X2 (1, n=165) = 24.28, p < 0.001) as the proportion of 
participants with acceptable serum albumin levels was higher (29.9% versus 2%) see figure 
2:4 (a))  
     
 
Figure 2:7: Proportion of participants at measurement time point 3 falling below, within and above the 
recommended levels for (a) Albumin and (b) Haemoglobin 
***significant association between setting and achievement of the recommendations P < 0.001, Chi-square test 
 
2.4.5.2 Haemoglobin 
Conversely, UK participants had significantly better haemoglobin status than Tz counterparts 
(X2
2 (2, n=190) = 68.58, p < 0.001).  
More than 71% of Tz participants were found to have haemoglobin levels below the 
recommended range while more than half (58.2%) of UK participants had levels within the 
recommended range (see figure 2:4(b)). The UK had also higher proportion of patients (26.5% 
Vs 3.3%) with Hb concentrations above the recommendations.   
(a) Albumin (b) Haemoglobin 
*** *** 
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Figure 2:8:Proportion of participants in Tz and U.K settings with below, within and above normal cut-off for 
(a) phosphate (b) Adjusted calcium, (c) potassium and (d) sodium at the third time point. 
*** Significant association between settings and achievement of recommendations P < 0.001; ** Significant 
association at P < 0.01; *Significant association at P < 0.05: Chi-square test.  
2.4.5.3 Phosphate 
The UK setting had a higher proportion of patients with phosphate levels within the normal 
range compared to Tz (49.0% and 32.5% respectively). The two settings had an almost equal 
proportion of patients (Tz: 33.8%, U.K: 34.7%) (see figure  2:5(a)) whose phosphate levels 
were above recommended standards. 
Although the difference in median phosphate level between the two settings was not significant 
(see table 2:4), when participants levels were classified according to recommendations (below, 
(a) Phosphate 
(c) Potassium (d) Sodium 
(b) Adjusted Calcium 
* 
*** * 
** 
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within and above), the association between settings and achievement of the recommendations 
was significant [X2 (2, n=175) =8.29, p=0.02] favouring UK HD patients. 
2.4.5.4 Adjusted Calcium 
Although the median calcium level of Tz participants was within the recommended level (see 
table 2:3) this was at the borderline and, when grouped, more than half (50.6%) of Tz 
participants had calcium levels below the recommended range. In comparison, more than half 
(66.3%, figure 2:5(b)) of all U.K HD participants had their adjusted calcium levels within the 
recommended range [X2 (2, n=176) =19.84, p < 0.001].  
2.4.5.5 Potassium 
Both settings had a high proportion of their patients with potassium levels within the normal 
range (see figure 2:5(c)). However, UK HD patients had a generally better status than Tz 
patients with a higher proportion having potassium levels within the normal range (U.K: 
82.7%, Tz: 66.3%) and a lower proportion with potassium above the recommended range (U.K: 
2.0%, Tz: 14.5%). 
Although the difference in the median potassium level between the two countries was not 
significant (see table 2:4), a significant effect of setting was observed when the levels where 
grouped according to recommended standards [X2 (2, n=181) =10.98, p=0.004] 
2.4.5.6 Sodium 
A high proportion of patients from both settings (U.K:85.7%, Tz: 76.2%) had their sodium 
status within the normal range (see figure 2:5(d)). The association between setting and sodium 
levels was not significant. [X2 (2, n=186) =3.612, p=0.16]. 
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2.5 Discussion 
This cross-sectional comparison study was carried out to observe nutritional status and 
biochemistry measures of adult chronic kidney disease patients receiving haemodialysis in two 
selected clinics in Tz and to compare these with outcome measures of satellite patients in one 
renal unit in the South of England (Portsmouth) which was taken as representative of the 
treatment given by UK renal units.  It was hoped that by identifying areas of potential dialysis 
and nutritional inadequacy in Tz and highlighting areas of best practice in the UK this work 
would inform the development of an appropriate and effective nutritional intervention for Tz 
HD patients.  
In this study, males outnumbered female patients in both clinics. This is consistent with 
findings of the international Dialysis Outcomes and Practice Patterns Study (DOPPS) 290 in 
which analysis of data from the national haemodialysis registries of ten developed countries 
(Australia, New Zealand, Canada, Japan, Belgium, France, Spain, Sweden, USA and UK) 
showed that male HD patients outnumbered female across different groups and across all 
regions despite the proportion of women being higher in the general population. The possible 
explanation for this could be the sex-specific distinctions that have been recognised in medical 
conditions (e.g. diabetes) that are co-existing or contributory factors to CKD. Specifically men 
have been found to have greater risk for diabetes291 and hypertension292 that are notably the 
leading causes for CKD development in these countries. This finding concurs with findings by 
Iseki293 and a nationwide survey of ESRD by the Japanese Society for Dialysis Therapy which 
also revealed a higher incidence and prevalence in men than in women294. The same survey 
also found that the mean age at the start of dialysis was higher in women than in men. This was 
replicated in the current study within the UK sample (age data not available for Tz) where the 
median age of women was slightly higher than men.  
Nevertheless, analysis showed that there were no gender effects on the biochemical profiles of 
the patients except for urea and creatinine which appeared to be higher in males than female 
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participants. This difference could be a reflection of gender differences in body muscle mass 
as males are known to naturally possess muscle mass than females295 and creatinine content is 
proportional to muscle mass. Males also tend to have a greater protein intake than females and 
the metabolic products of protein intake and muscle creatinine form urea and creatinine 
respectively. 
Despite similarities in the median dialysis duration that patients from the two countries 
received, serum creatinine and urea were higher in Tz patients as compared to UK patients 
across all three time points. This finding raises concern as to whether dialysis adequacy is being 
achieved by the Tz patients. K/DOQI (2001) recommended the use of Kt/V and URR (which 
indicate how much urea is removed during dialysis) values to assess dialysis adequacy. Kt/V 
is felt to be most accurate in assessing how much urea is removed during dialysis and apart 
from dialysis duration, it also depends on the rate at which the blood passes through the 
dialyser, which itself depends not only on qualities of the dialyser  but also on vascular access. 
This indicates that dialysis duration or frequency alone may not accurately determine dialysis 
efficiency, and hence possibly explain the findings of this study. Unfortunately, there was 
insufficient data to calculate URR and/or Kt/V in this study calls for further investigation to 
more accurately determine dialysis adequacy in Tz patients. The lack of appropriate data for 
dialysis adequacy raises a concern that clinical monitoring of patients dialysis adequacy might 
also be limited. High levels of creatinine and urea among Tz patients might also be related to 
diet. At the time of data collection, the clinic had no renal trained nutrition expert and this raise 
concerns on their nutritional management.  
Generally, the majority of patients had serum albumin levels within the recommended range. 
By setting, UK patients had significant lower median albumin level than Tz and had a higher 
proportion of patients whose serum albumin levels were below the recommend range compared 
to Tz HD patients. This suggests that, contrary to expectations, the Tz HD patients had better 
nutritional status. Another explanation could be the possible physiological differences due to 
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racial differences of patients in these two settings (i.e black in Tz Vs white in UK), which is 
likely to influence muscle mass and potentially influence differences in serum albumin 
levels296.  Similarly, serum creatinine, whilst a marker of kidney function and influenced by 
dietary protein, has also been reported to be a surrogate marker of muscle mass and nutritional 
status297. This could probably also be the reason for the observed higher creatinine levels in the 
Tz HD group. 
However, the efficacy of serum albumin in identifying malnourished patients, particularly in 
the absence of inflammation, has been questioned127 leading to recent criticism of this as a  
nutritional marker298.  Instead, low serum albumin has been strongly associated with 
inflammation216. UK patients also had high levels of C-RP (see table 2:4) which would again 
suggest  the existence of inflammation rather than malnutrition, a hypothesis which is further 
supported by their higher BMIs (see table 2:4) and which has been previously reported in this 
patient group by Beciragic et al.,299.  Unfortunately, data on C-RP and BMI for Tz patients 
were not available at the time of the study. It is therefore difficult to draw conclusions whether 
high albumin levels observed in the Tz patients were a reflection of nutritional status or not. 
Older age (> 65 years) was also found to be associated with hypoalbuminemia300. This could 
be another explanation for low albumin status observed in UK patients as their median age was 
68years, probably older than TZ patients as literature shows that in sub-Saharan Africa, CKD 
is prevalent in as young people 20 – 50 years old301.  
Although the median phosphate and calcium level of both TZ and UK patients were within the 
recommended standards, and SPANOVA analysis showed no significant effect of HD setting 
on the two markers, a higher proportion of UK HD patients had adequate phosphate and 
calcium status than TZ patients. This might be indicative of good bone turnover owing to better 
dietary practices and/or efficient use of phosphate binders. On the other hand, a high proportion 
of TZ patients were found to have calcium levels below the recommended range. The low 
calcium observed in Tz patients suggests dysregulation of calcium and phosphate, also raising 
60 
 
concern for active vitamin D status and PTH levels that are both involved in bone mineral 
homeostasis302,303. Moreover, according to the Tanzanian National Bureau of Statistics 
(2010)275, calcium intake of the general population in TZ in 2007 was 486mg/day. This is in 
contrast to the UK general population whose intake was reported to be 760 and 746 mg/day for 
men and women respectively during 2008 – 2009304 possibly explaining the difference in 
calcium status observed. This amount would be expected to be further reduced in HD patients 
due to dietary restrictions compounded by a lack of access to dietary services among those in 
Tz. Calcium, phosphate and PTH dysregulation (mineral bone disorders) in CKD patients have 
been linked with adverse health effects and mortality in this group of patients305.  
Generally, electrolyte levels (sodium and potassium) were satisfactory in the majority of 
patients. While there were disparities in sodium status between the two settings and across the 
three time points of measurements, potassium levels were significantly higher among Tz 
patients as compared to UK patients although arguably, the difference was not clinically 
significant. High potassium in HD patients is primarily related to poor dietary compliance, 
inadequate dialysis due to noncompliance or vascular access problems, medications such as 
ACEIs, potassium sparing diuretics, non-selective beta blockers, NSAIDs, and unfractionated 
heparin use306.  Although the specific causes of the high/ low potassium levels seen in this 
study could not be elucidated, for Tanzania cohort, the high levels are likely to be contributed 
by dialysis inadequacy coupled by poor dietary compliance. 
Tz patients were more likely to have sub-optimal haemoglobin levels compared to their UK 
counterparts. Their average Hb level was significantly lower and the majority (75%) had 
haemoglobin concentration below the recommended level. Anaemia is not uncommon in CKD 
patients due to insufficient erythropoietin (EPO) production from the failed kidneys87, 
however, the use of erythropoiesis-stimulating agents (ESAs) and intravenous iron injections 
should help to treat anaemia and reduce the need for blood transfusion in this group281. 
Nonetheless, Costa et al.,193 found an inadequate response to ESA in up to 10% of patients 
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despite the use of the correct dose and this might also be the case for Tanzanian patients. 
However, presence of anaemia in such a large proportion of patients likely indicates multiple 
contributory factors including sub-optimal dosage or non-compliance with EPO therapy (due 
to financial constraints), iron deficiency, vitamin D deficiency or resistance307 and 
inflammation308. Future work will focus on exploring and quantifying the relative contributions 
of these factors in this specific population to inform management.  
2.6 Study limitations 
There were limited data available from Tz HD patients for comparison with UK counterparts 
limiting the analysis that could be performed since a number of the variables of interest (e.g C-
RP, ferritin, bicarbonate) were not routinely measured or recorded in the Tz setting. Instead, 
these are performed as investigatory tests when clinically indicated. This not only limited data 
available for this research study, but is also likely to limit internal clinic’s audits and standard 
of care received by patients. 
In addition, because the study involved two different country settings with different laboratory 
facilities and technology, the potential confounding effect of differing assay methodology 
cannot be ruled out. 
2.7 Conclusion and recommendations 
Although there was limited biochemical data from Tz HD patients, for most of the parameters 
for which data was available, UK patients had better status, suggestive poorer health status 
and/or sub-optimal care for Tz HD patients. Haemoglobin levels were particularly low in TZ 
patients, raising concerns about the adequacy of their management and highlighting the need 
for further research to establish the cause of, and therefore the most appropriate interventions 
for this issue.  
It is recommended that the clinic considers including a wider range of biochemical tests in their 
monthly monitoring in particular inflammatory markers (C-RP) and ferritin for optimal patient 
care. Record keeping of basic demographic data like age and BMI should also be strengthened.  
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2.8 Future work 
The next stage of the research will include areas of clinical practice and treatment outcomes 
that were not within the scope of this initial study e.g EPO utilization, iron therapy, dietary 
intake, and inflammatory markers to build a more complete picture of the pathways leading to 
sub-optimal outcomes in Tanzanian adults with ESRD on HD. 
An in-depth investigation to ascertain the causes of the biochemical and nutritional 
inadequacies noted in this study is also required, specifically haemoglobin status in Tz patients; 
and albumin levels of UK patients to enable interventions to be planned to tackle these issues. 
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CHAPTER 3 
3 DIETARY INTAKE, NUTRITIONAL STATUS, BODY 
COMPOSITION AND UNDERLYING FACTORS FOR LOW 
HAEMOGLOBIN LEVELS IN TANZANIA 
HAEMODIALYSIS (HD) PATIENTS ON 
ERYTHROPOIETIN TREATMENT 
 
3.1 Introduction and rationale for the study 
The previous cross-sectional study (Chapter 2) revealed that the majority (75%) of Tanzanian 
haemodialysis (HD) patients assessed had haemoglobin levels below the acceptable range 
(mean Hb level being 81.5g/l). However, as discussed earlier on in chapter 1, anaemia is not 
uncommon among ESRD patients owing to the inadequate production of erythropoietin (EPO) 
hormone by the failed kidneys87 and/ or iron deficiency due to low intake and/or  impaired iron 
metabolism 154,169. For this reason, injectable EPO and iron supplementation are central to the 
treatment and management of anaemia and form an essential part of patients’ management. 
The status of Tanzanian HD patients is of concern as their haemoglobin levels were persistently 
low despite them being on erythropoietin hormone therapy. This was in contrast to the UK HD 
patients sampled where more than half of the group had haemoglobin levels within the 
recommended range.  
The condition whereby patients persistently fail to achieve the target haemoglobin level despite 
them being on an apparently correct dose of EPO is called EPO resistance/hyposensitivity 
193,194. The condition is relatively common and leads to unfavourable health outcomes such as 
increased cardiovascular morbidity, disease progression and all-cause mortality 160,195,196. 
Response to EPO is variable and can be modified by several factors. Iron deficiency155, 
malnutrition200,  inflammation309, mineral bone disorders203 and dialysis inadequacy310 among 
others are described to be modifiers of EPO responsiveness and hence anaemia management 
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in patients with renal failure. The detailed account of the proposed mechanisms behind EPO 
hyposensitivity are covered in section 1.3.2.4. 
Tanzania, like any other developing country of the sub-Saharan region, has limited resources 
(human and financial) which are likely to impact on the quality of care services available and 
on the patient’s access to adequate care (including adequate dialysis, anaemia management 
therapies and dietary care). The previous cross-sectional work carried out in Tanzania relied 
on clinic data that were limited in most parameters and it was therefore not possible to ascertain 
what could be the possible causes for the low response to EPO. 
This follow-on study therefore investigated more systematically the presence of the known 
aetiological factors of anaemia in ESRD, such as poor diet, inadequate nutritional status, raised 
inflammatory markers, dialysis inadequacy, impaired bone health, inadequate dosage of 
erythropoietin stimulating agents (ESAs) and iron therapies, and to studied their relative 
contribution to low Hb levels in the Tanzanian HD population. .  
The findings will help inform the care practices for this patient group and, in particular to 
identify the key monitoring and intervention strategies that could facilitate better diagnosis and 
management to optimise EPO response.  
3.2 Aim and Objectives 
3.2.1 Aim 
To investigate the contributory factors to low haemoglobin concentration among Tanzanian 
haemodialysis patients on erythropoietin maintenance therapy.  
3.2.2 Objectives of the study 
1. To recruit adult haemodialysis patients, that are on ESA therapy and with sub-optimal 
haemoglobin concentration from a major dialysis unit in Tanzania 
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2. To investigate dietary intake of iron, nutritional status and body composition, inflammatory 
markers and bone health of Tanzanian HD patients on ESA therapy and compare with 
recommended standards. 
3. To investigate the association between dietary intake, inflammatory markers, body 
composition, bone health and haemoglobin status of HD patients on ESA therapy 
4. To make practical recommendations to optimise the management of low Hb and anaemia 
in Tanzanian HD patients. 
3.3 Methodology 
3.3.1 Study design and study participants 
The study adopted an observational cross-sectional design and was conducted at the 
nephrology unit of the Muhimbili National hospital in Dar es Salaam, Tanzania. It involved 
adult (aged ≥ 18 years) patients who had been receiving HD maintenance therapy for at least 
three months at the time of the study. The study included patients who had Hb concentration 
less than 100g/l and were on ESA therapy. Participants with no capacity to consent or those 
critically ill were excluded from the study. The study also excluded participants with recent 
blood transfusions, malignancies or tumours or haematological disorders e.g sickle cell 
anaemia. 
3.3.2 Ethical consideration 
The study protocol received a favourable opinions from the Muhimbili research and publication 
committee on 20/07/2016, MNH/IRB/1/2016/21 (see appendix 5 for ethics certificate).  
A list of potential participants was obtained from the clinic personnel, who were then 
approached and provided with detailed information on the project (appendix 6) and invited to 
participate in the study. Only participants who provided written consent (appendix 7) were 
recruited into the study. For confidentiality, all recruited participants were assigned with an 
unique study ID code which were used instead of individual names throughout.   
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3.3.3 Sample size 
The target sample size for the study was 94 participants. The sample size was derived by using 
the formula for the sample size for the population mean described by Charan and Biswas311 
and presented below.   
𝑛𝑜 =
𝑧2𝜎2
𝑒2
 
Where: 
no = sample size  
z = the abscissa of the normal curve that cuts off an area at the tails 
e = the desired level of precision (in the same unit as variance) 
σ2= the variance of the attribute in the population 
The attribute of interest/primary outcome was Hb, the mean was obtained from the previous 
cross-sectional study findings (chapter 2) specifically 81.5g/l (SD =19.24), variance (SD2) is 
therefore 370.18g/l; desired level of precision is 5% (in variance units = 4.27g/l) and z = 1.96 
𝑛𝑜 =
1.96219.242
4.272
 
𝑛𝑜 = 77.9 ≈ 78 
20% (i.e. 16) was added into the sample to account for drop out. This makes a total sample size 
of 94. 
3.3.4 Data collection 
Participants were visited whilst receiving dialysis and interviewed to collect personal data 
including age, comorbidities and medication/therapy use. Their dietary intake and nutritional 
status were assessed, and blood tests performed. The proforma used for data collection is 
presented in appendix 8.  
3.3.4.1 Dietary intake assessment and estimation 
Patients were interviewed to assess their habitual food intake using a food frequency 
questionnaire (FFQ) adopted with modification from Beck at al.312. This is the FFQ that was 
designed and validated by the named author for assessment of dietary iron in New Zealand. To 
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adapt it for a Tanzanian settings, some food items included asked in the original FFQ but not 
available in Tanzania were omitted and replaced with local foods known to be a source of iron. 
The copy of the adapted questionnaires is presented in appendix 10. Patients were interviewed 
regarding the intake frequency of intake of different foods across a one month period. Food 
intake was rated as: never eaten, eaten less than once/month, 1 to 3 times/month, once a week, 
2 to3 times/week, 4 to 6 times/week, once/day, 2 to 3 times/day, 4+ times/day.  
More detailed information on the whole diet was also collected using the multiple pass 24 hour 
recall method (MPR) on three days of the week (dialysis day, weekend non-dialysis and 
weekday non-dialysis day). The diet record sheet used is presented in appendix 9. A 
photographic atlas of food portions from the Abu Dhabi Food Control Authority313 was used 
to guide patients’ estimation of their portion sizes (in grams). Where a particular food items 
was not present in the atlas book, a similar looking food alternative was used as a guide, then 
a researcher would prepare the missed food into a portion identified and weigh using a kitchen 
scale. Standard portion sizes and recommended intakes for dialysis patients were estimated 
with the help of NKF web resource314 on dietary guidelines for haemodialysis patients and the 
South African renal diet guide cited by Ameh et al.315 The mean daily energy and nutrient 
content of all foods consumed over three days were then estimated for each participant, using 
a local Tanzanian food composition table compiled by Lukmanji et al.316.  
3.3.4.2 Nutritional status and body composition 
Measurements of nutritional assessment were body dry weight, body height, mid arm 
circumference (MAC), triceps skinfold thickness (TSF), supra-iliac skinfold thickness (SSF), 
hand grip strength (HGS), lean mass (LM), fat mass (FM), % total body fat and Body Mass 
Index (BMI).  
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MAC was measured using non-stretchable measuring tape (®Seca) on the right arm whilst TSF 
and SSF were measured using Harpenden skinfold calliper.  Mid Arm Muscle Circumference 
(MAMC) was then calculated using the standard formula: 
MAMC = MAC (centimetre) − 3.14 × TSF (millimetre)/10317.   
Body height was measured using a column weight scale with height rod attached (Seca 755, 
USA). For convenience, all anthropometric measurements (except body weight) were 
measured before dialysis when patients were measuring their pre-dialysis body weight.  
Body weight, % total body fat and BMI data were obtained after dialysis using a portable 
bioimpedance analyser BIA (BF508, Omron Healthcare Co. ltd. Kyoto, Japan).  
Lean mass and fat mass were then calculated from body weight and % body fat data using the 
formula:  
Fat mass = % Body fat * Body weight; Body weight = Lean mass + Fat mass318. 
Hand grip strength was measured using a digital dynamometer (Takei 5401, Takei Scientific 
Co. ltd, Japan) before starting dialysis.  Subjects stood in a steady position holding the 
dynamometer with their non-fistula arm and gripped hard whilst the arm was down on the side 
of the body. Three measurements were taken from each participant and the average recorded. 
3.3.4.3 Biochemical profile 
Monthly bloods were collected as part of routine care before and after dialysis (on mid week 
dialysis day) and analysed within the hospital laboratory for: pre and post dialysis serum 
creatinine and urea; pre-dialysis serum albumin, C-reactive protein (C-RP), calcium, 
phosphate, total iron, ferritin, total iron binding capacity and haemoglobin concentration as per 
clinic standards. Results were then retrieved from the electronic clinic database.  At the time 
of this study, analysis of Intact Parathyroid hormone (iPTH) was not carried out as a routine 
measure. Therefore an extra sample (5mls) of pre-dialysis blood was collected in a serum 
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separating tube (SST) tube and immediately sent to an external laboratory for processing and 
analysis.  
3.3.4.4 Erythropoietin (EPO) response 
EPO resistance Index (ERI) was used as an indicator of patients’ response to the therapy and 
was calculated using the following formula:  
𝐸𝑅𝐼 =  
𝐸𝑃𝑂 𝑤𝑒𝑒𝑘𝑙𝑦 𝑑𝑜𝑠𝑒 
𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)⁄
𝐻𝑎𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 𝑐𝑜𝑛𝑐(𝑔/𝑑𝑙)
  
The formula takes into account the EPO weekly dose adjusted to the patient’s weight and 
expressed in relation to their haemoglobin concentration319. 
3.3.5 Data management and statistical analysis 
Anonymized data were entered into a password protected excel spreadsheet. Data were then 
exported to IBM®SPSS (version 22) for statistical analysis. Nutrient data were checked for 
normality then descriptive statistics performed to calculate each participant’s mean (SD) or 
median (25th, 75th) intake over their 3 days of records. Results were then grouped according to 
intakes recommended by National Kidney Foundation314 and percentage of patients with intake 
below and above the recommendation was computed. Mann-Whitney U-tests and T-tests were 
used to compare the intakes between males and females and bivariate correlation analyses were 
performed to study the association between variables and age.  
All biochemical parameter data that were not normally distributed were transformed using the 
two step inverse transformation method described by Templeton288 to allow application of 
parametric statistics. Bivariate correlational and multiple regression analysis were then 
conducted to ascertain the determinants of haemoglobin concentration and other markers of 
iron status.   
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3.4 Results 
3.4.1 Sample size and recruitment  
The following flow diagram (figure 3:1) shows the recruitment process of the study. Out of 
140 HD patients present in the clinic during the study period, 77 patients were recruited, which 
was below the target sample size of 97. For some parameters the sample was smaller due to 
missing tests/ data. 
 
 
 
 
                                            
                                                    Eligible to participate 
                                                                          N=120 
 
Figure 3:1: A flow diagram of sample recruitment process for study FFQ, Food frequency questionnaire; FD, 
Food diaries 
3.4.2 Demographic characteristics 
The median (25th 75th percentile) age of respondents was 49 (43, 56) years and males 
outnumbered females (figure 3:2(a)). The primary comorbidities present were hypertension 
and diabetes, independently or together (figure 3:2(b)). 
Total number of patients 
at the HD unit 
                N = 140 
Consent participants 
n = 77 
Completed FFQ 
n = 50 
Completed FD 
n = 38 
Available biochemical profile data 
n = minimum 50 (Urea); maximum 74 
(iPTH) 
Declined participation 
n = 43 
 
 
- Missing biochemistry data (n = up to 27) 
-Declined FFQ (n = 27) 
- Declined FD (n = 39) 
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Figure 3:2: (a) Gender distribution of participants and (b) frequency of comorbidities reported by study 
participants 
3.4.3 Dietary intake of participants 
3.4.3.1 Average consumption of selected foods   
A total of 50 participants completed food frequency questionnaires and 38 participants 
completed their food diaries (38 completed both dietary assessment tools). The diets were 
predominantly starch (including cereals, grains, roots and tubers), consumed 2 – 3 times/week 
with portion estimates equivalent to 500gm per day (table 3:1). Rice and maize meal/stiff 
porridge (Ugali) were the most frequently consumed starch dishes (consumed by 83 and 87% 
of respondents respectively, figure 3:3).  Cassava, potatoes and green bananas were the least 
consumed starchy dishes, reported to be consumed by less than 5% of the participants.  
Nevertheless, starch consumption for all participants was below the NKF recommendation and 
as a consequence they had low total energy intake (table 3:1). Analysed by gender, male 
participants consumed more portions of starchy food products compared to their female 
counterparts (median (25th, 75th percentile) = 4.3(4, 5.5) vs 3.5 (2.6, 4.5); p = 0.036 Mann-
Whitney test). This difference was however not significant when corrected for energy intake 
(expressed per 1000kcal), p = 0.85. 
 
 
Hypertension
33%
Diabetes
1%
Hypertension + 
Diabetes
26%
None
40%
(a) Gender distribution  (n= 77) (b) Comorbidity frequency (n= 77) 
male
57%
female
43%
72 
 
Table 3:1: The average portion size intake for selected foods by the studies participants presented as 
daily consumption and proportion of participants whose intake fall below and within NKF 
recommendation. 
Food type/group 
(measurements in serving/ 
portion and gram) 
Median 
consumption 
frequency  
Daily median 
(25th,75th 
percentile) gram  
% (n) above and 
below 
recommendations 
Recommended daily 
serving/portion by 
NKF314/Ameh et al.315 
Below Within 
MFP & eggs 
1 portion = 90 – 140g 
Once/day  113 (50,167) 88(30) 12(4)  8 - 10 oz  
(230 – 285g) 
Red meats 
1 portion = 90 g 
Less than 
once/month  
0 (0, 14) - -  N.A 
Fish 
1 portion = 140 g 
4 – 6 /week  27 (0, 112) - - N.A 
Poultry 
1 portion = 90g 
2 - 3 /week 5 (0, 40) - - N.A 
Vegetables 
(1 portion =1/2 cup =75g) 
2 – 3/day 76 (0,156) 74(25) 27(9) 2–3 / 4 
 
Fruits  
 (1 portion =1/2 cup= 1 
small fruit) 
4 – 6 /week 1 portion  (0, 2.5) 59(20) 41(14) 2–3 / 3 
 
legumes and nuts 
(1 portion = 150g) 
2 -3/week 0 (0, 89)    N.A 
Starches (Cereals, grains, 
roots and tubers) 
1 portion = 1 cup =200g 
2 – 3/day 508 (359, 617) 100(34) 0 6-11 / 8 
Dairy products (fresh milk 
& yoghurt)  
(1 portion = 1/2 cup = 
125mls) 
4 - 6/week 9 (0, 155)mls 73(24) 27(9) 1  
 
MFP = Meat, fish and poultry; NKF = National Kidney Foundation: N.A = No recommendations given by NKF 
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Figure 3:3: Different types of (a) starch staples (b) protein and (c) vegetables that were commonly consumed 
during the study period. The bars indicate the percentage of participants reporting consumption of each 
particular food type.  
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Participants consumed on average half of the recommended intake of animal protein foods per 
day. Only 12% (n=4) of participants met the recommendations for animal protein (table 3:1). 
Red meats (liver, beef and pork) were reported to be rarely consumed in the study period (table 
3:1 & figure 3:3 (b)). Fish was the most frequently consumed among the animal protein foods, 
reported to be consumed by 62% (n=24) of participants, on average 4 - 6 times/week but in 
very small quantities equivalent to 27 g/day (table 3:1 & figure 3:3(b)).   
Although males participants appeared to consume more portions of animal protein than their 
female counterparts (figure 3:4), this difference was not significant (p=0.54, Mann-Whitney 
test). 
 
 
 
 
 
 
 
 
 
The majority of participants had intakes of fruits and vegetables below the recommendation 
(58.8%, n=20 and 73.5%, n=25 respectively) (table 3:1). Participants reported to consume an 
average of 1 portion each per day of fruits and vegetables (table 3:1).  However, fruits were on 
average more frequently consumed (4 to 6 times/week) than vegetables (2 – 3/week). 
Cucumber and cabbage were vegetables reported to be consumed by the greatest percentage of 
Figure 3:4: Consumption of different food types (colour coded) by female and male participants. The 
circles represents mean number portions consumed and the lines above and below the circles 
represent 95% confidence intervals. 
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respondents (32%, n=12) whereas African eggplant, cassava leaves and tomatoes were less 
frequently reported (3%, n=1).  
The fruits reported to be consumed most frequently were watermelon and apples (21%, n=8) 
and the least frequently consumed fruits were banana and oranges (3%, n=1) (figure 3:3(c).  
Females had a significantly higher consumption of fruit than their male counterparts (figure 
3:4; p = 0.008, Mann-Whitney test). Vegetable consumption was also higher in females than 
males, however this difference was not statistically significant (p = 0.183, Mann-Whitney test). 
3.4.4 Dietary intake, nutritional status and their association among the study 
participants 
The majority of patients had protein and energy intakes below the NKF and UK Renal 
Association recommendations (table 3:2). Males had slightly higher median intakes of total 
protein, (median (25th, 75th percentile) = 0.7g/kg/day (0.5, 1.1)) Vs female: 0.5g/kg/day (0.4, 
0.9) and energy, (male: 27.2kcal/kg/day (22, 31.4) Vs female: 21.8kcal/kg/day (17.2, 30.8)). 
However, Mann-Whitney tests showed that the differences were not significant for either total 
protein or energy intake (table 3:3).  
Table 3:2: The average intake of energy and selected nutrients, nutritional status and proportion of 
participants falling outside the recommended range for dietary intake and nutrition status for adults 
patients in Tanzania (n = 38) 
Parameter Recommendation 
 
Median(25th,75thpercentile)/ 
Mean(±SD) 
%(n)below 
recommendation 
%(n)within 
recommendation 
Protein 
(g/kg/d) 
≥ 1.2131,135 0.6 (0.5,0.9) 87.2 (34) 12.8 (5) 
Energy 
(Kcal/kg/d) 
≥ 35131,135 24.4 (18.4, 30.8) 87.2 (34) 12.8 (5) 
Total iron 
(mg/day) 
Male ≥ 8mg 
Female ≥ 12mg 
7.2(5,10) 
6.3 (5, 9) 
64.7 (11) 35.3 (6) 
84.0 (21) 16.0 (4) 
BMI (kg/m2) ≥ 23150 23.1 (20.4,26.4) 49.2 (30) 50.8 (31) 
Albumin (g/l) ≥ 40150 36 (34,39) 80.0 (56) 20.0 (18.2) 
HGS (kg)320  Male > 30 
Female > 20 
Male=25.4(±9.8)  
Female =16.1(±5.5) 
71.9 (23) 
74.1(20) 
28.1(9) 
25.9(7) 
MAMC (cm) N.A 23.7 (±3.1) N.A N.A 
BMI = Body mass index; HGS = Hand grip strength; MAMC = Mid arm muscle mass; N.A = no recommendations 
Nutritional status, as indicated by BMI, was border line for the cohort overall and albumin was 
not satisfactory as the majority of participants had levels below the acceptable range. Mean 
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HGS was also at the lower acceptable range according to the Consensus Definition of 
Sarcopenia Among Older Adults proposed by the European working group320 (table 3:2). 
Male participants had significantly higher albumin (median (25th, 75th percentile) = 39g/l (35.5, 
40) male Vs 34g/l (32, 37) female; p= 0.001, Mann-Whitney), however, this difference was not 
significant when albumin levels were corrected for BMI (p = 0.17). HGS was significantly 
higher among males (p < 0.001, T-test) even after adjusting for their BMI (p < 0.001, T-test).  
Although MAMC appeared to be higher among males as compared to females (mean (SD) = 
24.3cm (±2.6) male Vs 22cm (±3.5) female), this difference was not significant (p= 0.099) 
even after adjusting for BMI levels (p= 0.43). The BMI of male participants was also higher 
than their female counterparts, but this was not statistically significant (median (25th, 75th 
percentile) = 23.9kg/m2 (21.4, 25.9) male Vs 22.1 kg/m2 (27.2, 19.1) female; p = 0.43).  
There was no association between age and any of the studied parameters of dietary intake or 
nutritional status with the exception of HGS, which was found to decrease with aging (r=-0.35, 
p=0.019), and energy intake, which also decreased with age (r=-0.31, p = 0.064) (table 3:3).  
Table 3:3: Effect of gender and age on dietary intake and selected indices of nutrition status in 
Tanzanian HD patients (n = 38) 
aMann-Whitney test; b T-test; cSpearman correlation analysis; MAMC = Mid arm muscle circumference; BMI = 
Body mass index 
Parameter Gender cAge 
 Female Male p r p 
Dietary intake      
Protein (g/kgwt/day) 0.53 (0.4, 0.9) 0.69 (0.6, 1.1) a 0.20  -0.12 0.496 
Energy (g/kgwt/day) 21.8 (17.2, 30.8) 27.2 (22.9, 31.4) a 0.16 -0.31 0.06 
Total iron intake (mg/d) 6.3 (4.7, 9.2) 7.2 (5.4, 9.8) a 0.62 -0.19 0.238 
 
Nutritional status      
Albumin (g/l) 34.00 (32.0,37.0) 38.5 (34.8, 40.0) a 0.002 0.06 0.676 
MAMC (cm) 22.96 (±3.5) 24.33 (±2.6) b 0.09 0.02 0.897 
BMI kg/m2 22.10 (19.1, 27.2) 23.90 (21.4, 25.9) a 0.43 0.15 0.311 
Hand grip strength (kg) 16.14 (±5.5) 25.37 (±9.8) b <0.001 -0.40 0.007 
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Although there was no association between total energy or total protein intake with BMI and 
serum albumin or muscle mass (data not shown), Spearman correlation analysis showed that 
hand grip strength significantly increased with an increase in total protein and energy intake 
(figure 3:5 a & b). This association remained significant when energy intake was adjusted for 
individuals body weight (r= 0.373, p=0.025) but disappeared when protein intake was adjusted 
for body weight (r= 0.214, p=0.210).  
 
 
 
 
 
 
 
 
 
 
Figure 3:5: Correlation between hand grip strength and (a) total protein, (b) energy intake in Tanzanian 
haemodialysis patients (n=36) 
 
3.4.5 Inflammation, bone mineral health and iron status  
The median of C-RP level was far above the recommended level (table 3:4), and more than 
half of patients (58.5%, n=38) had C-RP above the recommendations (figure 3:6). C-RP levels 
did not differ between genders (p = 0.117) or by age (r = -0.12, p = 0.417). 
Calcium levels were generally below the UK-RA recommendation as more than 70% of 
participants had calcium level below the recommendations (figure 3:6). Although the average 
phosphate level was within the UK-RA guidelines there was a trend towards low phosphate 
since the almost half of the patients (47.2%, n=34) had a phosphate level below the NKF-
K/DOQI recommendation. There was also a small proportion of patients (15.3%, n=11) whose 
phosphate was above the desirable level (figure 3:6). 
(b)  (a)  
(a) Protein (b) Energy 
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Table 3:4: Biochemical profile of participants and the recommended reference range for the studied 
parameters 
 
Variables 
 
 
Median(25th,75thpercentile)/ 
Mean (SD) 
 
N 
 
Reference range 
 
Reference source 
C- RP  
(mg/l) 
6.1  
(3.2, 16.9) 
62 < 5 NKF-KDOQI289  
Hb (g/l) 87.1 (±16.7) 62 100 – 120 UK-RA321 
Ferritin  
(ng/ml) 
151 
(53.7, 283.6) 
 
62 
  
200 -500  
 
UK-RA180 
Serum iron 
(µmol/l) 
9 (6, 12.5) 67 11 – 31 
 
 
Daugirdas, 2011 
(Handbook of CKD 
Management)322 
%TSAT 17.9 (±8) 43 > 20%, 20 – 50 % MNH Laboratory 
iPTH  
(pg/ml) 
125.2  
(81.6, 183) 
 
74 
150 – 300  NKF-KDOQI323  
2-9 X upper local range KDIGO324 & UK-RA174 
Calcium 
(mmol/l) 
2.1 (2, 2.2) 71 2.2 – 2.5  UK-RA174 
Phosphate 
(mmol/l) 
1.2 (±0.5) 72 1.1 – 1.7 UK-RA321 
URR 66.9  
(56.5, 77.3) 
50 > 65 UK-RA321 
Creatinine 
(mmol/l) 
812 ( 538, 1099) 73 N/A  
C-RP = C-reactive protein; TSAT = Transferrin saturation; iPTH = Intact Parathyroid hormone; URR = Urea 
reduction ratio; UK-RA= UK Renal Association; KDIGO = Kidney Disease – Improving Global Outcomes; NKF-
K/DOQI = National Kidney Foundation – Kidney Disease Outcome Quality Initiative; MNH = Muhimbili 
National Hospital 
 
The median iPTH was within the recommended level of the UK-RA, NKF-K/DOQI and 
KDIGO guidelines. However, according to the KDIGO and UK-RA guidelines, a high 
proportion of patients (66.2%, n=49) had iPTH levels below the reference range. There was no 
gender difference or effect of age on calcium, phosphate or iPTH levels (table 3:5).  
 
Figure 3:6: Proportion of patients falling outside the normal range for the studied biochemical parameters 
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Patients’ Hb levels were exceptionally low (table 3:4) and the majority of patients (76.5%, 
n=48) had Hb levels below the recommended range (figure 3:6). Slightly higher (but 
statistically insignificant) Hb concentrations were observed among male participants compared 
to their female counterparts (mean (SD) = 88.3g/l (16.3) male Vs 85.5g/l (17.2) female; p = 
0.5). The median serum iron level was also below recommendations and the majority of 
patients (68.7%, n=46) had iron levels below the range of 11 – 31μmol/l  recommended by 
Daugirdas322 in the Handbook of CKD Management (table 3:4 & figure 3:6). The median 
ferritin level was within the recommended range as per UK reference ranges (table 11). 
However, more than half (59.4%, n=38) had ferritin levels below the lower recommended cut 
off (figure 3:6). The mean %TSAT was below the recommendation and a high proportion of 
patients (62.8%, n= 27) had their %TSAT below the recommendation (<20%) (table 3:4 & 
figure 3:6).  
Table 3:5: Effect of gender and age on, selected indices of nutritional status and other biochemical 
parameters in Tanzanian HD patients  
C-RP = C-reactive protein; URR = Urea reduction rate; TSAT = Transferrin saturation; iPTH = Intact Parathyroid hormone; 
aMann-Whitney test; bT-test; Significance = p < 0.05 
 Gender Age 
Biochemistry n Male n Female p r p 
Haemoglobin 
(g/l) 
35 88.29 (±16.3) 28 85.54 (±17.2) b0.519 -0.004 0.979 
Iron (μmol/l) 35 10.80 (7,7, 14.0) 32 7.00 (4.7, 10.1) a0.001 -0.216 0.141 
Ferritin (μg/l) 35 207.86  
(101.4, 308.4) 
27 78.98  
(37.9, 227.6) 
a0.02 0.081 0.598 
TSAT (%) 24 17.99 (±5.5) 19 17.89 (±10.5) b0.969 -0.35 0.049 
Calcium 
(mmol/l) 
39 2.06 (1.9, 2.2) 32 2.1 (2.0, 2.2) a0.51 0.21 0.157 
Phosphate 
(mmol/l) 
40 1.19 (±0.4) 32 1.1(±0.5) b0.456 -0.209 0.154 
iPTH (pg/ml) 40 127.45 
(88.9, 167.6) 
33 122.80  
(52.2, 208.6) 
a0.37 -0.25 0.08 
Creatinine 
(mmol/l) 
41 968.40  
(677.2, 1267.8) 
32 593.25  
(392.9, 993.5) 
a0.006 -0.38 0.008 
URR (%) 29 62.73 (±15.8 ) 21 73.3 (±13.5) b0.02 0.06 0.737 
C-RP (mg/l) 35 6.1 (2.4, 14.7) 27 6.1 (4.2, 46) a0.12 -0.12 0.417 
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Males had significantly higher median (25th, 75th percentile) ferritin (208μg/l (101, 308) male 
Vs 79μg/l (38, 228) female) and serum iron levels (11μmol/l (8, 14) male Vs 7μmol/l (5, 10) 
female) than female participants even after adjusting for body size (table 3:5).  
However, there was no gender difference in %TSAT. %TSAT decreased with age but there 
was no age effect on ferritin, serum iron or haemoglobin levels (table 3:5).       
Generally, urea reduction ratio (URR) was at the borderline of the UK-RA guideline (table 3:4 
and figure 3:6) and female participants had significantly higher levels compared to their male 
counterparts (mean = 73.3% (±13.5) female Vs 62.7 (±15.8) male). 
3.4.6 Association between dietary intake, nutritional status, haemoglobin 
concentration and other haematological markers. 
Pearson correlation analyses were undertaken to ascertain the relationship between nutrition 
(dietary intake and indices of nutritional status) and Hb concentrations and other 
haematological markers (as secondary outcomes). Results showed no association between the 
consumption of green vegetables, red meat or total dietary iron intake with Hb concentration 
or ferritin status (all p > 0.05). However, red meat intake appeared to be positively associated 
with serum iron and consumption of green vegetables to be significant associated with reduced 
transferrin saturation (table 3:6). 
There was a significant positive correlation between Hb and indices of nutritional status i.e 
albumin, BMI, MAMC, FTI and HGS. There was also a significant positive association 
between serum iron and albumin, FTI and HGS.  
Percentage transferrin saturation was significantly and positively associated with FTI.  
Correlation analysis also showed that ERI correlated significantly and negatively with, 
MAMC, BMI and HGS and correlated positively with FTI (table 3:6). However, MAMC was 
the strongest predictor accounting for 46.2% of variance in ERI (p= <0.001). 
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3.4.7 Association between inflammatory markers, haemoglobin concentration 
and other haematological markers. 
Pearson correlation and multiple regression analyses were performed to study the association 
between inflammatory markers and other known contributory factors with Hb and other 
haematological markers (as secondary outcomes) in renal patients. 
Age correlated with %TSAT, but not with ferritin, serum iron or Hb levels (table 3:5). 
Similarly, there was no association between dialysis vintage (DV) and Hb (r=0.228, p=0.32), 
serum iron concentration (r =0.148, p=0.48), ferritin (r =-0.244, p=0.26) or %TSAT (r =-0.323, 
p=0.22).  There was no significant difference on Hb (t = -1.38, p=0.18), serum iron 
concentrations (U=179, p=0.097), ferritin (U=179, p=0.562) or %TSAT (U=73, p=0.138) 
among participants with diabetes from those without diabetes. 
In addition to nutritional indices (section 3.4.6), haemoglobin (Hb) level correlated positively 
with serum iron and intact Parathyroid hormone (iPTH) (table 3:6). Multiple regression 
analyses were performed to study the independent effect of the correlated parameters on Hb 
levels. Seven variables (serum albumin, serum iron, iPTH, BMI, HGS, muscle mass and fat 
tissue index) were entered by stepwise method into the linear regression model. Three models 
were generated but the model incorporating muscle mass, iPTH and serum iron was the overall 
best fit accounting for 40.1% of Hb variance (p<0.001). Muscle mass (MAMC) was the best 
unique predictor of Hb (table 3:7).  
Serum iron concentration was also positively associated with Hb, ferritin, %TSAT in addition 
to nutritional indices (albumin and HGS)(Table 3:6). A stepwise multiple regression with  Hb, 
albumin and HGS entered into the model as independent variables, produced two models but 
that ferritin and haemoglobin concentration accounted for a greater variance of serum iron 
42.9% (p =0.005). Ferritin was the best unique correlate of serum iron (table 3:7). 
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Table 3:6: Bivariate correlations between haemoglobin and the known contributory factors for renal anaemia 
Variables Hb Fe Ferr %TSAT C-RP ALB BMI MAMC LTI FTI HGS iPTH G.V R.M T.D.I ERI 
1.Hb 1                
2.Serum iron .375** 1               
3.Ferritin -.138 .480** 1              
4.%TSAT .035 .308* .183 1             
5.C-RP -.251 -.162 .094 .062 1            
6.Albumin .300* .257* -.072 .185 -.304* 1           
7.BMI .294* .210 -.091 .135 .070 .194 1          
8.MAMC .485** .196 -.107 -.091 -.051 .167 .645** 1         
9. LTI .182 .190 -.215 .065 -.075 .282* .922** .630** 1        
10. FTI .248* .255* -.152 .303* -.149 .242* .732** .667** .709** 1       
11.HGS .371** .413** .004 .214 -.179 .457** .125 .267* .054 .129 1      
12. iPTH .347** .083 -.223 .125 .020 .168 .17 .029 .115 .136 .120 1     
13. Green veg. .257 -.215 -.172 -.500* -.100 -.003 -.249 -.055 -.145 -.079 -.210 -.133 1    
14. Red meat  .312 .434* .158 .343 .100 -.043 .145 .314 .095 .179 .545** -.446 -.014 1   
15.Total 
dietary iron 
-.111 .172 .135 .149 -.058 -.070 -.164 -.087 .057 .059 .214 -.263 .295 .601 1  
16. ERI -.490** -.182 -.121 .075 .100 -.130 -.476** -.674** .107 .241* -.274* -.038 -.163 -.166 .022 1 
*Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed). Hb = Haemoglobin; %TSAT= Transferrin saturation percentage; C-RP = C-reactive 
protein; BMI = Body Mass Index; MAMC = Mid arm muscle circumference; LTI = Lean Tissue Index; Fat Tissue Index; HGS = Hand Grip Strength;  
iPTH = intact Parathyroid hormone; ERI = Erythropoietin resistance Index ;  
 
Table 3:7: Multivariate analysis between haemoglobin, serum iron and the associated variables 
 Haemoglobin  Serum iron 
 Models R2 β P  Models R2 β P 
1 MAMC 0.203 0.451 <0.001 1  
Ferritin 
 
0.230 
 
0.480 
  
       0 .024 2 MAMC    
0.315 
0.441  
iPTH 0.334 <0.001 
3 MAMC  
0.387 
0.390   
2 
 
Ferritin 
 
0.429 
 
0.542 
 
0.005 iPTH 0.313 <0.001 
serum iron 0.275  Haemoglobin 0.450 
iPTH = intact Parathyroid hormone; MAMC = Mid arm muscle circumference 
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3.5 Discussion 
The previous study (chapter 2) showed that the Hb status of Tanzanian HD patients was 
particularly low and that this was of concern as their Hb levels remain persistently low despite 
them being on erythropoietin hormone therapy. We conducted a cross-sectional study to 
investigate the presence and relative contribution of known aetiological factors of anaemia in 
ESRD such as dietary intake, nutritional status, inflammatory markers, dialysis adequacy, bone 
health, the use of Erythropoietin stimulating agents (ESAs) and iron therapies in order to 
determine their association with Hb and iron status of HD patients to try and explain this 
clinical phenomenon.  
Generally, participants were of middle age (median age 49 yrs) and once again males 
outnumbered female participants. The observed median age is substantially lower than that 
reported in developed countries including the UK where the majority of patients are in their 
sixth to seventh decades (64.8years)325 but comparable with other African countries like  Ghana 
(43.86yrs)326, Nigeria (42.55yrs)327,south Africa (43.4 – 55yrs)55 and Cameroon (47.4yrs)328 
In this study, participants’ diets were predominantly starch, with maize meal and rice being the 
most consumed foods. This is not surprising as a report by the Tanzanian Ministry of 
Agriculture, Food Security and Cooperatives in its 2006 publication275 showed starchy roots 
and cereals such as maize, rice and cassava were the main staple foods at a national level. 
Maize meal is widely consumed by people from varying socio-economic backgrounds in sub-
Saharan Africa accounting for almost half of the energy intake in Eastern and Southern Africa 
(ESA) and 41% of the energy intake in Tanzania specifically329. Rice consumption is also 
growing because of rapid urbanization and changes in eating habits 330. Participants’ 
consumption of starchy roots and tubers like cassava, potatoes and plantains were minimal, 
possibly because of the concern for their high potassium content. However, there has also been 
a declining trend in starchy roots supply at national level since the 1960s whereas the supply 
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of cereals has been increasing replacing the former in the Nation’s diets331. Generally, patients’ 
consumption of carbohydrate foods were below the NKF-K/DOQI recommendation314 of 6 to 
11 portions/servings per day to provide 35 kcal per ideal body weight per day. Participants 
reported consuming on average 500gm of starch foods per day, and only 12.8% of participant 
met the NKF-K/DOQI135 and UK RA131 recommendations of energy intake of ≥ 35 
kcal/kg/day. Their total average energy intake normalized by body weight was 24.4kcal/kg/day 
which is below recommendations.  
Protein foods were minimally consumed and the majority of patients had intakes of animal 
protein below NKF-K/DOQI recommendations. On average, patients ate only a half 
(113gm/day) of what is recommended (8 to 10oz)  by NKF-K/DOQI314 and their total protein 
intake was indeed only a half of the recommended 1.2g/kg/day131,135. This is not very different 
from the general Tanzanian population where animal protein consumption is low accounting 
for only 20% of total dietary protein. The population get its highest proportion of protein from 
plant sources like beans 329. Lower consumption of animal protein is likely a reflection of low 
financial access as meat, poultry and fish are highly priced and hence less affordable compared 
to plant sources. The current price of beef steak is 8000tsh/kg (approximately 4USD or 3 GBP), 
chicken and fish are usually higher priced than beef (± USD7 or 5GBP per kilo depending on 
the kind).  Beans which are the most commonly consumed plant protein are priced at about 
2000tsh/kilo (± 1 USD or less than 1 GBP depending on the kind). The ratio of cost to caloric 
supply is 10.33, 3.67, 1.73 and 0.87 for fish, poultry, beef and beans respectively329. 
Unfortunately, assessing the socio-economic status of participants was beyond the scope of this 
study. Beef was reported to be barely eaten by the participants, although they reported that this 
was primarily due to concern for its potassium content and the fear of rising uraemic toxins. 
Patients are therefore left with two major options for animal products, fish and poultry. 
Regardless of its higher cost to calorie ratio, fish was the most frequently consumed animal 
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protein source by the study participants with 62% of participants consuming a portion of fish 
4 to 6 times a week. This is probably because data analysis in this study combined all kinds of 
fish including the relatively cheaper species like anchovy and sardines. Also, unlike poultry, 
small portions of fish (which is fairly affordable) can conveniently be purchased either ready 
cooked or uncooked in streets or local markets, and this would be served as special meal for an 
individual patient instead of family meal. This is further supported by analysis that showed, 
although there was high frequency of fish consumption, the actual quantity consumed per day 
was very small.  
In the present study male participants consumed more portions of starch and animal protein 
than their female counterparts. This is probably because males generally consume bigger 
portions than females due to the larger body size and higher muscle mass, and therefore 
metabolic rate and energy requirements. In the analysis, the number of portions were estimated 
from the weight of the food consumed. Moreover, there was no significant association between 
gender and total energy and protein nutrients intake estimates when adjusted for individual’s 
body weight. 
Inadequate intakes of high biological protein and essential amino acid among dialysis patients 
have been previously reported 332.  The HEMO study that investigated 1901 HD patients found 
a caloric intake of 22.7 ± 8.3kcal/kg/day and a dietary protein intake of 0.93±0.35g/kg/day, 
with 92% and 81% of participants not meeting recommendations for energy and protein 
respectively 333. This is comparable to the intake of energy (22.9 ± 8.4kcal/kg/day) and protein 
(0.93±0.36g/kg/day) reported by Rocco et al. 334 in the further analysis of the same HEMO 
study but with just the 1000 first patients to be randomized into the study. Inadequate intakes 
of energy and protein were also reported in other small studies like that by Kalantar-Zadeh et 
al. 220 who observed energy and protein intakes of 26.4 ± 11.9kcal/kg/day and 
0.88±0.57g/kg/day respectively in a pool of 102 haemodialysis recipients. Another study 
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reported adequate dietary protein (1.27g/kg/day) but sub-optimal energy (25.8kcal/kg/day) 
intake with 74.6% of HD patients failing to meet their recommendation for energy and 32.3% 
for protein335. A French study of 99 HD patients also reported slightly high protein intake 
(1.18±0.28g/kg/day) but sub-optimal energy intake (29.8 ± 7.5kcal/kg/day) 336 suggesting the 
protein may be used for energy rather than muscle mass.   In a study by Arslan and Kiziltan 
337, energy intake was adequate (34.2 ± 8.89kcal/kg/day) while protein intake was sub-optimal 
(0.94±0.26g/kg/day) in one Turkish dialysis centre and 75 and 67% of HD patients aged less 
than 60 years did not meet NKF-KDOQI and UK RA recommendation for dietary energy and 
protein respectively. Cumulatively, this shows that dietary inadequacy is not uncommon 
among dialysis patients despite the presence of nutritional guidelines calling for frequently 
monitoring and investigating the causes and possible ways of improving the situation. 
Several observational studies have suggested the beneficial effect, in terms of improved HD 
patients’ survival, of a high protein intake i.e. 1.2 – 1.4g/kg/day338   Although an increase in 
protein is advised for HD patients, it should also be borne in mind that this can also result in a 
substantial increase of phosphorus and also an increased risk of metabolic acidosis. In a study 
by Araujo et al.339 the rate of survival was higher in HD patients with a higher intake of protein 
(0.92±0.34 g/kg/day Vs 1.01±0.38 g/kg/day) and higher intake of energy (27.4 ± 8.9 
kcal/kg/day Vs 23.5±7.4 kcal/kg/day) as compared to lower intakes. An increase in patients’ 
survival was also observed with intakes of protein ≥ 1.2g/kg/day whilst an intake < 1.2g/kg/day 
was a predictor of mortality in a cohort of 79 Brazilian dialysis patients340. Patients therefore 
need appropriate dietary counselling and guidance in the proper selection of their diet to 
incorporate adequate dietary protein sources with least amount of inorganic phosphate and a 
low phosphate to protein ratios (alongside adherence  to an appropriate phosphate binder 
regime)341,342. Adequate caloric intake is also crucial as there is evidence that inadequate energy 
may negate the benefit of adequate protein by catabolizing it for energy343.  It is therefore 
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important that patients have adequate protein intake  together with a high energy intake 344 to 
maintain a neutral nitrogen balance. In a study by Kang et al.277 energy intake was 
independently and negatively associated with all-cause mortality and this emphasizes the 
importance of adequate caloric intake. 
In the current study there was also a low consumption of fruits and vegetables with patients 
consuming on average one portion of fruit/day as compared with NKF-K/DOQI 
recommendations of 2 – 3 servings per day314. This was reported to partly be due to concerns 
for the potassium content that is high in majority of fruits and green vegetables. Patients 
reported being advised to eat only green apples and red grapes. Grapes are seasonal fruits while 
apples are imported fruits in Tanzania limiting access and therefore intakes within this sample. 
Male participants had lower intakes of fruits and vegetables but higher carbohydrate and 
protein intakes when compared to their female counterparts. This generally reflects the gender 
difference in dietary habits within the wider Tanzanian population. Although it is not formally 
documented for the Tanzanian population, its culture is not dissimilar from many other parts 
of African where fruits and vegetables are mostly consumed by women and children.  Although 
potassium restriction is of high importance in disease management, this does not preclude the 
importance of fruits and vegetables as good sources of vitamin, minerals and dietary fibre. 
Studies have shown an increased nutritional related cardiovascular risk in CKD population 
337,345 highlighting the importance of achieving a balance between low potassium but adequate 
micronutrients and fibre intakes through careful selection , preparation and portion control of 
fruit and vegetables in the diets of HD recipients. 
As disease progresses, patients’ appetites tend to decrease 346 and their taste is altered which, 
coupled with dietary restrictions and the inability of patients to prepare their meals due to 
fatigue, compromises dietary intakes in these patients 333,347 as patients are likely to be left with 
limited and monotonous choices. It is therefore not uncommon for ESRD patients to suffer 
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from dietary inadequacy. However, there could be more social factors that exacerbate the 
problem among Tanzanian patients. Tanzania has a diverse culture with different food 
preferences and availability, mostly regionally categorised depending on local food 
production348.  Having relocated from their local areas into the city for dialysis means their 
access to their usual foods may be limited physically or less affordable. Furthermore separating 
from their family or having to relocate with the whole family for treatment can be stressful and 
depressing worsening patients’ appetites 349.   
Lack of renal dietitians or renal trained nutritionists in Tanzania and few nephrology 
consultants who are already burdened with other clinical roles means patients are unlikely to 
receive comprehensive dietary advice and monitoring. Moreover, there are no local guidelines 
for renal diets and this is likely to make it more difficult to provide standard nutrition care to 
these patients. 
Although their average BMI levels were borderline satisfactory, their albumin was below the 
recommended range. Their HGS was also below the safe level recommended by the European 
working group on sarcopenia320 suggesting the presence of sarcopenia despite the satisfactory 
BMI status. Similar findings was also found in Leal et al.350 where HGS was negatively 
associated with percentage body fat and in Cordeiro et al.351 where lower HGS was observed 
in HD patients with higher estimated levels of abdominal fat. This shows that it is possible for 
patients to have muscle loss despite high or normal BMI. Furthermore, BMI was only found to 
be protective against mortality in patients with normal or high muscle mass352 calling for 
muscle function tests to be performed and interpreted alongside BMI.   Handgrip strength is a 
reliable marker of muscle strength and nutritional status alteration 353-355 in these patients 
considering the poor sensitivity and specificity of other indices such as BMI which are likely 
to be affected by oedema, and albumin which is affected by inflammatory state. It is now 
evident that muscle strength/function has significant implications for health outcomes and 
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quality of life among dialysis patients 356,357 and can predict of all-cause mortality of dialysis 
patients 356,358.   In the present study, although there was no association between macronutrient 
(protein and energy) intakes and nutrition status (measured through BMI, serum albumin and 
muscle mass), the intake correlated positively with muscle strength irrespective of individual 
body weight or gender and this should not be overlooked. As expected, HGS also appeared to 
decrease with aging, a reflection of normal physiological change across age spectrum359,360.  
Although there was also no direct relationship between dietary intake and haemoglobin status, 
results suggest that consumption of red meat might help increase serum iron concentration. 
This is expected as red meat is well known to be a good source of heme iron. This suggests 
that there could be some benefit of red meat consumption on anaemia management as there is 
a direct association between serum iron and haemoglobin level. It is understood that 
encouraging increased intake of beef and other red meat like liver may be associated with 
concerns around phosphate content. A balanced diet approach, aiming at diversified meals 
(including fruits, vegetables, varied protein sources) whilst closely monitoring biochemical 
profile and adjusting diets (when indicated) to ensure their biochemical profile remains within 
the required limits, could be a practical way of achieving adequate nutrition including dietary 
iron. 
Iron deficiency was evident among the studied patients reflected by low serum iron and ferritin 
levels. There also seemed to be a low %TSAT (an indication of iron uptake for erythropoiesis) 
for the majority of patients, a possible indication of functional iron deficiency. In this study, 
serum iron correlated positively with Hb concentration. This is logical because of the 
involvement of iron in erythropoiesis.  
Surprisingly, in this cohort iPTH was observed to be on the lower side.  This finding is rare in 
ESRD patients due to phosphate retention which often cause raised PTH. In the situation where 
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low PTH is observed, it is normally linked with utilization of calcium based phosphate binders 
and/or the use of high calcium concentration (1.75mmol/l) dialysate which are supposed to 
cause an inhibitory effect of PTH to counteract high serum Ca361. However, in this study, 
calcium status was also low. Another factor for low PTH level in these patients is 
parathyroidectomy, which was not investigated in this study. The study suggested a link 
between iPTH and haemoglobin such that patients’ Hb levels significantly increased with 
increase of iPTH. The association between malnutrition-inflammation complex and low 
PTH362 may explain the indirect effect of PTH on anaemia through inflammation. In the present 
study, there was indeed evidence of high inflammation, signified by high levels of C-RP. 
Opposing this, a study by Chutia et al.363 linked hyperparathyroidism with low Hb and anaemia 
in CKD calling for more research to ascertain the association contribution of PTH in anaemia 
pathogenesis. 
All indices of nutritional status (BMI, muscle mass, fat mass, albumin and HGS appeared to 
have a strong relationship with Hb status. Muscle mass (although it didn’t correlate with total 
iron) was independently and positively associated with Hb concentration, suggesting the link 
between muscle mass and EPO response. A significant increase in EPO response was indeed 
observed with an increase in muscle mass in the present study.  The modification effect of body 
composition on EPO response has recently gained recognition and proposed by other 
investigators 12,13,222. Kotanko et al.,13 and Guinsburg et al.,222 showed a better EPO response 
in patients with higher tertiles of both body fat and muscle mass. Do Sameiro-Faria et al.12 also 
found BMI to be among the independent predictors of EPO dose required to reach desired 
target and that the higher the BMI the lower the EPO dose required. These authors suggest that 
the protective effect of increased body fat, lean mass or BMI might simply be an indication of 
survival advantage of better nutritional status and the reduced uraemic distribution volume 
(consequently, reduced inflammatory syndrome) in patients with larger body size.  Fat mass 
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and BMI but not lean mass was further suggestive to have a protective role by Vega et al.364 
The additional explanation for his finding is probably the reduced distribution of Hb due to 
lower water content in fat and the leptin hormone (known to increase with obesity) that is also 
found to play a role in erythropoiesis228 and associated with increased Hb concentration365.   
In the present study, Hb concentration was found to be positively associated with both muscle 
mass and muscle strength. It is possible that this association is linked with the shared role of 
iron in muscle metabolism and haemoglobin/red blood cell production.  
As previously explained, iron plays an important role not only in production of the RBC, which 
Hb is part of, it is also an essential part of myoglobin (a primary oxygen carrying pigment in 
the muscle) hence indirectly influencing muscle cellular energy metabolism231,232.  Because 
iron is an essential component of both Hb and Myoglobin, it is possible that the positive 
association observed between the two pigments is confounded by the iron availability. In the 
event of low iron bioavailability, a patient is likely to experience both low Hb and myoglobin 
production and hence experience muscle weakness.   
3.6 Study limitations 
This study relied on the retrospective analysis of biochemical data recorded in the clinical 
database. Retrieving data was challenging due to constant power outages.  There was also a lot 
of missing data and poor recording of pre- and post-dialysis biochemistry values.  
There was limited availability of research facilities (e.g. laboratory and nutritional assessment 
equipment) in Tanzania. This necessitated the change of location for the subsequent follow up 
studies from Tanzania to the UK. 
The methods used for dietary intake assessment have inherent limitations. Both FFQ and 
multiple pass 24 hours dietary recall methods are subject to recall and reporting bias. Although 
the two methods were used together to collect as reliable data as possible this doesn’t remove  
the limitations of the individual methods. The FFQ was administered with the intention of 
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assessing habitual dietary intake. However, it is possible for participants  to overestimate /under 
estimate frequency of consumption unintentionally or in an attempt to report a more desirable 
/ socially acceptable diet . Similarly, reporting of food portion size can be a challenge, the 
situation potentially being worse in cultures with no standard food portion sizes like Tanzania. 
Moreover, there was no local dietary analysis software that included Tanzanian local foods, 
potentially limiting the accuracy of the analysis and related outputs. The available paper 
version of the local food composition table was not comprehensive and was not user friendly.  
There were also limitations in the techniques used for assessing body composition. 
Anthropometric measurements are commonly subjected to intra and inter-observer variations. 
In the present study, the inter-observer variation was reduced as all measurements were 
performed by one person. However, the most striking limitation of anthropometric measures is 
their inability to accurately measure and distinguish body fat from muscle. The two measures 
are normally estimated using mathematical formula whose accuracy and validity to this 
population group, in light of their disturbed hydration status, could also be challenged. The 
portable bio impedance analyser used in this study was not validated to be used by dialysis 
patients. This limits the reliability of the outcome measures. A validated tool such as the BCM 
from Fresenius Corporation (which use algorism that takes account of over hydration status of 
haemodialysis patients)366-368 could have provided more reliable results provided that 
manufacturer’s measurement instructions are adhered to.   
For this reason, the findings related to both dietary intake and body composition in the present 
study should be interpreted in the light of these limitations. 
3.7 Conclusion and recommendations 
Patients had borderline nutritional status and inadequate dietary energy and protein. There was 
a co-existence of iron deficiency, inflammation and poor intakes of iron rich foods, the possible 
reasons for persistent low haemoglobin levels. Nutritional status is suggested to modify EPO 
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responsiveness with muscle mass favouring the response. This calls for nutrition to be 
considered along with other pharmacological therapies used for anaemia management. Renal 
nutrition services should be well integrated into renal care services in Tanzania. We would 
advocate for continuously monitoring and recording patients’ nutritional status (dietary intake 
and body composition). An individualised nutritional care plan for renal patients including 
those receiving haemodialysis is paramount. This should aim at ensuring optimal dietary 
protein, energy and iron intakes whilst remaining cognisant of individual social economic 
circumstances without compromising other clinical outcomes. Other interventions to preserve 
muscle mass including regular physical exercises should also be considered.  This can only be 
achieved if the government and hospitals invest in providing renal nutrition training for 
available nutritionists working in clinical areas. 
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CHAPTER 4 
4 LONGITUDINAL OBSERVATION OF NUTRITIONAL 
STATUS, BODY COMPOSITION AND INFLAMMATORY 
MARKERS AND THEIR ASSOCIATION WITH 
ERYTHROPOIETIN RESPONSE AMONG UK 
HAEMODIALYSIS PATIENTS WITH SUB-OPTIMAL 
HAEMOGLOBIN STATUS. 
4.1. Introduction and rationale of the study 
The previous cross-sectional study conducted to investigate the possible contributory factors 
for low responses to erythropoietin (EPO) hormone among haemodialysis(HD) patients 
confirmed a role for nutritional status. In particular, dietary intake and body composition (body 
fat and muscles) were found to modify patients’ responses. The modifying effect of body 
composition on EPO response is a new phenomenon in addition to the well-known 
conventional factors like uremic toxin accumulation207, inflammatory syndrome168,197, 
secondary hyperparathyroidism202, iron deficiency and inadequate dosage of iron and EPO.    
Nevertheless, the contributory effect of body composition is still not clearly understood, 
particularly the relative contributions of body fat and muscle mass or the mechanisms involved. 
Recent studies on the matter present contradictory results with some supportive of a positive 
influence of body fat on EPO sensitivity228, while others, including the previous findings of 
this project (presented in chapter 3), suggest both body fat and muscle/lean mass13,222 or high 
BMI12 to be beneficial. This study was therefore designed and carried out to further expound 
on the involvement of body composition on EPO responses. 
The study also considered other important confounding factors specifically inflammation. As 
previously explained, ESRD and HD treatments themselves tend to induce inflammatory 
responses within the immune system. Conditions like uremic toxin accumulation, vascular 
access infections and blood–membrane interactions enhance the production of C-RP and 
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inflammatory mediators, including  cytokine like Interleukin(IL)-6, IL-1, IL-2 and tumor 
necrosis factor – α (TNF- α) that is responsible for activation of the immune system. As an 
attempt to control inflammatory processes, anti-inflammatory and modulatory cytokines such 
as IL-4, IL-5 and IL-10 can also be produced369.  
Chronic inflammation has a negative consequence on muscles126,209,210 and iron 
metabolism197,198. The interplay between inflammations, nutritional status and anaemia in 
ESRD patients is detailed in section 1.4. This study measured and considered C-RP, IL-6 and 
IL-10 as markers of inflammation commonly reported among HD patients.  
The study also chose to measure leptin hormone (which increases with adiposity223,224) which 
has recently been suggested to have haematopoietic effects228,229,370 and therefore may provide 
a possible link between increased body fat and Hb levels.  
It was important for this study to be conducted over an extended period of time sufficient to 
monitor patients’ response to the prescribed iron and EPO and included biochemical 
parameters that were not available in the previous cross-sectional observational study.  
The findings from this study will significantly add to the existing body of knowledge in this 
area and will help to explain possible ways that anaemia management therapies and patients’ 
treatment outcomes could be optimized. 
4.2 Aims and Objectives of the study 
4.2.1 Aim 
To investigate and monitor over time the nutritional status, body composition and inflammation 
status of haemodialysis patients and the impact of these factors on patients’ responses to 
erythropoietin hormone. 
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4.2.2 Objectives 
i. To recruit a sample of haemodialysis patients that are on erythropoietin (EPO)  
maintenance therapy  
ii. To investigate and monitor over a four month period:  dietary intake, nutritional status 
and body composition  
iii. To investigate and monitor uremic and inflammatory markers  
iv. To investigate the association of erythropoietin hormone response with nutritional   
status, body composition, inflammation and iron markers. 
4.3 Study hypothesis 
i. HD patients with better nutritional status (reflected by dietary intake, muscle mass 
and body fat) will respond better to EPO treatment (reflected by higher haemoglobin 
concentration) than those with lower muscle mass and/or who are underweight. 
ii. The relationship between EPO response and nutritional status (reflected by dietary 
intake, muscle mass and body fat) among HD patients will be modified by their 
inflammation status.   
4.4 Methodology 
4.4.1 Study design 
This study adopted a longitudinal observational design and was conducted over four months. 
The study setting was haemodialysis clinics at St, George’s hospital in London and its affiliated 
satellite units (i.e. Colliers Wood and North Wandsworth dialysis centres). 
4.4.2 Inclusion and exclusion criteria 
The study included adult (aged ≥ 18 years) patients registered at the three named dialysis units 
who had been on haemodialysis for at least 3 months; and were on anaemia management 
therapies (i.e erythropoietin hormone and/iron).   
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The study excluded patients who lacked capacity to make informed decision or lacked 
sufficient command of English, those who changed, or were due to change, dialysis modality, 
received a kidney transplant or changed dialysis unit during the study period. It also excluded 
patients with anaemia of non-renal aetiology, e.g. anaemia due to sickle cell or malignancies. 
Patients who had recently received a blood transfusion, or received a transfusion during the 
study, were also excluded. 
4.4.3 Sample size calculation 
The desired sample size was determined using a formula for sample size in observational 
studies described by Charan and Biswas311 and presented below: 
 
𝑛 =
𝑧2𝜎2
𝑒2
  
 
 
 
The attribute of interest in the study was Hb concentration. The baseline data from the 
PIVOTAL study (a recent multicentre study on iron therapies administration to haemodialysis 
patients in the UK)190 presented the mean Hb concentration as 10.5 g/dl with a standard 
deviation of ±1.4g/dl190. To obtain a representative sample considering the same standard 
deviation (σ = 1.4g/dl); desired level of precision of 5% (i.e e = (0.05*10.5g/dl) and z = 1.96, 
n = 28 was found to be a desirable sample size.  When twenty percent (i.e. 6) was added into 
the sample to account for drop out, the final sample size became 34.  
4.4.4 Ethical application and approval 
Permission to conduct the study was sought from the individual dialysis centres involved and 
the St. George’s University Hospitals NHS Trust which became the sponsor of the study with 
reference no. 18.0016.  This was followed up by an NHS ethics application to the Health 
Research Authority - Research Ethics Committee (HRA-REC). The study received a 
Where: 
n = sample size  
z = the abscissa of the normal curve that cuts off an area at the tails 
e = the desired level of precision (in the same unit as variance) 
σ2= the variance of the attribute in the population 
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favourable ethical opinion on 01/05/2018 with REC reference number 18/LO/0443 (See 
Appendix 11).  
4.4.5 Subject Consent and Recruitment  
The list of potential participants (according to inclusion and exclusion criteria) was generated 
by the unit anaemia nurse. These patients were then approached and provided with study details 
and invited to participate in the study. Potential participants were left with an information sheet 
(appendix 17) and approached after a minimum of 48 hours for their decision. Those willing 
to take part were asked to provide written consent (appendix 19). Consenting participants were 
then recruited into the study and assigned a study identification numbers for use throughout the 
study instead of individual names or hospital numbers. Figure 4:7 in section 4.6.1 shows the 
recruitment process at the main St. George’s dialysis unit (SDU) and its satellite units (Colliers 
Wood (CW) and North Wandsworth (NW) dialysis centres). 
4.5 Data collection 
4.5.1 Demographic data 
Personal data including age, gender and ethnicity and dialysis vintage were retrieved from 
clinic electronic databases. 
4.5.2 Assessment of Iron and Erythropoietin dosage and erythropoietin response  
Data on the type of iron supplements and erythropoietin hormone prescribed to participants 
and their dosage were retrieved from participants’ paper files available in the clinics.  
Erythropoietin index (ERI) was calculated and used as a proxy indicator for patients’ response 
to the hormone. The ERI was calculated using the formula below which take into account the 
EPO weekly dose adjusted to the patient’s weight and expressed in relation to their Hb 
concentration as described in the article by Chait et al319 
𝐸𝑅𝐼 =  
𝐸𝑃𝑂 𝑤𝑒𝑒𝑘𝑙𝑦 𝑑𝑜𝑠𝑒 
𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)⁄
𝐻𝑎𝑒𝑚𝑜𝑔𝑙𝑜𝑏𝑖𝑛 𝑐𝑜𝑛𝑐(𝑔/𝑑𝑙)
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ERI was then defined as inability of the EPO dosage of 300 IU/kg (20,000 IU/week) or 1.5 
µg/kg (100 µg/week) to achieve the target Hb (11.0-12.0 g/dl) according to the European Renal 
Best Practice Guideline194 
4.5.3 Assessment of dietary intake and nutritional status 
4.5.3.1 Dietary intake  
Patients were provided with standard food diaries used by the dietetic team in SDU and 
requested to record all foods and drinks consumed on three days of the week (one weekend and 
two weekday’s including a dialysis day) at each monthly recording point. Information on the 
type of food and quantity were then entered into a dietary analysis software Nutritics (Nutritics 
Ltd, Co.Dublin, Ireland) to quantity nutrient intake for the three days. The average intakes of 
energy and nutrients across the three days were then computed.  
4.5.3.2 Anthropometric measurements  
Height was measured using a wall mount stadiometer (SECA, JPen Medical. UK) available in 
the dialysis clinics to the nearest 0.1cm. Body weight was measured to the nearest 0.1kg before 
dialysis using calibrated digital scales (SECA, JPen Medical. UK) also available at the clinics; 
waist circumference was measured using a non-elastic tape measure to the nearest 0.1cm as an 
estimate of abdominal obesity before beginning dialysis session.  
Muscle strength was assessed before a dialysis session using hand grip dynamometer (Takei 
Scientific Instruments Co. LTD, Japan). Three measurements were taken (with about 5 seconds 
rest between each) using the non-fistula arm and the average of the three measurements 
recorded.  
4.5.3.3 Subjective global assessment (SGA) 
Patients were assessed using the original 3 – point (A, B & C) score SGA questionnaire 
described by Detsky et al.371 and reviewed by Steiber et al.136(see appendix 12) to collect 
information on changes in body weight, dietary intake, gastrointestinal symptoms, physical 
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functioning and muscle wasting for calculation of malnutrition risk score. A score of A denotes 
well-nourished individual whilst C is severely malnourished. This was performed by the study 
PI during a dialysis session. 
4.5.4 Assessment of body composition 
Body composition (muscle/lean mass, fat mass and body fluid) was assessed using a Body 
Composition Monitor (BCM) (Fresenius Medical Care AG & Co, Germany). The BCM 
employs the bio impedance spectroscopy technique and it is reported to be validated against 
gold standard dilution methods in various studies involving more than 500 dialysis patients and 
healthy controls372.  
4.5.4.1 BCM measurement procedures 
Measurements were performed as per manufacturer’s instructions before a dialysis session.  
Electrodes were attached to one hand and one foot with the patient in a supine position. The 
patient cable was then connected and the measurement initiated with results displayed within 
2 minutes. 
Results were then stored on the patient’s card and transferred to the computer.  
 
Figure 4:1:Pictorial illustration of body composition measurement using the Fresenius® Body composition 
monitor. Source: ©Fresenius Medical care 
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4.5.4.1.1 Principles of the BCM measurements 
The manufacturer reports that the BCM measures at 50 frequencies over the range of 5 to 1000 
kHz to determine the electrical resistances of the total body water (TBW) and extracellular 
water (ECW). While the high frequency current (1000 kHz) passes through the total body 
water, low-frequency current (5 kHz) cannot penetrate cell membranes and thus flows 
exclusively through the extracellular water (figure 4:2(a)). To obtain the body composition 
parameters, BCM uses two advanced physiological models illustrated in figure 4:2(b): 
i. The volume model that describe electrical conductance in a cell suspension enabling 
the total body water and extracellular water as well as the intracellular water (ICW) 
to be calculated. 
ii. Body composition model based on three principal body compartments 
overhydration (OH), lean tissue mass (LTM) and adipose tissue mass (ATM) from 
Extracellular water (ECW) and Total body water (TBW) information. 
 
 
 
Figure 4:2:(a)Different frequencies of electric current distinguishing and measure Extracellular water (ECW) 
and Total body water (TBW) (b) Three steps taken by BCM to display the final output parameters: Over hydration 
(OH), adipose tissue mass(ATM) and lean tissue mass (LTM).Source: ©Fresenius Medical Care 
 
(a) (b) 
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4.5.5 Biochemical profile 
Haemodialysis patients undergo monthly routinely blood tests to monitor their renal-related 
biochemistry to assess disease progression and inform treatment plans. Biochemical data for 
pre-and post-dialysis serum urea and creatinine were retrieved from the clinic databases. In 
addition data for pre-dialysis serum albumin, c-reactive protein (C-RP) and Hb were retrieved 
for each participant at each four time points. These were entered into an excel spreadsheet and 
stored in a password protected storage device.   
For other biochemical parameters of interest for the study, but not routinely or less frequently 
performed as part of the standard clinical care, (i.e serum ferritin, iron, total iron binding 
capacity, hepcidin -25, transferrin receptor (sTfR), IL-6, IL-10 and leptin hormone), an extra 
5ml sample of pre-dialysis blood was requested for independent analysis. 
4.5.5.1 Blood sample collection and handling   
A pre-dialysis venous blood sample was drawn from the point of dialysis access by a dialysis 
nurse, using a 6ml Vacutainer® SST™ tube, every month alongside clinic routine blood 
collection. Samples were inverted at least five times and allowed to clot at room temperature 
for 1 hour and centrifuged at 3000 r.p.m for 10 minutes on (Eppendorf™ 5702 Centrifuge). 
Serum was then separated using a disposable pipette, divided into 0.5mls aliquots in cryogenic 
propylene tubes and temporarily stored in -20°C freezer at the satellite units. At the end of each 
blood collection day, samples were transported to St. George’s University Hospital and stored 
at -80°C in one of the immunology department laboratories.  
At the end of the follow up period, all samples were transported on dry ice to the Nutrition 
laboratory at the University of Surrey and stored at -80°C until analysis.  
Before each analysis serum sample to be used was allowed to thaw at a room temperature and 
vortexed then centrifuged at 3500 r.p.m for 4 minutes at 4°C (Eppendorf® centrifuge 5430). 
Further pre-analysis sample preparation were performed depending on the analysis protocol. 
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4.5.5.2 Analysis of serum hepcidin-25  
Hepcidin-25 levels in the serum samples was measured by sandwich enzyme-linked 
immunosorbent assay (ELISA) using a commercially available kit from CUSABIO® (Cusabio 
Biotech Co. LTD, Houston, USA). The detection range of the assay was 4.69 – 300ng/ml, with 
a minimum detection limit of 1.17ng/ml. The assay is reported to have no significant cross-
reactivity or interference between human hepcidin-25 and its analogues.  The intra-assay 
precision of the kit is < 8% and inter-assay < 10%373.  
4.5.5.2.1 Principle of the sandwich ELISA 
The assay uses a microplate that has been pre-coated with antibody that reacts specifically to 
hepcidin-25 antigen to form antigen-antibody complex (such that any hepcidin-25 present is 
bound). The reaction is washed to remove unbound substances leaving the complex attached 
to the surface of microplate. The biotin-conjugated antibody specific for hepcidin-25 is then 
introduced which reacts with the available antigenic determinants of the molecule. The mixture 
is washed again to remove unbound substances followed by introduction of avidin-conjugated 
horseradish peroxidase (HRP) enzyme. Addition of this enzyme conjugated to avidin allows 
binding of biotin to avidin forming a stable complex.  
 
 
 
 
 
 
 
 
Figure 4:3: Pictorial illustration of the principle and steps involved in the sandwich ELISA determination of the 
analyte. 
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The plate is then washed to remove any unbound avidin-enzyme reagent, followed by addition 
of Tetramethylbenzidine (TMB) substrate solution. The enzyme acts on the substrate and a 
colour proportional to the amount of hepcidin-25 bound in the initial step develops. The colour 
development is then stopped and its intensity measured on the plate reader at 450nm.  
4.5.5.2.2 Assay procedure 
The reagents and standards were reconstituted and the assay carried out according to the kit 
manufacturer’s instruction presented in appendix 13. The summary of the assay procedure is 
presented in figure 4:4 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:4: A flow diagram showing a summary of assay procedure for determination of hepcidin-25 using 
quantitative sandwich ELISA technique 
Preparation of reagents, samples and standards 
Add 100μl of standards and samples (in duplicate) to the 
wells and incubate for 2 hours at 37°C 
Remove the liquid from each well, do not wash 
Add 100μl Biotin-antibody to each well. Incubate for 1 
hour at 37°C 
Aspirate and wash 3 times letting it stand for 2 minutes 
between each wash 
Aspirate and wash 5 times  
Add 100μl HRP- avidin to each well. Incubate for 1 hour 
at 37°C 
Add 90μl TM substrate soln to each well then incubate for 
15 – 30 minutes at 37°C. Protect from light 
Add 50μl stop soln to each well. Then read at 450nm 
within 5 minutes 
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The unknown hepcidin-25 concentration of samples were then interpolated from the colour 
intensity using a four parameter logistic (4-PL) standard curve-fit of hepcidin-25 standards 
(supplied by the kit manufacturer) against their absorbance intensity according to 
manufacturer’s instructions. The reconstitution concentration of standards was 300ng/ml, this 
was subjected to 2-fold dilution to create a series of 7 dilutions (S7 – S1) plus S0 (blank) table 
4:1.  
Table 4:1: Concentration values of the standard dilution series for determination of hepcidin-25 
Tube S7 S6 S5 S4 S3 S2 S1 S0 
Conc (ng/ml) 300 150 75 37.5 18.75 9.38 4.69 0 
 
4.5.5.3 Analysis of serum transferrin receptor (sTfR), ferritin, IL-6, IL-10 and leptin hormone. 
Analysis of the above named parameters was performed using commercially available Bio-
plex Multiplex immunoassay system (Bio-Rad Laboratories, Inc.USA). The assay technique 
uses luminex magnetic beads for quantification of analytes and the technique can be used to 
assess levels of several biomarkers from a single sample in a multiplexed sandwich ELISA. 
Three different kits were used (two different single plex kits for serum ferritin and transferrin 
receptor and  a 3-plex kit for serum IL-6, IL-10 and Leptin hormone) based on the sample 
dilution requirements.  
4.5.5.3.1 Principle of the Luminex assay 
The principle of this assay is similar to that of sandwich ELISA except that in this case the 
capture antibodies specific for analytes of choice are pre-coated onto magnetic microparticle 
beads solution pre-mixed in a single vial rather than the antibodies being coated directly to the 
well. These microparticle beads are also internally labelled with a unique combination of 
fluorescence dye. By mixing different beads, up to 100 different analytes can be detected 
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simultaneously. Biotin-antibodies specific for each analyte of interest are also pre mixed in a 
single vial. The assay principle involves the following main steps (see Figure 4:5):  
Step 1: Samples are added into the wells followed by a mixture of colour-coded beads pre-
coated with analyte-specific capture antibodies and incubated for antibodies to bind the 
analytes of interest.  
 
 
 
 
 
 
 
 
 
 
Figure 4:5: Pictorial presentation of steps and principles in the magnetic luminex quantification of the analyte(s) 
Step 2: After washing away the unbound substances, biotinylated detection antibodies specific 
to the analytes of interest are added and incubated to form an antibody-antigen sandwich.  
After a second wash to remove unbound biotinylated antibody, Phycoerythrin (PE) – 
conjugated streptavidin is added and incubated to bind to the biotinylated detection antibodies.  
STEP 3 
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Step 3: After a final wash to remove unbound Streptavidin–PE, the microparticles are 
suspended in a buffer and read at Luminex analyser. The magnet in the analyser captures and 
hold the superparamagnetic microparticles in a monolayer. Two lasers illuminates the 
microparticles. The first laser excite the dyes inside each particle to identify the analyte that is 
being detected and the second laser excite the PE to measure amount of analyte bound to the 
microparticles. All fluorescence emission from each microparticle as it passes through the flow 
cell is then analysed to differentiate emission levels using a Photomultiplier Tube (PMT). 
4.5.5.3.2 Magnetic luminex assay procedures 
The reagents and standards were reconstituted and the assay carried out according to the kit 
manufacturer’s instructions as presented in appendix 14. Standard(s) reconstitution volume, 
initial concentration and sample dilution for the analytes are presented in the table 4:2 below: 
Table 4:2: Initial concentration of the standard provided and the sample dilution protocol as directed 
by the kit manufacturer 
Analyte/Kit Sample dilution Standard reconstitution 
volume(ml) 
Standard initial 
concentration (pg/ml)  
Ferritin 1:50 300μl 6,190 
sTfR 1:200 250μl 95,990 
IL-6, IL-10 
and leptin 
1:2 A. 225μl 
B. 250μl 
IL- 6: 730 
IL-10: 900 
Leptin: 107,320 
sTfR = serum Transferrin receptor 
Standards were subjected to 3-fold serial dilution series to form six standards (S1 – S6), where 
S1 served as a high standard. The Calibrator diluent served as the blank.    
The unknown concentration of analytes in samples were then interpolated using a five 
parameter logistic (5-PL) standard curve-fit of standards (supplied by the kit manufacturer) 
against their fluorescence reading according to manufacturer’s instruction. A sample dilution 
factor was applied to obtain the final concentration of the analytes. 
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The flow diagram below (figure 4:6) summarize the assay procedure for magnetic luminex 
assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:6: A flow chat diagram illustrating the summary of magnetic luminex assay procedures 
4.5.6 Quality of Life 
Patients were provided with a quality of life questionnaire (SF-36v2™ OPTUM® PRO CoRE) 
and requested to fill it at home and return to the clinic on their next visit. The form is attached 
in Appendix 15. The questionnaire consists of 36 items, which are summarised and scored as 
8 domains, physical function (PF), role physical (RP), bodily pain score(BPS), general health 
(GH), vitality (VT), social function (SF), role emotional (RE) and mental health (MH).  The 
Preparation of reagents, samples and standards per instruction 
Add 50μl of standards and samples (in duplicate) to the wells  
Add 50μl of diluted micro particle cocktail beads to each well and 
incubate for 2 hrs at room temperature on a shaker at 800rpm 
Add 50μl Biotin-antibody cocktail to each well. Incubate 
for 1 hour at room temperature on a shaker at 800rpm 
Aspirate and wash 3 times using 100μl wash buffer, letting 
it stand for 1 minutes between wash 
Aspirate and wash as previously  
Add 50μl Streptavidin-PE to each well. Incubate for 30 
minutes at room temperature on a shaker at 800rpm 
Add 100μl of wash buffer to each well then incubate for 2 
minutes at room temperature on a shaker at 800rpm 
Read within 90 minutes using a Bio-Rad minutes 
Aspirate and wash as previously  
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eight domains are further summarised into Physical component (PCS) and Mental Component 
scales (MCS). For each scale, the item scores are summarised and transformed to the eight 0 – 
100 scales, (0 = poorest possible health state, 100 = best possible health state) according to the 
SF 36 normed-based scoring algorithms. 
4.6  Data management and Statistical analysis 
All collected data (anonymised) were entered into the password protected excel spreadsheet. 
These were then exported into the SPSS software (Version 25) for analysis. Data distribution 
were checked and the data were descriptively analysed.  
Mann-Whitney U-tests (for skewed variables) and T-tests (for normally distributed variables) 
were used to compare baseline data between males and females. One way ANOVA and 
Kruskal-Wallis test were used to the compare baseline status between three ethnicity groups. 
Skewed variables were transformed using two steps transformation method described by 
Templeton288  in order to allow further analysis using parametric tests. Bivariate correlation, 
multiple and logistic regression analysis were performed to study the association between 
variables at baseline.  
Repeated measure ANOVA was used to monitor changes in variables over time where-as Split 
– plot ANOVA (Mixed Between-Within subjects ANOVA) was used to study the influence of 
markers of body composition, inflammation and dialysis adequacy on iron markers across the 
four time points.  
4.7  Results 
4.7.1 Recruitment of study participants 
A total of 116 patients were eligible to participate in the study, of which 47 consented to take 
part and 41 completed the four months follow up period. Figure 4:7 shows number of 
participants from recruitment stage to study completion.  
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Figure 4:7: A flow diagram illustrating participant flow through the study period. NW=North Wandsworth; SDU 
= St.George’s Dialysis Unit; CW = Colliers Wood; HD = Haemodialysis 
 
4.7.2 Demographic characteristics of study participants 
Males outnumbered female participants recruited into the study. The age of participants ranged 
from 31 to 92 years and dialysis vintage ranged from 6 to 339 months. Participants were mainly 
of three ethnic backgrounds (Black, White and Asian-Indian) with Black being the dominant 
ethnicity among the participants recruited.  Aranesp® was the most commonly prescribed EPO 
and Venofer® the most prescribed iron supplement. Table 4:3 summarizes the demographic 
characteristics of the participants.  
 
 
NW  SDU  CW  
Consent and enrolled  
 
Drop off the study 
 
 
n = 24 n = 4 n = 13 
Total N = 41 
Declined participation 
n =18 n = 130 
n = 56 
n = 81 
 n = 10 n = 85 
n = 5  n = 44 n = 21 
n = 16 n = 25 n = 5 
n = 1 n = 1 n = 3 
Completed the study 
 
 
HD units involved 
 
Patients at HD unit 
 
Eligible and approached 
 
111 
 
Table 4:3: Demographic characteristics of participants recruited to a study of nutritional status, body 
composition, inflammation and EPO responses 
Characteristic %(n) Median (25th,75th percentiles) (Min, Max) 
Age (years)  64.5 (49.5, 72) 31, 92 
Dialysis vintage (months)  36.5 (15, 58.3) 6,  336 
Gender    
Female 28 (13)   
Male 72 (33)   
Ethnicity    
Black 41 (19)   
White 35 (16)   
Asian-indian 24 (11)   
Iron supplement  *Dosage/wk  
Venofer®(mg) 97 (30) 50 (25, 100)  
Ferrinject®(mg) 3 (1) 500  
EPO  *Dosage/wk ERI 
Aranesp® (μg) 85 (33) 50 (30, 60) 0.07 (0.03, 0.1) 
Neorecormon® (IU) 15 (6) 2500 (1662, 7000) 4.01(2.5, 9.5) 
EPO, Erythropoietin hormone; ERI, Erythropoietin resistance index; *data presented as median (25th, 75th) 
4.7.3 Baseline data for the study parameters 
This section presents data on dietary intake (dietary iron, protein and energy), nutritional 
status (including measures of body composition), inflammation and dialysis adequacy as 
described in methodology section (section 4.5, page 98 - 108). Data on IL-10 are not 
presented in this report because their florescent readings were too low and therefore 
undetectable according to the standard curve making extrapolation unreliable. 
4.7.3.1 Dietary intake 
The average dietary intake of protein was at borderline as compared to recommendations 
whereas the intakes of iron and total energy were far below the recommended levels (table 4:4). 
The majority of participants (both females and males) had intakes below the recommended 
range for protein and total energy whereas it was more common for females to have sub-
optimal iron intake compared to males (X2 = 7.5, p <0.01). There is no renal specific 
recommended intake for fat and carbohydrate and there were no gender differences in their 
intake. 
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Table 4:4: The baseline dietary intakes, nutritional status and body composition in adults on haemodialysis recruited to a study of nutritional status, body 
composition, inflammation and EPO responses – median intakes and comparisons to recommended values 
Parameters N  Median (25th, 75th 
percentiles) 
Mean (±SD) 
Recommendations Reference source Proportion of participants falling out of 
recommendations 
% below % within % above 
Dietary intake  
Iron (mg/day) 27 9.7 (±2.5) Male ≥ 8; Female ≥ 15 EBPG 18(M),80(F) 82(M),20(F)  
Protein (g/kgwt/day) 25 1.1 (0.8, 1.3) ≥ 1.2 NKF-KDOQI135; UK-RA131 64 36  
Fat (g/kgwt/day) 25 1.1 (0.7, 1.3) N.A     
Total energy 
(Kcal/kgwt/day) 
25 25.6 (18.2, 29.6) ≥ 35 NKF-KDOQI135; UK-RA131 92 8  
Nutritional status and body composition  
BMI(kg/m2) 36 27.15 (23.9, 32.1) ≥ 23 EBPG on nutrition286 19 81  
LTI (kg/m2) 35 12.5 (±3.5) N.A     
FTI (kg/m2) 32 15.1 (8.7, 21.4) N.A     
OH (l) 32 1.6 (±1.3) N.A     
W.C (cm) 33 99 (88.5, 110.3) N.A     
HGS (kg) 34 21.9 (18.7, 32.7) Male > 30; Female > 20 EWG on Sarcopenia320 52(M),73(F) 48(M),27(F)  
Albumin (g/l) 42 34.3 (±4.2) ≥ 40 EBPG on nutrition286 91 9  
Leptin (ng/ml) 41 9 (2.9, 16.9)      
Iron status and metabolism  
Haemoglobin (g/l) 44 101.5 (±13.1) 100 – 120 UK-RA179 50 41 9 
Iron (μmol/l) 42 11.56 (±4.1) 11 - 31 Daugirdas et al.374 48 52 0 
TSAT (%) 42 29.9 (23.6, 41.9) > 20% UK-RA179 14 86 0 
sTfR (mg/l) 41 6.1 (±2.4)      
Ferritin (ng/ml) 39 404.2(±212.9) 200 -500 UK-RA179 18 49 33 
Hepcidin-25(ng/ml) 41 23.1 (15.1, 39.1)      
Inflammatory markers      
C-RP (mg/l) 42 3.3 (1.4, 7.2) < 5 NKF-KDOQI289  62 38 
IL-6 (pg/ml) 39 3.9 (2.9, 5.6)      
Dialysis adequacy  
URR (%) 40 78.9 (73.7, 83.4) ≥ 65 UK-RA114 12 88  
CHO, Carbohydrate; BMI, Body mass index; LTI, Lean tissue index; FTI, Fat tissue index; OH, Overhydration; W.C, Waist circumference; HGS, Hand grip strength; TSAT = Transferrin 
saturation; sTfR, serum Transferrin receptor; C-RP, C- reactive protein; IL-6, Interleukin-6; URR, Urea reduction ratio; UK-RA, UK-Renal   Association; NKF-KDOQI, National Kidney 
Foundation – Kidney Disease Outcome Quality Initiative; KDIGO = Kidney Disease – Improving Global Outcome;EWG, European  Working group; EBPG, European Best Practice Guideline 
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4.7.3.2 Nutritional status and body composition 
The majority of participants (76.3%, n =29) had SGA score of A (well nourished) and 23% (n 
= 9) scored B (mildly- moderately malnourished). There were no significant differences on 
SGA scores across gender or ethnicity groups.  
The mean albumin concentration of participants was below the recommended level and there 
was no gender or ethnicity difference in the levels. On the other hand the median BMI of 
participants was within the healthy range and only 19% (n= 6) were classified as being 
underweight and this was regardless of gender and ethnicity (Table 4:5). Median HGS levels 
in both males (median (25th, 75th percentile) = 27.4kg (21.7, 35.4)) and females (median 
(25th,75th percentile)  = 17.3kg (13.7, 21.7)) were below the gender specific cut off points of 
the general population but above the values suggested by Vogt et al.,375 to be the cut-off for 
increased risk of all-cause mortality among HD patients (i.e 22.5kg and 7kg for male and 
female respectively). Although there was a significant difference in absolute HGS score 
between males and females (Table 4:5), when the scores were grouped according to gender 
specific cut-off points this difference disappeared (X2 = 1.3, p = 0.26). There were no 
differences in gender specific HGS scores due to ethnicity. 
There was a significant difference in lean tissue index (LTI) between genders (table 4:5) with 
male participants having a higher LTI (mean (SD) = 13kg/m2 (±3.5)) than their female 
counterparts (mean (SD) =10.3/m2 (±1.4)). One way ANOVA also showed significant 
differences in LTI levels by ethnicity (table 4:5), with participants of Asian-Indian ethnicity 
presenting the lowest LTI (mean (SD) = 9.5kg/m2 (±2.6)) followed by white (mean (SD) 
=11.5kg/m2 (±2.7)) and black (mean (SD) =13.7kg/m2 (±3.1)) participants.  LTI was also 
negatively influenced by age (table 4:6).  
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There were no gender or ethnic difference in waist circumference, albumin, fat tissue index or 
hydration levels of participants (table 4:5)
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Table 4:5: Analysis results showing gender and ethnicity comparison on indices of nutritional status and body composition at baseline 
  BMI(kg/h2) LTI(kg/m2) FTI(kg/m2) HGS(kg) WC(cm) Albumin(g/l) OH(l) SGA 
#Gender  Female 28.2 
(24.8, 33.2) 
10.3  
(± 2) 
18.3  
(11.4, 21.5) 
17.3  
(13.7, 21.7) 
97.8 
(79.4, 109.4) 
34.5 
 (± 4.2) 
1.1  
(± 1.4) 
6 
Male 26.7  
(23, 31.6) 
12.8  
(± 3.6) 
12.6  
(8.2, 21.1) 
27.4  
(21.7, 35.4) 
99  
(90, 114) 
34.3  
(± 4.3) 
1.9 
 (±1.1) 
6 
 
P 
 
0.48 
 
0.02 
 
0.2 
 
<0.01 
 
0.52 
 
0.88 
 
0.11 
 
0.13 
`†Ethnicity Black 26.4 
(23.2, 30.8) 
13.6  
(±2.3) 
11.4  
(8.2, 19.1) 
24.7  
(20.6, 31.5) 
96.2  
(85.6, 109) 
33.8 
 (±4.2) 
1.3  
(±0.9) 
6 
White 26.3  
(24.4, 30.2) 
11.1 
(±3.2) 
16.6 
(8.2, 20.6) 
20.8  
(15.7, 36.2) 
98  
(85.8, 106.8) 
34.9  
(±2.9) 
1.8  
(±1.3) 
6  
(5, 7) 
Asian-
Indian 
34.7 
(26.5, 44.3) 
11.8  
(±4.4) 
21.6 
(14.4, 34.1) 
21.8  
(18.6, 27.4) 
107.7  
(91.3, 121.9) 
34.3 
(±5.9) 
1.8  
(±2) 
6  
(5, 7) 
P 0.2 0.02 0.2 0.7 0.5 0.64 0.62 0.7 
BMI= Body mass index; LTI = Lean tissue index; FTI = Fat tissue index; HGS = Hand grip strength; WC = Waist circumference; OH = Overhydration; SGA = Subjective 
global assessment; T=T-test; F = One way ANOVA test;U=Mann-Whitney test; X2=Kruskal-Wallis test; P <0.05. Data presented as median (25th, 75th) or mean (±SD) 
 
Table 4:6: Correlations (Pearson correlation coefficients) between indices of nutritional status and body composition and demographic characteristics, 
inflammatory markers and dialysis adequacy 
 BMI LTI FTI HGS WC Albumin OH 
C-RP -0.16 -0.47** -0.06 0.26 0.01 -0.34* 0.21 
IL-6 0.03 -0.51** -0.22 -0.34 0.09 0.11 -0.04 
HD vintage 0.07 -0.06 0.03 -0.43** 0.03 0.11 -0.02 
Age -0.09 -0.36* -0.04 -0.39* -0.10 -0.06 0.08 
URR -0.28 -0.56** -0.04 -0.54* -0.33 -0.04 -0.01 
BMI= Body mass index; LTI = Lean tissue index; FTI = Fat tissue index; HGS = Hand grip strength; WC = Waist circumference; OH = Overhydration; C-RP = C-reactive 
protein; HD = Haemodialysis; URR = Urea reduction ration; * Statistically significant at p <0.05; ** statistically significant at p <0.01 
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HGS appeared to be influenced by age, haemodialysis vintage and urea reduction ratio (table 
4:6). A stepwise multiple regression analysis with these three variables as predictors accounted 
for 44.8% of HGS variance (F (3, 26) = 7.03, p <0.01) and HD vintage was found to be a 
strongest negative predictor of HGS (β= -0.4, p = 0.02).   
LTI was also found to be negatively associated with age and URR (table 4:6). 
There were no relationships between other nutritional indices (BMI, FTI, WC, OH and 
albumin) and age, HD vintage or URR (table 4:6).  
Among all nutritional indices, LTI and albumin were found to be negatively related to 
inflammatory markers (table 4:6).   
Analysis showed a positive association between baseline gender specific HGS categories and 
LTI quartile (Likelihood X2 = 6.72, p = 0.03). There was also a close positive association 
between baseline BMI status and FTI quartile (Likelihood X2= 12.82, p < 0.01) but not with 
LTI (Likelihood X2= 4.29, p = 0.37), albumin status (Likelihood X2= 1.37, p = 0.24) or HGS 
(Likelihood X2= 1.6, p = 0.21). 
4.7.3.3 Inflammatory status 
The median C-RP of study participants were within the recommended range as per NKF-
KDOQI recommendations (table 4:4) although 38% were above the normal range. 
Table 4:7: The median baseline values of inflammatory markers and their gender and ethnicity 
comparison in a sample of adults on haemodialysis 
 N Median  
(25th,75th percentile) 
#Gender  †Ethnicity 
IL-6(pg/ml) 39  
3.9 (2.9, 5.6) 
Male = 3.8 (2.7, 5.6) 
Female = 4.2 (3, 6.4) 
Black = 3.1(2.6, 4.2) 
White = 4 (3.3, 6.2) 
Asia-Indian = 5.5 (3.5, 9.1) 
   P = 0.5 P =0.1 
C-RP(mg/l) 42  
3.3 (1.4, 7.2) 
Male = 3.9 (2.4, 10.7) 
Female = 1.8 (1.1, 4.9) 
 
Black = 3.6 (1.3, 7) 
White = 2.9 (1.5, 5.2) 
Asia-Indian = 4.4 (1, 15.3) 
   P = 0.1 P = 0.8 
C-RP, C-reactive protein; IL-6, interleukin 6; #Mann-Whitney U- test; †Kruskal-Wallis test; Significance at 
p<0.05; Data presented as median (25th, 75th percentile)  
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There were no gender or ethnic differences in levels of C-RP and IL-6 (table 4:7). Similarly, 
there was no influence of age, HD vintage or urea reduction ratio on the inflammatory markers, 
except for IL-6 which was found to be a positively associated with URR (table 4:8). 
Table 4:8: Correlations between markers of inflammation and age, dialysis vintage and clearance 
 IL-6 C-RP Age HD Vintage  
IL-6 1     
C-RP 0.31 1    
Age 0.24 0.05 1   
HD vintage 0.28 0.04 0.11 1  
URR 0.36* 0.24 0.09 0.19  
* Significance at p<0.05 Spearman coefficient; C-RP =C- reactive protein; URR = Urea reduction ratio, HD = 
haemodialysis;  
 
4.7.3.4 Iron status and metabolism 
The median Hb concentrations of participants were borderline with respect to the 
recommended range according to the UK-Renal Association guideline, and half of the 
participants had low Hb status. Mean serum iron, ferritin and median transferrin saturation 
(%TSAT) levels were all within the recommended range. The majority of participants had their 
serum iron and %TSAT within recommendations, whereas for ferritin, more than a third of 
participants had their levels above the recommendations (table 4:4). 
There were no significance differences in the levels of Hb, ferritin, serum iron, serum 
transferrin receptor (sTfR), %TSAT and hepcidin-25 between genders or between the three 
ethnic groups (all P > 0.05). The trend towards significance gender difference was observed on 
hepcidin-25, males having higher values than females (table 4:9). 
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Table 4:9 Analysis results showing gender and ethnicity comparison on the mean/ median values of 
indices of iron status and metabolism at baseline 
  Hb* 
(g/l) 
Ferritin* 
(ng/ml) 
sFe* 
(μmol/l) 
sTfR* 
(mg/l) 
%TSAT† Hepcidin-
25†(ng/ml) 
ERI† 
Gender  Male 102.9 
(±12.8) 
422.2 
(±241) 
11.5 
(±4.2) 
6 
(±2.3) 
31.8  
(±23.8) 
27.5  
(16.8, 41) 
0.006 
(0.003,0.009) 
Female 98.5 
(±13.8) 
363.8 
(±129.3) 
11.2 
(±3.8) 
6.3 
(±2.7) 
28.8  
(22.8,36.9) 
19.4  
(12, 24.2) 
0.008  
(0.003, 0.01) 
P 0.3 0.4 0.8 0.7 0.5 0.05 0.3 
Ethnicity Black 101.3 
(±15.3) 
418.6 
(±240.9) 
12.2 
(±4.9) 
6.5 
(±2) 
30.1  
(23.8,44.2) 
19.1  
(14.1,34.9) 
0.005  
(0.002, 0.01) 
White 102.8 
(±9.8) 
350 
(±158) 
10.2 
(±2.5) 
5.5 
(±2.2) 
25.6  
(22.1,39.3) 
21.5  
(14.9,37.3) 
0.005  
(0.002,0.008) 
Asia-
Indian 
100.4 
(±14.8) 
443.9 
(±227.5) 
12 
(±4.3) 
6.3 
(±3) 
35  
(23.5,42.5) 
34.9  
(17.6,41.8) 
0.007 
(0.005,0.009) 
P 0.9 0.6 0.4 0.5 0.5 0.3 0.9 
Hb = haemoglobin; sFe = serum iron; sTfR; serum transferrin receptor; TSAT= transferitin saturation; *Mann-
Whitney test; †Kruskal Wallis Test, significance <0.05. Data presented as median (25th, 75th) or mean (±SD) 
 
There was no influence of age, HD vintage or URR on markers of iron status or metabolism 
(Hb, ferritin, iron, sTfR and %TSAT) (all P > 0.05). Similarly, there were no association 
between inflammatory markers,  PTH, dietary iron intake or indices of body composition and 
these markers, except for dietary iron which correlated positively with serum iron (r = 0.39, p 
= 0.05) and with %TSAT (r = 0.41, p = 0.04). There was also a positive association between 
Hb concentration and leptin hormone (table 4:11) and a significant negative correlation 
between sTfR and hepcidin -25 (r = -0.33, p = 0.04). 
Spearman correlation coefficient showed no relationship between EPO or iron dose and Hb, 
serum iron, ferritin, %TSAT or transferrin receptor (all P > 0.05).  
There were no differences in Erythropoietin resistance index (ERI) by gender (t=-0.54, p=0.6) 
or ethnicity (F=0.36, p=0.7). ERI did not correlate with any of the study’s nutritional indices, 
body composition variables, inflammation markers or biomarkers of iron status and 
metabolism (table 4:11). 
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4.7.3.5 Quality of life (QoL) 
The scores for quality of life in physical component were below 50th percentile, whereas the 
score of mental component was at the borderline above the 50th percentile of the general 
population in a 0-100 score range. There was no gender or ethnicity differences on the QoL 
score (table 4:10).  
Table 4:10: The median score, gender and ethnicity comparison for physical and mental component of 
quality of life among the study participants 
 N Median  
(25th,75th percentile) 
#Gender †Ethnicity 
PCS 31 38 (29, 47) Male = 38(29.3,47.1) 
Female = 32.2 (27.7, 39.2) 
Black = 38.3 (28.6, 47.4) 
White = 30 (21.5, 48.2) 
Asian-Indian = 37.4 (34, 39.4) 
P = 0.3 P = 0.8 
MCS 31 52 (42, 59) Male = 55.2 (42.6, 60.3) 
Female = 47.3(28.6, 56.2) 
Black = 43.8 (39.5, 58.9) 
White = 52.4 (40.5, 57.5) 
Asian-Indian = 56.2 (50.2, 64.1) 
P = 0.1 P =0.3 
PCS = Physical component score; MCS = Mental component score; Mann-Whitney test; Kruskal-Wallis test; P 
< 0.05 
Physical component of QoL was positively associated with lean tissue index (r = 0.5, p = 0.02) 
and negatively associated with dialysis vintage (r = -0.43, p < 0.01). There was no significant 
correlation between either of the two components of QoL with other markers of body 
composition, inflammation or dialysis adequacy (p > 0.05).
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Table 4:11: Correlations between iron status or metabolism and markers of nutritional status, dietary iron, body composition, inflammation, dialysis adequacy 
and PTH in adult on haemodialysis (n = 41) 
* Statistically significant at p < 0.05; ** Statistically significant at p < 0.01, Pearson correlation coefficient; sFe = serum iron; TSAT = Transferrin saturation; ERI = 
Erythropoietin resistance index; BMI – Body mass index; LTI = Lean tissue index; FTI = Fat tissue index; HGS = Hand grip strength; WC= Waist circumference; OH = 
Overhydation; PTH = Parathyroid hormone; C-RP= C-reactive protein; URR = Urea reduction ratio
 Age HD  
vintage 
URR Leptin IL-6 C-RP Dietary  
iron 
Alb. BMI LTI FTI HGS WC OH PTH ERI 
 
Hb 0.25 0.14 -0.02 0.34* 0.09 0.11 0.18 0.13 0.08 -0.21 0.04 0.11 -0.04 -0.07 0.03 -0.37* 
sFe 0.08 0.13 0.07 -0.09 -0.16 -0.17 0.39* 0.02 -0.24 0.20 -0.35 -0.17 -0.31 -0.05 0.06 -0.21 
Ferritin -0.04 0.12 0.13 0.04 0.06 0.10 0.04 -0.02 0.07 -0.31 0.12 -0.22 0.66 -0.12 0.62 0.06 
TSAT -0.02 0.11 0.14 -0.15 -0.00 -0.03 0.41* -0.14 -0.22 0.07 -0.36 -0.22 -0.27 -0.03 -0.02 -0.02 
sTfR 0.29 0.17 0.04 0.14 0.24 0.13 -0.3 0.09 -0.001 -0.13 0.15 0.15 0.08 -0.21 -0.51 -0.02 
Hepc-25 -0.02 -0.02 -0.03 -0.06 0.24 0.19 0.48 -0.05 -0.08 -0.002 0.05 -0.09 0.03 0.22 0.25 -0.03 
ERI -0.34 -0.07 0.45* -0.25 -0.06 0.19 -0.16 -0.28 -0.27 -0.31 -0.29 -0.19 -0.22 0.07 0.13  
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F (3, 96) = 1.04, p = 0.38, Partial ƞ2 = 0.03 
n1= 42; n2 = 40; n3 = 39; n4 = 39 
 
4.7.3.6 Dialysis adequacy 
The mean Urea Reduction Ratio (URR) of the study participants was within the recommended 
range and indeed the majority of participants had satisfactory levels (table 4:4). There was no 
significant difference in URR across three ethnic groups (F = 0.34, p = 0.71) and there was a 
trend but not statistically significant gender difference in URR (t=-1.73, p = 0.09) whereby 
females had better URR than males. Similarly, age (r = 0.09, p=0.56) or HD vintage (r = 0.19, 
p = 0.24) had no influence on URR levels of the study participants. 
4.7.4 Longitudinal analysis of the studied parameters 
4.7.4.1 Nutritional status and body composition 
A repeated measure ANOVA analysis showed that there was no effect of time on albumin, 
BMI, LTI, FTI, HGS,WC, OH or leptin hormone levels across the four month follow-up period 
(figure 4:8 (a - b) and figure 4:9 (a - f).  
 
 
 
 
(a) Albumin (g/l) 
 
 
Figure 4:8: Results from repeated measure ANOVA analysis showing the mean levels of nutritional indices and body 
composition markers over four measurement time points for study participants. Error bars represent 95% confidence intervals 
 
F (3, 27) = 1.87, p = 0.2, Partial ƞ2 = 0.17 
n1= 36; n2 = 37; n3 = 36; n4 = 36 
 
(b) BMI (kg/m2) 
           Cut off point     
for normal range 
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Figure 4:9: Results from repeated ANOVA analysis showing the levels of nutritional indices and body composition markers 
over four measurement time points for study participants. Error bars represents 95% confidence interval 
F (3, 33) = 1.34, p = 0.28, Partial ƞ2 = 0.11 
n1= 35 ; n2 = 35; n3 = 34; n4 = 31 
 
F (3, 24) = 0.29, p = 0.64, Partial ƞ2 = 0.04 
n1= 35 ; n2 = 35; n3 = 34; n4 = 31 
 
F (3, 30) = 1.36, p = 0.27, Partial ƞ2 = 0.12 
n1= 33 ; n2 = 35; n3 = 34; n4 = 31 
 
F (3, 81) = 0.99, p =0.38, Partial ƞ2 = 0.04 
n1= 35 ; n2 = 37; n3 = 34; n4 = 34 
 
F (3, 21) = 0.89, p = 0.46, Partial ƞ2 = 0.11 
n1= 32 ; n2 = 35; n3 = 34; n4 = 31 
 
F (3, 33) = 0.05, p = 0.86, Partial ƞ2 < 0.01 
n1= 34 ; n2 = 35; n3 = 34; n4 = 31 
 
(a) LTI (kg/m2) (b) FTI (kg/m2) 
(c) Leptin (ng/ml) 
(d) Waist circumference (cm) 
()(kg/m2) 
(e) Overhydration (l) 
(f) HGS (kg) 
(kg/m2) 
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F (3, 75) = 2.33, p = 0.08, Partial ƞ2 = 0.09 
n1= 41; n2 = 38; n3 = 34; n4 = 37 
 
4.7.4.2 Iron status and metabolism 
There was no time effect on Hb, ferritin, serum Transferrin receptor(sTfR) and hepcidin-25 
levels across four month follow-up period (figure 4:10 (a - e)). 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:10: Results from repeated measure ANOVA analysis showing the levels of markers of iron status and metabolism 
over four measurement time points for study participants. Error bars represent 95% confidence intervals 
F (3, 99) = 1.19, p = 0.31, Partial ƞ2 = 0.04 
n1= 44; n2 = 40; n3 = 39; n4 = 38 
 
F (3, 60) = 1.03, p = 0.35, Partial ƞ2 = 0.05 
n1= 39; n2 = 34; n3 = 29; n4 = 31 
 
F (3, 78) = 0.44, p = 0.72, Partial ƞ2 = 0.02 
n1= 41; n2 = 37; n3 = 34; n4 = 36 
 
F (3, 60) = 0.7, p = 0.49, Partial ƞ2 = 0.03 
n1= 33; n2 = 35; n3 = 28; n4 = 25 
 
(a) Haemoglobin 
(b) Ferritin (ng/ml) 
(c) Hepcidin-25(ng/ml) 
(ng/ml) 
……………Cut off point     
for normal range 
(d) sTfR (mg/l) 
(e) ERI 
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Similarly, the levels of serum iron (F (3, 84) = 3.82, p = 0.31) and transferrin saturation 
percentage (F (3, 84) = 3.05, p = 0.33) did not differ across four time points.  
4.7.4.3 Inflammatory markers 
There was no time effect on either C-RP and IL-6 levels of the study participants (figure 4:11 
(a-b)) 
 
 
 
 
 
 
 
Figure 4:11: Results from repeated measure ANOVA analysis showing the levels of inflammatory markers over   
four measurement time points for study participants. Error bars represent 95% confidence intervals 
 
4.7.4.4 Dialysis adequacy 
Analysis showed that Urea reduction ratio (URR) did not differ across the four month period 
(figure 4:12). Gender (F(1,14)=7.45, p=0.02, Partial ƞ2 = 0.35) influenced URR levels (females 
had better URR across four months) where-as ethnicity (F(1,14)=0.71, p=0.51, Partial ƞ2 = 
0.09), age (F(2,10)=1.52, p=0.27, Partial ƞ2 = 0.23) and HD vintage (F(2,10)=2.21, p=0.16, 
Partial ƞ2 = 0.31) had no influence on the dialysis adequacy of participants across four time 
points. 
F (3, 90) = 0.29, p = 0.83, Partial ƞ2 =0.01 
n1= 42 ; n2 = 39; n3 = 39; n4= 38 F (3, 63) = 0.32, p = 0.81, Partial ƞ2 = 0.02 
n1= 39; n2 = 32; n3 = 31; n4 = 31 
 
(a)C-RP (mg/l) 
(b) IL-6 (pg/ml) 
……………Cut off point     
for normal range 
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Figure 4:12: Results from repeated measure ANOVA analysis showing the levels of Urea reduction ratio over four   
                 measurement time points for study participants. Error bars represent 95% confidence intervals 
 
4.7.5 The impact of body composition on haemoglobin and erythropoietin resistance 
index over four months’ period 
A mixed design two ways-repeated measure ANOVA (Split-plot ANOVA) was performed to 
analyse the impact of markers of body composition on Hb and ERI across four time points. 
The model included the mean score (of four time points) of body composition markers as 
independent variable of interest, adjusting for gender, EPO type, EPO dosage.  
Table 4:12: Split-plot ANOVA analysis results showing the impact of markers of body composition on haemoglobin 
concentration and ERI across four months periods for a cohort of haemodialysis patients (N = 41) 
 Haemoglobin (g/l) ERI 
 F P Effect size F P Effect size 
BMI 1.896 0.18 0.07 0.577 0.47 0.06 
FTI 4.747 0.04 0.17 0.001 0.97 < 0.001 
LTI 2.494 0.13 0.09 0.046 0.84 0.01 
HGS 0.632 0.43 0.03 0.000 0.99 < 0.001 
WC 2.825 0.11 0.11 0.344 0.57 0.04 
OH 1.066 0.31 0.04 2.127 0.18 0.19 
Albumin 2.542 0.12 0.09 0.196 0.667 0.02 
Leptin 0.013 0.91 0.001 0.031 0.86 0.003 
BMI = Body mass index; FTI = Fat tissue index; LTI=Lean tissue index; HGS = Hand grip strength; WC = Waist 
circumference; OH = Overhydration; ERI = Erythropoietin resistance index 
 
F (3, 54) = 1.03, p = 0.39, Partial ƞ2 = 0.05 
n1= 40 ; n2 = 35; n3 = 34; n4 = 31 
 
……………Cut off point     
for normal range 
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Among all studied markers of body composition, only FTI showed a significant association 
with Hb concentration (table 4:12). Hb concentration was positively associated with FTI at all 
four time points. There was no impact on all markers of body composition on ERI (table 4:12). 
Similarly, there was no impact of the studied indices of body composition on other markers of 
iron status and metabolism (serum iron, ferritin, sTfR or %TSAT), P > 0.05. 
4.7.6 The impact of inflammatory markers and hepcidin-25 hormone on haemoglobin 
and erythropoietin resistance index over four months period 
Analysis results from a Split-plot ANOVA (controlling for gender, EPO type and dosage) 
showed no significant impact of inflammatory markers on either ERI or Hb concentration 
across four time points (except for a trend towards a significant positive association between 
IL-6 and Hb concentration). Equally, hepcidin-25 had no impact on either Hb or ERI (table 
4:13). There was no relationship between inflammatory markers and other studies markers of 
iron status and metabolism (serum iron, ferritin, sTfR and %TSAT), all p > 0.05. 
Table 4:13: Split-plot ANOVA analysis results showing the impact of markers of inflammation and hepcidin-25 on 
haemoglobin concentration and ERI across four months periods for a cohort of haemodialysis patients (N = 41) 
 Haemoglobin (g/l) ERI 
 F P Effect size F P Effect size 
IL-6 3.797 0.06 0.15 0.566 0.47 0.07 
C-RP 0.705 0.41 0.03 0.182 0.68 0.02 
Hepcidin-25 0.756 0.39 0.03 0.104 0.76 0.01 
IL-6 = Interleukin 6; C-RP = C-reactive protein 
4.7.7 The impact of dialysis adequacy and PTH level on haemoglobin and 
erythropoietin resistance index over four months period 
Split-plot ANOVA showed no significant impact of URR or PTH on either Hb concentration 
or ERI over four months’ period (table 4:14). This was independent of gender, EPO type or 
dosage.  
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Table 4:14: Split-plot ANOVA analysis results showing the impact of dialysis adequacy and PTH hormone on 
haemoglobin concentration and ERI across four months periods for a cohort of haemodialysis patients (N = 41) 
 Haemoglobin ERI 
 F P Effect size F P Effect size 
URR 0.411 0.53 0.12 1.813 0.21 0.15 
PTH 0.241 0.63 0.01 2.450 0.15 0.197 
URR = Urea reduction ratio; PTH = Parathyroid hormone 
Similarly, there was no impact of URR and PTH on other studies markers of iron status and 
metabolism (serum iron, ferritin, sTfR and %TSAT), all p > 0.05. 
4.8 Discussion 
The findings from our previous cross-sectional study (chapter 3) suggested that there could be 
an influence of nutritional status and body composition on patients’ response to EPO therapy.  
In particular, Hb positively correlated with serum Iron, Albumin, HGS and a measure of muscle 
(MAMC). This study was therefore designed to study further that association by involving a 
broader range of markers of nutritional status, body composition and iron status and 
metabolism. It also involves investigation of other potential modifiers including inflammatory 
markers and dialysis adequacy. Moreover, the investigation was conducted longitudinally in 
an attempt to gain a greater more insight into the subject.    
The study was conducted in the outpatient dialysis units and a total of 41 HD patients on EPO 
therapy were consented and recruited to take part, representing 35% of the eligible population 
across the three sites. The age of participants ranged from 31 to 92 (median = 64) years and 
male participants outnumbered females (72%). This was not surprising as all the dialysis units 
had more male patients on haemodialysis, so the sample appeared to be representative with 
regards to gender. Moreover, the recent UK renal registry376, whilst not specifying the type of 
renal replacement (RRT) modality, shows that generally, there are more male patients on RRT 
than female independent of age in the UK (incidence 63% male).  Similarly, the median age 
observed in this study cohort was similar to that of HD patients reported in the UK renal registry 
(64 ‘vs’67 yrs). The gender differences in favour of male also appeared in previous sub-studies 
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presented on the previous chapters of this work and has also been reported by other 
authors290,294,377 in different geographical regions. As explained in previous chapters this 
difference could be because males  have higher risk of developing CKD risk factors such as 
diabetes291 and hypertension292 than females. It has also been noted that the females tend to 
start dialysis later in life than males294 and that the protective effects of oestrogen in women 
and/or the damaging effects of testosterone, together with unhealthier lifestyles, might cause 
kidney function to decline faster in men than in women378. 
This study cohort had most participants of black ethnicity (41%) followed by white (35%), 
with those of Asian-Indian (24%) race being the smallest sub-group. Studies that have looked 
at racial differences in CKD have shown high rates of declining kidney function379 and of 
developing ESRD condition380,381 in black compared to white ethnic groups in the USA. A 
similar observation was made in a UK (London) diabetic population382. Genetic differences are 
suggested to be one of the possible explanations for the racial differences but also high levels 
of diabetes and malignant hypertension in the black population 383,384.  
Nutrition, body composition and handgrip strength differences between genders and race 
The findings showed that participants had sub-optimal intakes of energy and protein 
independent of gender. It is ideal for HD patients to maintain their protein and energy intake 
above 1.2kg/body weight/day and 35kcal/body weight/day respectively131,135. This is in order 
to cope with the loss of nutrients associated with the dialysis treatment and raised uremic 
catabolic state that predisposes this group to protein energy wasting. Participant dietary iron 
intake was also at borderline with the majority of female participants exhibiting low intake 
compared to male counterparts.  Nevertheless, nutritional status as indicated by their average 
BMI was within the recommended range and only 19% (n=6) of participants had their BMI at 
the lower end of the normal range.  Moreover, although their HGS were below the cut off point 
for general population, the median values were comparable or above those reported in other 
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haemodialysis cohorts. The median HGS level were also above cut off pointed reported to be 
linked with increased risk of all-cause mortality among haemodialysis patients.  
Conversely, albumin levels were below recommendations making the nutritional status of these 
participants questionable despite their satisfactory BMI and HGS status. The accuracy of both 
BMI and albumin to identify nutritional status has also been challenged and is discussed in a 
previous chapter 1. BMI is simply the ratio of crude body weight and height and it does not tell 
us much about the body composition. It is therefore likely for patients to have muscle wasting 
and present with an optimal BMI level simultaneously, for example in the case of sarcopenic 
obesity or when muscle wasting is masked by an oedematous state which are all highly 
prevalent among dialysis patients. Similarly, albumin is also an acute phase reactant decreasing 
with inflammation and therefore limiting its limitation in inflamed individuals.  
This study found that being male and of black ethnicity had a positive advantage on muscle 
mass. With regards to gender, the difference is believed to be related to the physiological 
differences in gene expression in human skeletal muscles between males and females, hence 
differences in body composition proportions385, similarly  for different ethnic groups. 
Comparable results of ethnic difference in lean mass among dialysis patients were reported in 
a recent study by Yoowannakul et al.386 where male and female patients of Black ethnicity had 
the highest lean mass (measured by bioimpedance), followed by their White counterparts and 
then those of Asian ethnicity. 
Iron parameters, inflammation and dialysis adequacy (URR) 
It was evident that the median levels of haemoglobin and ferritin were satisfactory. However, 
half of participants exhibited sub-optimal Hb levels, and their status was independent of gender, 
ethnicity, age, HD vintage and URR.  Also 48% had low serum Iron; 14% had low transferrin 
saturation percentage and 18% had low ferritin. However, about one third of participants had 
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ferritin levels above the UK-RA recommendation of 200 – 500ng/ml179. This could be a 
reflection of both iron overload and/or inflammation. The median transferrin receptor was 
beyond the reported threshold for detecting iron deficiency (> 1.5mg/l)387 meaning that these 
patients’ low haemoglobin levels are likely to be due to functional iron deficiency. There were 
no significance differences in ferritin, and transferrin receptor nor in weekly EPO dosage or 
erythropoietin resistance index (ERI) between gender or the ethnic groups.  
As reported above, participants’ average inflammatory marker (C-RP) levels and the status of 
the majority (68%) of individual participants (at baseline were within acceptable ranges (< 5 
mg/l). The median IL-6 in the present study was also lower than that reported in several studies 
of haemodialysis patients 388-391 and could result in a lower cardiovascular mortality risk392. 
Generally, participants in this cohort were adequately dialysed reflected by URR > 65 in 88% 
of participants, although females appeared to achieve greater adequacy than males, probably 
due to a higher metabolic burden (greater muscle mass) in males as compared to female393,394.  
There were no ethnic differences for measurements of C-RP, IL6, HD vintage or URR. 
Relationships between the investigated parameters 
In the present study, the albumin levels are negatively associated with C-RP, decreasing with 
the increase in the inflammatory marker. As discussed earlier in chapter 1, there are some 
limitations in the utilization of albumin as a nutritional marker (for inflamed individuals), as 
the marker is also a negative acute phase reactant and tends to decrease with 
inflammation126,127,129. Although it is not uncommon for malnutrition and inflammation to co-
exist in this population group (specifically in the condition called Malnutrition-Inflammation 
Syndrome, MIS) 218,395,396, interpretation of nutritional status based on albumin level should 
thus be done with caution and with consideration of other nutritional and inflammatory 
biomarkers or indices.  
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In the present study, BMI was associated positively with fat tissue but not with lean tissue, or 
HGS whereas HGS was significantly associated with lean tissue and albumin status of 
participants. This is in line with the current state of knowledge that in this physiological state, 
HGS is often more informative of muscle status as it provides a reliable measure of muscle 
function350,353,397.  The level of HGS (and similarly lean tissue mass) decreased with an increase 
in participants’ age, a possible reflection of normal physiological loss of muscle function with 
aging398,399.  This study found dialysis vintage to be the unique predictor of HGS with a 0.99 
fold decrease in HGS with every month increase in HD vintage. The finding concurs with other 
researchers400, suggesting the long term negative effect of dialysis on muscle strength which 
may be due to the relationship with inflammation. LTI was also found to decrease with the 
increase of CRP and IL-6, i.e higher levels of inflammation were associated with lower muscle 
mass measurements.  
Interestingly, URR correlated negatively with LTI and handgrip strength, which may imply 
that patients with better muscle mass (and hence better grip strength) were receiving less 
dialysis.  This could have a negative long term consequences as it might increase the risk of 
uraemia and inflammatory responses.  
There were no associations between baseline markers of iron status and metabolism with 
anaemia therapies prescribed, baseline nutritional status, body composition, inflammation or 
PTH level. However, the level of serum iron and % TSAT significantly increased with dietary 
intake of iron suggesting that improving intake might be beneficial for iron status in these 
patients. There was a significant association between dietary protein and iron intake suggesting 
that the better protein intake might also help to increase dietary iron and hence improving iron 
status. The baseline Hb concentrations of participants in the previous cross-sectional study 
(chapter 3) were lower than those of the present cohort which may explain the lack of 
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association seen here.  It is likely that the previously observed association between body 
composition and EPO response index exists for severely anaemic cases.  
However, baseline Hb concentration was found to be positively associated with leptin. Leptin 
is a peptide hormone secreted by the adipose tissue and known to be responsible for regulating 
food appetite401 and energy expenditure402. Leptin is also a positive acute phase protein 
upregulated by cytokines403 and normally cleared by the kidneys 404. The level of leptin is thus 
often elevated in patients with kidney failure405,406 due to the reduced kidney clearance and 
elevated inflammatory cytokines. In agreement with findings from the current study, other 
authors have shown a positive correlation between leptin hormone and haematological markers 
like Hb406,407 supposedly due to its long established haematopoietic role (stimulating 
proliferation of haematopoietic stem cells)370 which when acting synergistically with EPO will 
consequently increase erythropoiesis.  Leptin is also known to be elevated in obese individual 
as a response to increased adiposity408. It is possible that the mechanism behind the 
advantageous effect of body fat seen in the present study is through leptin upregulation as there 
was also a positive correlation between baseline leptin hormone and body fat.  However, it is 
also worth noting that, leptin hormone did not correlate with any other haematopoietic markers 
like sTfR whose positive association would have confirmed an increase in erythropoiesis with 
the increase in leptin. Similarly, one would expect to see the decrease in ERI with an increase 
in leptin hormone. The involvement of leptin and body fat in erythropoiesis is therefore still an 
area requiring further investigation to establish causal relationship.  
There was negative correlation between Serum Transferrin receptor (sTfR) and hepcidin-25 
hormone and also with ferritin levels. Hepcidin-25 is a peptide hormone produced by the liver 
cells and it is responsible for iron metabolism, controlling intestinal absorption of iron and its 
release from the reticuloendothelial cells166,409. In the present study, the levels of hepcidin-25 
were higher than those reported in other studies of haemodialysis patients410,411. Upregulation 
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of hepcidin-25 reduces iron availability for red blood cell production412, and therefore it is not 
surprising that it was found to be negatively correlated with sTfR (reflecting a reduction in iron 
availability/uptake413) in the present study. The median sTfR in the present study (6.2mg/l) 
indeed met the suggested threshold value (>1.5mg/l) for iron deficiency387. A prospective study 
of pre-dialysis patients supplemented with iron conducted by Drakou et al414 also found a 
negative correlation between hepcidin-25 and sTfR. Other studies have also shown a negative 
association between hepcidin-25 and other biomarkers of iron status, such as haemoglobin 
concentration, in both CKD non-dialysis415,416 and dialysis410 patients.  In the present study, 
sTfR also appeared to increase with a decrease in ferritin, this is a normal relationship such that 
it is expected for sTfR expression to be enhanced as a response to iron depletion in order to 
increase iron uptake417,418. Similarly, in the context of ESA treatment, the increase in sTfR 
means an increase in erythropoiesis activity and it is found to increase with increase with ESA 
dosage419.  
The quality of life (QoL) of the participants in the present study were satisfactory on the mental 
component as their scores were above the 50th percentile of the general population. On the other 
hand, their scores on the physical function component were very low and this was associated 
body composition, EPO resistance and dialysis vintage. Quality of life decreased with the 
decrease in lean tissue index (LTI) and also decreased with an increase in dialysis vintage and 
EPO resistance index. The association between LTI and QoL was also evident in another study 
of dialysis patients 420 and this emphasizes the importance of maintaining good muscle mass in 
this vulnerable group. Similarly, it is not surprising for resistance to EPO to correlate with poor 
quality of life as anaemia significantly reduces physical performance of patients and treatment 
with EPO has been demonstrated to improve QoL421. The reduced QoL with the length of time 
since the initiation of dialysis could be linked with the cumulative disadvantage of catabolic 
properties of the treatment and the psycho-social burden of dialysis. It has long been noted that 
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the contact between blood and the dialyzer membrane stimulates protein catabolism422 and this 
could potentially translate to muscle wasting and poor physical functionality of patients. There 
is also loss of amino acids into the dialysate during haemodialysis423, which is another potential 
cause of muscle wasting in the presence of poor dietary intake which these patients exhibited. 
Longitudinal changes in body composition and inflammation and their association with 
anaemia markers 
The present study found no significant changes in nutritional status and body composition 
across the four months follow up period. This was irrespective of gender or ethnicity. Similarly, 
there were no significant changes on haemoglobin, serum iron, ferritin, serum Transferrin 
receptor (sTfR), transferrin saturation percentage and hepcidin-25 levels. There were no 
changes in inflammation status or dialysis adequacy.  
The negative association between albumin levels and C-RP that was observed at baseline 
remained across the follow up period. Also, although there was no direct relationship between 
inflammation and muscle strength at baseline, in longitudinal analysis both IL-6 and C-RP had 
a negative association with HGS. This shows that inflammation might have has a long term 
negative impact of nutritional status and muscle strength of patients. 
 The baseline analysis had showed a negative association between dialysis adequacy (URR) 
and a measure of muscle strength (HGS). This relationship remains true at longitudinal analysis 
and it does raise concerns about the dialysis adequacy of patients with high muscle mass.  
Although there were no baseline associations between markers of iron status and metabolism 
with nutritional status and body composition, longitudinally, there was a positive association 
between Hb concentration and a measure of body fat. As previously discussed, this suggested 
the long term effect of body fat on Hb could be due to the action of leptin hormone as observed 
by other researchers225,365,406.  
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Other markers of iron status and metabolism remained independent of nutritional status and 
body composition during follow up period. Similarly, there was no influence of inflammation 
or dialysis adequacy on Hb, ERI or other markers of iron status and metabolism (serum iron, 
ferritin, sTfR or %TSAT) across the four month period. 
4.9  Limitations to the study 
The ethics application process was longer than anticipated which caused a delay in 
commencing research activities, and consequently, the study was conducted within a shorter 
time frame than originally planned. This study was conducted in a clinical setting and all 
activities were in line with clinic routine care. The researcher had no control over clinic 
activities and so the research activities had to be continually adapted to fit in with clinical 
schedules, staffing and patient availability. This had significant implications for not only the 
timing of the research but also the ability to recruit the number of patients required and 
subsequently to achieve the research outputs originally planned.  
The study design could have been better planned such that patients who were better respondent 
of EPO i.e those with Hb concentration within the target (100 – 200g/l) are included into the 
study and used as a reference cohort. It is understood that EPO treatment is prescribed to 
patients with suboptimal Hb levels. Therefore even if these were intentionally included in the 
study, we are not confident that a comparable number to those with Hb concentration below 
range would have been obtained and recruited. The study therefore missed the reference cohort 
group hence limiting its findings and could not reach a definite conclusion as to the association 
between muscle mass, body fat and EPO responses.  
Although the BCM ©Fresenius Co. is validated for estimation of body composition in this group 
of patients, the accuracy of the measurements are still questionable due to the known 
confounding effect of hydration status. Specfic measurement techniques (e.g subject 
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positioning, cleanliness of the skins) have also been found to reduce the accuracy of the 
measurement. Nevertheless, this tool, like any other Bio-impedance analyser that utilises body 
fluid conductance theory in the estimation of body composition, has inherent limitations as a 
measure of true body fat and muscles. There are alternative robust techniques that employ 
imaging technologies,  are more sensitive and are deemed to provide a more accurate measure 
of body fat and muscle, for example Dual-energy X-Ray Absorptiometry (DEXA), magnetic 
resonance imaging (MRI) and Computed Tomography (CT). However, these are expensive and 
require a level of expertise that was not available in the present research work.  
All research activities were to be conducted during the participants’ usual dialysis visits to 
minimise burden yet this created issues with regard to the time available within a session to 
speak to all relevant  participants and to conduct all desirable measures without interfering with 
the  clinic processes. 
There were technical challenges with analysis of some of the biomarkers of inflammation and 
iron metabolism. There was a fault with the instrument (Bio-plex luminex) used for analysis 
and parameters were out of range for most samples limiting the reliability of the results. For 
this reason results for IL-10 (an anti-inflammatory marker) could not be included in this report 
as the readings obtained were far below the standard curve.   
4.10 Conclusion  
Participants’ dietary intakes were below the recommended range but this did not appear to have 
a significant association with their nutritional status (the overall condition as assessed by SGA 
was generally satisfactory). However, iron intake correlated positively with protein intake and 
also with iron levels.  
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Although there was no significant changes in haemoglobin concentration across the four 
months of the follow up period, the findings suggested a positive association between body fat 
and leptin on haemoglobin levels.  
The known influence of hepcidin-25 on iron status and metabolism (and interaction with 
transferrin receptors) was also observed.  
There were a significant association between inflammation status, dialysis adequacy and LTI 
(an index of muscle mass) which suggested that people with larger muscle mass were not being 
adequately dialysed. This may lead to a negative impact on quality of life. Participants’ quality 
of life based on the mental health component were satisfactory but they had low quality of life 
on physical function component. Moreover, this deteriorated with dialysis vintage as did hand 
grip strength. This may highlight the need for physical rehabilitation interventions to improve 
physical function and quality of life. It might be beneficial for the renal clinics to include 
physical rehabilitation services alongside other clinical care. 
4.11  Recommendations 
 The clinics should consider a regular and more in depth assessment of iron and 
protein intake as these were found to be sub-optimal and influencing iron status 
 The dialysis adequacy of patients with larger muscle mass should be reviewed to 
reduce the risk of them being under dialysed 
 Physical rehabilitation interventions to improve physical function should be 
implemented 
 Interaction between body composition, inflammation, quality of life and anaemia 
needs further investigation with larger cohort and over longer period of time 
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4.12 Future work 
Following on from this work, an exercise intervention trial was adopted and conducted to test 
its feasibility and continue investigating if changes in body composition, dialysis clearance, 
inflammation and physical functioning that can be achieved via exercise among haemodialysis 
patients. We also assessed whether these changes could modify how patients respond to 
erythropoietin treatment. The findings will inform the clinic of alternative practical therapeutic 
options that can be used to improve patients’ response to therapies and their well-being. If 
patients respond better to the EPO treatment, this could also reduce costs associated with the 
treatment. 
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CHAPTER 5 
5 A COMBINED AEROBIC (WALKING) AND RESISTANCE 
INTRADIALYTIC EXERCISE INTERVENTION: 
FEASIBILITY, ACCEPTABILITY AND IMPACT ON 
NUTRITIONAL STATUS, BODY COMPOSITION, 
INFLAMMATORY MARKERS AND QUALITY OF LIFE 
AMONG UK HAEMODIALYSIS PATIENTS ON 
ERYTHROPOIETIN THERAPY  
5.1. Introduction and rationale of the study 
Patients with kidney failure receiving haemodialysis experience a high symptom burden424,425. 
The symptoms can include tiredness and fatigue, muscle cramps, drowsiness, dry skin, bodily 
pain, and itching 426-429 to name a few. These are attributed to several factors including the 
demographic characteristics of the patients (e.g. age, gender, socio-economic status)424,427,430; 
the disease itself and associated comorbidities (e.g. bone mineral disorders431, anaemia430, 
muscle wasting) and treatments 430,432; Increases in the presence of these symptoms have a 
significant impact on patients’ physical and emotional functioning and ultimately contributes 
to  a reduced quality of life433.  
For this reason, interventions to alleviate the symptoms have been investigated and exercise/ 
increased physical activity has been proposed to have the potential to improve patients’ quality 
of life across the CKD spectrum434. Exercise interventions have not only been proven to be 
beneficial in improving physical functioning of dialysis patients435, but have also been shown 
to help improve dialysis adequacy264, reduce inflammatory symptoms, improve vascular 
health265 and body composition436. Moreover, Reboredo Mde et al.270 found an increase in 
Haemoglobin (Hb) concentration among patients with ESRD following 30 minutes of 
intradialytic aerobic exercise on a cycle ergometer performed three times weekly for 12 weeks. 
The Tanzanian based cross-sectional study (presented in chapter 3) showed a relationship 
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between body composition and erythropoietin (EPO) response such that the Hb concentration 
and erythropoietin response index (ERI) increased with the increase in muscle mass. Also, a 
longitudinal study presented in chapter 4 found a relationship between better LTI and lower 
inflammatory markers. It would be interesting to investigate further the mechanism involved 
and establish whether an exercise programme will be beneficial in improving both body 
composition and EPO response or inflammatory response among haemodialysis patients.  
Exercise intervention approaches that combine aerobic and resistance training have been shown 
to have an added advantage in improving functional performance compared to when either of 
the training approaches is applied alone253. However, most exercise studies involving dialysis 
patients have utilized stationary bikes (cycle ergometer) for aerobic exercise263-265,267,270,437 but 
these are expensive (£200 to £10,000 each) and their availability is limited in resource 
constrained settings. Few studies have opted for a simple and flexible form of aerobic exercise 
such as walking and although benefits are reported for this approach, these studies have mostly 
been conducted in non-dialysis patients 438,439.  In the current study, the exercise intervention 
protocol combined a flexible aerobic exercise (walking) with progressive intradialytic 
resistance training for HD patients with the aim of improving not only muscle strength but 
overall physical functionality. This exercise protocol was considered to be safe in this patient 
group as no adverse effects were reported with the use of a similar training programme carried 
out in a HD population by Cheema et al.440 and Bennett et al.441. Moreover, in the meta-analysis 
of 24 intradialytic exercise RCTs (aerobic (n=13), resistance (n=7) and combined (n=4)) by 
Sheng et al. 442, only three studies reported adverse events and these were mainly 
musculoskeletal complications (injury and limb pain) and hypotension. 
We conducted this exercise intervention as a feasibility pilot RCT study in preparation of a 
potential large RCT intervention in the future.  Although The UK Medical Research Council 
(MRC) guidance on designing and evaluating complex interventions443 recommends that 
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“pilot” and “feasibility” studies are conducted in preparation for definitive RCT interventions, 
it does not give distinctive definitions of the two terms. However, the guidance suggests these 
studies are conducted with the aim of testing, e.g the study procedures for their acceptability, 
estimating the likely rates of recruitment and retention of subjects, and the calculation of 
appropriate sample sizes. Nevertheless, the UK National Institute for Health Research (NIHR) 
has given definitions of the terms, suggesting that feasibility studies occur slightly earlier in 
the research process whilst pilot studies are ‘a mini version of the main study that is run to test 
whether the components of the main study can all work together’. Developing a conceptual 
framework defining the two terms, the Delphi study444 reviewed different studies and 
international expert consensus on the two terms. They agreed that “a feasibility study asks 
whether something can be done, should we proceed with it, and if so, how?” where as “a pilot 
study is the one in which a future study or part of a future study, is conducted on a smaller 
scale to ask the question whether something can be done, should we proceed with it, and if so, 
how?”. Within this framework, “feasibility” is seen as an overarching concept, with all studies 
done in preparation for a main study open to being called feasibility studies, and with pilot 
studies as a subset of feasibility studies. Therefore the present study, carried out to investigate 
if the protocol can be effectively implemented and whether it will have any impact on physical 
functioning, body composition, and other treatment outcome measures including dialysis 
clearance and markers of Hb status, can be considered as a pilot study.    
If the exercise intervention protocol is feasible, acceptable to staff and participants and can 
promote beneficial changes in body composition which are then shown to influence health 
outcomes, particularly in relation to optimising anaemia treatment, this will inform the 
management of these dialysis patients with the potential for universal roll out and therefore 
patient benefit due to the relatively low resource implications.  This study will also increase 
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the understanding of the cost effective therapeutic options for improving anaemia treatment 
outcomes and potentially reducing costs associated with the treatment.  
5.2 Study aim and Objectives 
5.2.1 Aim 
To test a flexible exercise intervention protocol that combines aerobic (walking) and 
intradialytic progressive resistance training and to study its feasibility and associated benefits 
on physical functioning, body composition, anaemia treatment outcomes and quality of life 
among UK haemodialysis patients on erythropoietin (EPO) therapy. 
5.2.2 Objectives 
i. To test exercise intervention protocol that combines walking and intradialytic 
progressive resistance training with patient input. 
ii. To recruit a sample of haemodialysis patients that are on erythropoietin therapy to 
undertake the exercise intervention programme.  
iii. To evaluate the feasibility and acceptability to dialysis patients and nursing/allied health 
professional staff of the exercise intervention  
iv. To investigate the impact of a combined walking and resistance exercise intervention 
on physical strength and functional performance 
v. To investigate the impact of the exercise intervention on different components of body 
composition, quality of life, dialysis adequacy, inflammatory  and anaemia status 
among haemodialysis patients on EPO treatment 
5.3  Hypothesis of the study 
i. An exercise intervention involving walking and resistance training will improve 
physical functioning, muscle mass and strength and dialysis clearance, and will reduce 
inflammation and improve quality of life among HD patients on EPO treatment. 
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ii. Haemoglobin concentration among HD patients on EPO treatment will increase with 
the increase in muscle mass and strength, dialysis clearance and reduced inflammation. 
5.4 Methods 
5.4.1 Study design 
This study was originally planned to be a continuation of the study presented in chapter 4. 
However, it was scaled down and conducted as a randomized controlled trial (RCT) pilot study 
in order to test the feasibility of the exercise protocol. It was conducted over 8 weeks involving 
participants from longitudinal study (chapter 4) at haemodialysis clinics of St. George’s 
University Hospitals NHS Trust in London and its affiliated satellite unit.  
5.4.2    Inclusion and exclusion criteria 
The sample for this study was drawn from among the participants of the previous longitudinal 
observational study in Chapter 4. Participants were asked to proceed into the exercise 
intervention after they finished 4 months follow up period. These were adult (aged ≥ 18 years) 
patients registered at the two named dialysis units who had been on haemodialysis for at least 
3 months and were on anaemia management therapies (i.e erythropoietin hormone and/iron).   
The study in chapter 4 excluded patients who lacked capacity to make informed decision or 
lacked sufficient command of English, those who changed, or were due to change dialysis 
modality, or received a kidney transplant or changed dialysis unit during the study period. 
Patients with anaemia of non-renal aetiology, e.g. anaemia due to sickle cell or malignancies 
and those who had recently received a blood transfusion, or received a transfusion during the 
study, were also excluded.  
Specifically for this chapter, patients were also excluded if they were contraindicated for 
exercise (e.g. those patients with recent myocardial infarction (within 6 weeks), uncontrolled 
arrhythmias, uncontrolled hypertension, unstable angina, active malignancy, symptomatic left 
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ventricular dysfunction, uncontrolled diabetes or neurological disorders with functional deficit 
and unstable haemodialysis). 
5.4.3 Sample size 
The desired sample size was therefore 24 participants (12 participants each for exercise and 
control groups) determined on the basis the availability of time and resources including a 
physiotherapist who would supervise the exercise. 
5.4.4   Ethical application and approval 
Because this was a continuation of the work presented in chapter 4, permission to conduct this 
exercise intervention was sought in conjunction with the previous longitudinal observation 
study. This was obtained from St. George’s University Hospitals NHS Trust followed by NHS 
ethics application to the Research Authority - Research Ethics Committee (HRA-REC). The 
whole study received a favourable ethical opinion on 01/05/2018 with REC reference number 
18/LO/0443 (certificate attached on Appendix 11) 
Participants were informed that they were free to withdraw from the study at any time without 
giving a reason and without affecting their treatment. 
5.4.5 Consent and recruitment process 
The nephrology consultants for the respective clinics were requested to provide their expert 
opinion on the suitability of potential participants (from the longitudinal study) for the exercise 
intervention. The generated list was then passed along to the dialysis clinic lead nurses for a 
final check. Patients that were deemed fit for the exercise study by both the nephrologists and 
lead nurse were then approached and provided with study details and invited to participate. 
Potential participants were left with the information sheet (appendix 18) and approached after 
a minimum of 48 hours for their decision. Those willing to take part were asked to provide 
written consent (appendix 20). Consenting participants were then recruited into the study. For 
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easy association with data from the longitudinal observation study, participants retained the 
previously assigned study identification numbers.   
5.5  Exercise Intervention protocol  
A video featuring the exercise protocol was developed by a Physiotherapist completing his 
Masters project at the University of Surrey and patient comments were collected as part of the 
patient involvement in the study. The protocol was then reviewed based on comments collected 
and the final administered protocol was as presented in the followed sections. 
5.5.1 Aerobic (walking) 
As defined by the encylopedia, aerobic exercises are sustained exercises that increase blood 
flow and hence oxygen supply to the lungs, cardiovascular system and muscles. They are in 
forms of low to moderate intensity performed for moderate or extended duration. Walking is 
among the highly effective form of exercise particularly for sedentary individuals who are 
starting exercise. In the present study, walking was a selected form of aerobic exercise. 
Participants were encouraged to walk for a minimum of 30 minutes, five times a week and they 
were provided with a pedometer to track their steps. They were also requested to record their 
exercise every day in the provided exercise log book and bring this to the dialysis unit to be 
checked and recorded by the physiotherapist or dietitian at regular intervals. This data, together 
with pedometer step counts, were used to monitor participants’ compliance to the intervention. 
5.5.2 Intradialytic resistance training 
Unlike aerobic exercise, resistance training, or synonyms such as strength training, focus on 
the use of resistance to induce muscular contraction which in turn builds muscle strength and 
endurance. In the present study, resistance training was implemented using free-weight 
dumbbells for upper body exercise and weighted ankle cuffs for lower body exercises.  Unless 
reasons for exclusion existed (such as musculoskeletal injury/restrictions), the upper body 
exercise included shoulder press, lateral raise, triceps extension, biceps curl and external 
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shoulder rotation. The lower body exercises included seated knee extension, hip flexion, hip 
abduction, and inner range quads exercises. Before initiation of the intervention, a 
physiotherapist conducted functional tests on all individual participants to assess their exercise 
capacity and determine the suitable baseline exercise intensity (e.g. weight of dumb bell and 
ankle weight).  
Participants were prescribed an exercise programme at a rate of perceive exertion (RPE) of 12-
14 on the Borg scale445 (appendix 16). Participants started with 2 sets of 12 repetitions for each 
exercise and it was expected that the number of sets would be increased to 3 or 4 sets at weekly 
intervals. The weight of the dumbells and ankle weights were also increased. A maximum 
exercise time of 40 minutes duration was set. 
All training was performed after being on HD for a minimum of 30 minutes and not beyond 
the second hour of the dialysis session with participants maintaining a comfortable seated 
position while continuing to receive HD. The intradialytic exercise sessions were all supervised 
by the physiotherapist who also recorded the performance in the participants’ exercise log 
books (see Appendix 22). 
Although, based on similar studies, this exercise programme was considered to be safe for this 
population, for maximum safety, a check list was produced prior to each exercise intervention 
and patients’ vital signs (heart rate, blood pressure and respiratory rates) were monitored 
throughout the session and the intervention was terminated during any individual session if 
clinically contraindicated (see SOP on Appendix 23).  Individuals were also free to be 
withdrawn from the exercise intervention by their clinical team if it was clinically 
contraindicated (e.g. dyspnoea). 
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5.5.3 Control group 
No exercise programme was advised to participants allocated into the standard care (control) 
group. They were advised to continue with their normal care practices whilst monitoring their 
walking (step counts) in the same way as the intervention group.  
5.6   Data collection 
5.6.1 Patients and Public Involvement (PPI) data 
Whilst on dialysis or awaiting for dialysis session, patients were approached and requested if 
they were happy to view a short video recording of simulation of intradialytic exercise. They 
were then requested to provide their feedback by responding to the interview questions 
(appendix 21). 
5.6.2 Demographic data 
Personal data e.g. age, gender, dialysis access details, disease comorbidities and complications 
and dialysis vintage were retrieved from clinic electronic databases. 
5.6.3 Assessment of dietary intake  
Patients were provided with standard food diaries used by the dietetic team in the renal unit of 
St. Georges’ University Hospital NHS Trust (see appendix 24) and requested to record all foods 
and drinks consumed on three days of the week (one weekend and two weekday’s including a 
dialysis day). Information on the type of food and quantity were then entered into Nutritics 
dietary analysis software to quantify nutrient intake for the three days. The average intakes of 
energy and nutrients across the three days were then computed and compared with  renal 
nutrition guideline150. 
5.6.4 Anthropometric measurements 
Body weight was measured to the nearest 0.1kg before dialysis using calibrated digital scales 
(SECA, JPen Medical. UK) available at the clinics. Waist circumference was measured using 
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a non-elastic tape measure to the nearest 0.1cm as an estimate of abdominal obesity before the 
beginning of dialysis session.  
5.6.5 Subjective global assessment (SGA) 
Patients were interviewed using the  original 3 point (A, B & C) score SGA questionnaire 
described by Detsky et al.371and reviewed by Steiber et al.136(attached in appendix 12) to collect 
information on changes in body weight, dietary intake, gastrointestinal symptoms, physical 
functioning and muscle wasting for calculation of a malnutrition risk score. A score of A 
denotes a well-nourished individual whilst C is severely malnourished. 
5.6.6 Assessment of Body composition 
Body composition (muscle/lean mass, fat mass and body fluid) were assessed using a Body 
Composition Monitor (BCM) (Fresenius Medical Care AG & Co, Germany) prior to a dialysis 
session. The details on the principle and procedure of BCM measurement are presented in 
section 4.4.4. 
5.6.7 Functional tests 
Muscle strength was assessed before a dialysis session using and hand grip dynamometer 
(Takei Scientific Instruments Co. LTD, Japan). Three measurements were taken (with about 5 
seconds rest between each) using the non-fistula arm and the average of the three measurements 
was recorded.  
The sit-to-stand test was also carried out with all patients as described in a study by Jones et 
al.446 This test assesses leg strength and endurance. A plastic moulded straight-back chair, 
without arms or seating cushion and with approximate seating height was placed against the 
wall to prevent movement. The participant was then advised to seat in the middle of the chair, 
with back straight and feet approximately shoulder width apart at an angle slightly back from 
the knees; feet were positioned parallel to aid balance and the arms were crossed in front of the 
chest. Participants were instructed to look straight ahead and rise to the full standing position 
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(at a signal “go”) with their weight evenly distributed between both feet before returning to the 
seated position as many times as possible in 30 seconds. Patients were then assessed for the 
number of times they are able to sit and stand from a chair during a period of 30 seconds.  
To assess patients’ mobility/walking, 3D pedometers (Realalt 3DTriSport) were provided to 
participants and they were instructed to wear them throughout their waking hours in order to 
count the number of steps taken per day. At each dialysis visit, pedometers were seen by the 
physiotherapist and steps counts recorded. Physiotherapist was able to see and enquire about 
any missing records or low counts. This information helped to monitor patients’ compliance to 
the walking program. The average daily step counts were then computed for each week. 
5.6.8 Quality of life 
Patients were provided with a quality of life questionnaire (SF-36v2™ OPTUM® PRO CoRE) 
(see appendix 15) and requested to fill it in at home and return to the clinic on their next visit.  
5.6.9 Exercise intervention evaluation 
After the intervention period, participants were provided with a short questionnaire (appendix 
25) and requested to provide their personal opinion on the intervention and their attitude toward 
exercise before and after the intervention.  
Clinic personnel that were direct member of dialysis care team were also given questionnaires 
(appendix 26) and requested to evaluate the intervention.  
5.7   Data management and Statistical analysis 
Anonymised data were recorded into a password protected excel spreadsheet. These were then 
entered into IBMI®SPSS v 25. Data was checked for normality and descriptively summarised. 
Mann-Whitney test was conducted to study the gender and intervention Vs control comparison 
differences on outcome measures. Wilcoxon test was used to test the differences between pre 
and post intervention whereas Friedman test was performed to analyse the differences on 
outcome measures across eight weeks.  
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5.8   Results 
5.8.1 Recruitment and randomisation of participants 
Out of 16 participants that completed the longitudinal exercise study from the North 
Wandsworth and St.George’s dialysis units (see Chapter 4) and were eligible for the exercise 
study, a total of 10 participants consented to continue onto the intervention phase.  
These were randomly allocated to control and intervention groups using simple random method 
(random draws of folded papers with participants ID numbers) as described in the figure 5:1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:1: A flow diagram illustrating participants’ recruitment, randomisation and their 
participation in the exercise study. SDU = St. George’s dialysis unit; NW = North Wandsworth 
dialysis centre 
 
Patients available at 
the HD unit 
SDU (n = 18) NW (N = 81) 
Control  
(n = 3) 
N = 10 
n = 4 
Drop out 
Transplant (n=1) 
Randomisation 
Participants consented 
Participants completed 4 weeks 
of exercise trial 
n = 6 
Intervention 
(n = 7) 
Intervention 
N = 6 
Control 
N = 3 
N = 4 N = 12 Participants eligible and 
approached 
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5.8.2 Baseline finding of the study 
Tables 5:1, 5:2 and 5:3 below show a summary of baseline demographic characteristics, 
anaemia management therapies, inflammatory markers, dialysis adequacy, dietary intake and 
markers of nutritional status and body composition of the haemodialysis patients recruited to 
the study. Data are presented as median (25th, 75th percentile) for the sample as a whole and by 
intervention group. Because there only three participants in the control group, the descriptive 
data is presented as range (minimum, maximum) or as a single absolute value. 
5.8.2.1 Demographic characteristics of participants 
The median age of the recruited participants was 51 years and they were predominantly male 
(table 5:1). The median haemodialysis vintage was 27 months. Hypertension and Diabetes type 
II were the leading morbidities reported affecting a third of the sample. All study participants 
were prescribed Venofer® iron infusion with the median dose of 100mg/week where-as 
Aranesp® was the most commonly prescribed EPO (table 5:1).   
Table 5:1: Demographic characteristics and anaemia treatment therapies for participants recruited to an 
exercise study by intervention group (median (25th, 75th percentile)) 
Characteristics All 
(n=9) 
Intervention 
(n = 6) 
Control 
(n = 3) 
†P 
Age (yrs) 51 (39, 64) 51 (40, 64) 51 (31, 51) 0.80 
Gender (number (%) male) 8 (89%) 5 (83%) 3 (100%) 0.48 
HD vintage (months) 27 (16, 78) 51 (18, 100) 27 (9, 27) 0.36 
Comorbidities (n (%)) 
Hypertension  
 
3 (33%) 
 
3 (50%) 
 
- 
 
Diabetes type II 4 (44%) 2 (33%) 2 (66%)  
Obesity 1 (11%) - 1 (33%)  
Polycystic kidney disease 1 (11%) 1 (17%) -  
#Iron supplement dose 
(mg)/wk 
100 (50, 100) 100 (42, 100) 75 (50, 75) 0.85 
EPO dose 
Aranesp®(μg/week)  
 
60 (25, 100), 
n =7 
 
 60 (30, 90), n 
= 4  
 
 60 (25, 60), n = 3   
 
0.71 
Neorecormon®(IU)  1250, n=2 1250,  (n = 2)    
#Venofer; EPO, Erythropoietin hormone; †Mann-Whitney test between control and intervention groups, 
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Two participants were prescribed an alternative EPO formulation, Neorecormon. Mann-
Whitney tests showed that there were no significance differences in demographic 
characteristics between the intervention and control groups.  
5.8.2.2 Dietary intake of participants 
The dietary and protein intakes of participants were below the recommendations. The majority 
of participants met the recommended intake of iron but this was borderline. In particular, the 
dietary iron of female participant was below recommendations.  The majority of participants 
met the dietary vitamin C recommended by the British Nutritional Foundation (table 5:2). 
There was no significant difference in dietary intake between the exercise and control groups 
(all P > 0.05). 
Table 5:2 Baseline dietary intake of participants recruited in exercise study, data presented as median 
(25th, 75th percentile) 
 
 
Variables 
 
Reference  
 
 
All  
(n = 9) 
Proportion of 
participants outside of 
recommendations 
 
Exercise  
(n = 6) 
Control 
group  
(n = 3) 
P† 
 Value Source Below Within    
Dietary 
energy 
(Kcal/bwt/d) 
≥ 35 NKF-
KDOQI135; 
UK-RA131 
21 (15, 28)  100% (n=7) 0 20 (15, 28) 28 0.32 
Dietary 
protein 
(g/bwt/d) 
≥ 1.2 NKF-
KDOQI135; 
UK-RA131 
0.9 (0.8, 1) 86% (n = 6) 14%(n = 1) 1 (0.8, 1.1) 0.8 0.45 
Dietary iron 
(mg/d) 
Male≥ 8; 
Female ≥ 
12 
EBPG150 8.7 (8, 10) 29% (n = 2) 71%(n = 5) 9 (8, 10) 11 0.13 
Dietary 
vitamin C 
(mg/d) 
40 BNF 90(51,103) 14% (n = 1) 86%(n = 6) 88 (43, 98) 123 0.13 
 National Kidney Foundation – Kidney Disease Outcome Quality Initiative; UK-RA, UK Renal association; 
EBPG, European Best Practice Guidelines; BNF, British Nutritional Foundation; †Mann-Whitney test between 
control and intervention groups,  
 
5.8.2.3 Nutritional status, inflammation and quality of life of the study participants 
The median BMI of participants was within the recommendation and the majority were 
classified by SGA as being well nourished (table 5:3). However, the albumin levels were below 
recommendations for over three quarters of the sample. There was an equal split between those 
with and without adequate hand grip strength (according to the cut off point for sarcopenia 
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definition). The majority of participants had Hb levels within the recommendation but the 
median haemoglobin levels were consistently at the lower end of the adequate range (table 5:3). 
The median C-RP was within the normal range and 56% were categorised as not inflamed 
(however, 44% had raised C-RP). The median URR was also within the UK-RA 
recommendation and only 1 participant did not meet the recommended URR (table 5:3). 
Participants’ quality of life in the domains of general health, physical function, mental health 
and social function were all less than 50% meaning that they were below the 50th percentile of 
the normal population reference (table 5:3).  
There were no significant differences in any markers of nutritional status, inflammation, 
dialysis adequacy or quality of life between exercise and control group at baseline (all P > 0.05)
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Table 5:3: Baseline characteristics of participants showing nutritional status, biochemistries and quality of life for intervention and control groups. 
Data presented as median (25th, 75th percentile) 
  
              Reference 
 
All 
(n = 9) 
Proportion of participants 
within/outside of recommendations 
Intervention 
group 
(n = 6)  
Control 
group 
(n = 3) 
†P 
Variable Range Source Outside#  Within 
BMI (kg/m2) ≥ 23 EBPG on 
nutrition286 
30(24, 32) 
11%(n = 1) 
89% (n = 8) 30 (24, 32) (21, 29)  0.80 
HGS (kg) Male > 30; 
Female > 20 
EWG on 
Sarcopenia320 
27(19, 36) 50% (n = 4) 50% (n = 4) 27 (18, 40) (23,28)  1.00 
WC (cm) N.A  100(92, 111)   100 (95, 108) (98,127)  1.00 
Albumin (g/l) ≥ 40 EBPG on 
nutrition286 
35(33, 40) 78% (n = 7) 22% (n = 2) 37 (33, 45) (33,35)  0.70 
Haemoglobin (g/l) 100 – 120 UK-RA179 108 (102, 121) 33% (n = 3) 67% (n = 6) 116 (105, 125) (94,107)  0.07 
C-RP (mmol/l) < 5 NKF-KDOQI289 3.8 (1, 12) 44% (n = 4) 56% (n = 5) 11 (1, 14) (1.0,1.9)  0.29 
Lean tissue index 
(kg/m2) 
 N.A  17(11, 21)   17 (12, 20) 
(11, 17) 
0.70 
Fat tisue index (kg/m2) N.A  8 (5, 17)   15 (3, 18) (7, 8)  0.70 
Sit to Stand (counts) N.A  9 (4, 11)   11 (3, 13) (4,6)  0.40 
URR (%) ≥ 65 UK-RA114 78(68, 82) 14% (n = 1) 86% (n = 6) 78 (69, 81) (33,78) 1.00 
ERI N.A  0.08(0.02, 0.1)   0.07 (0.03, 0.10) (0.01, 0.1)  
SGA 
A (n (%)) 
B (n (%)) 
 
N.A 
  
7 (78%) 
2 (22%) 
   
6 (100%) 
0 
 
1(33%) 
2(67%) 
 
QoL 
Physical function (%) 
N.A   
45(36, 53) 
   
48 (39, 55) 
 
(35,39) 
 
0.24 
Mental health (%) N.A  43(36, 53)   48 (37, 54) (33,38)  0.24 
Social health (%) N.A  30(27, 44)   30 (26, 49) (27,30)  0.86 
General health (%) N.A  40(32, 60)   40 (31, 57) (31,50)  0.50 
BMI, Body mass index; HD, Haemodialysis; HGS, Hand grip strength; WC, Waist circumference; ERI, Erythropoietin resistance index; C-RP, C-reactive protein; URR, Urea reduction ratio; 
SGA, Subjective global assessment; QoL, Quality of life; †Mann-Whitney test between control and intervention groups,  # Percentage below reference range except for C-RP (data is % above 
reference range
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5.8.3 Follow up data 
This section presents data on exercise performance, nutritional status, inflammation and quality 
of life as measured across the eight weeks of the trial. 
5.8.3.1 Walking programme performance  
Table 5:4 below shows the two weekly average step counts recorded by the participants. Due 
to poor response rates (2 participants in the control group did not complete their step count 
logs) data are presented by individual subject number.  
Table 5:4: Biweekly exercise records of step counts for control (n = 3) and intervention (n = 
6) groups of participants of the exercise pilot study 
 Intervention  Control 
Week NW06 NW08 NW11 NW13 NW14 SDU02 Median  
(25th, 75th percentile) 
NW01 SDU03 SDU04 
1 & 2 1056 N.R N.R 1254 7846 6282 3768 (1106, 7455) N.R N.R 2138 
3 & 4 1030 625 723 2164 8813 4537 1597 (698, 5606) N.R N.R 2191 
5 & 6 N.R N.R 733 948 6805 6130 3539 (787, 6636) N.R N.R 1719 
7 & 8 328 N.R 977 1810 9223 7933 1810 (653, 8578) N.R N.R 1605 
#Friedman test X = 5,  p = 0.17    
†Wilcoxon signed rank test Z = -1.09, p = 0.27    
N.R, No response; †eight weeks (biweekly) step counts comparison; # pre and post intervention step counts 
comparison 
 
Three participants (NW12, NW14 and SDU02) had better compliance to the walking 
programme where-as the remaining three (NW06, NW08 and NW11) had missed records for 
at least two weeks (table 5:4). Friedman test showed no significance difference in median step 
counts across the intervention period. Similarly, there was no significance difference in the 
number of steps at baseline Vs post intervention (Wilcoxon test) see table 5:4. Despite being 
asked to record their step counts only one of the control group provided step data.  
5.8.3.2 Resistance training performance 
Six participants were in the intervention group, and these trained under supervision for the 
muscle groups described in section 5.4.2.  
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Generally, participants differed in number of exercise sessions they received throughout the 
intervention period largely due to the availability of the physiotherapist. The lowest attendance 
/ availability was for participants who were dialysed on Tuesday, Thursday and Saturday 
afternoon sessions, whereas there was good attendance for those participants who were 
dialysed on Monday, Wednesday and Friday twilight session. The number of sessions attended 
by each participants is presented in table 5:5.   
Table 5:5 The number of exercise sessions attended by each of the study participants 
Participant ID Planned exercise 
session (n) 
Exercise sessions attended 
(n) 
% of total planned sessions 
SDU02 24 20 83 
NW06 24 2 8 
NW08 24 4 17 
NW11 24 17 71 
NW13 24 22 92 
NW14 24 21 88 
 
The individual participants’ performance across the 8 weeks of intervention period is as follows 
(data on table 5:6 and 5:7): 
Participant NW06: Only had two exercise sessions largely due to lack of availability of the 
physiotherapist however he also refused two sessions due to tiredness. He maintained the rate 
of perceived exertion at 12 -14 (somewhat hard)  on both sessions except for lateral raise which 
he reported to have difficult performing at the highest intensity (i.e 3kg dumbbell, 3 sets of 12 
repetition). 
Participant NW08: Only had four exercise sessions due to lack of availability of the 
physiotherapist. Was not able to perform the upper body exercises due to problems with fistula 
sites. He was able to perform the lower body exercise well as prescribed using ankle weights 
157 
 
of 1-2kg, in 2 - 3 sets of exercise, each with 12 repetitions. The RPE was maintained between 
11 and 12-14 (easy – somewhat hard). 
Participant NW11: There was considerable irregularity in the intensity of exercise performed. 
The participant was unable to adhere to the intended intensity progression. Both the intensity, 
number of sets and repetition were adjusted (increased/decreased) day by day depending on 
physical status or motivation of the patient. It was communicated before the start of the 
programme that this participants tended to show distress behaviours at some points, therefore 
both physical state and behaviour were considered when conducting the exercise session. 
Participant NW13: There was a progression in the weight used for upper and lower body 
exercises throughout the four weeks. However, there was irregularity in the number of sets and 
repetitions for each exercise achieved and these were adjusted day to day depending on the 
physical state of the patient. This participant experienced leg pain hence his lower body 
physical functioning tended to be limited. 
Participant NW14: There was a good progress of training intensity. The weight of dumbbells 
and ankle weight increased week by week, similarly the number of sets and repetitions of 
exercise. The RPE was either maintained at 10 – 11 or increased to 12- 14 for most exercises.  
Participant SDU02: There was a good progress of training intensity. For upper body exercise, 
the weight of the dumbbell increased week by week but the number of sets and repetitions was 
maintained at 2 and 12 respectively.  For lower body exercise, the ankle weight was maintained 
at 1 kg until it was increased to 2.5kg in the last week and the number of sets for each exercise 
progressed from 2 to 3 to maintain the RPE of 12 – 14. Fatigue due to anaemia reduced 
performance in the last week. 
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Table 5:6 The participants' exercise performance in terms of median (25th, 75th percentile) weight lifted at week 1-2, 3-4, 5-6 and 7-8 for different type of upper 
body  resistance training (n = 6). 
 Right arm    Left arm 
 Week 1-2 Week 3-4 Week 5-6 Week 7-8 †P #P Week 1-2  Week 3-4 Week 5-6 Week 7-8 †P #P 
Shoulder press 
(kg) 
66 (61, 72) 108 (74, 192) 102 (69, 212) 102 (83, 232) 0.29 0.44 62 (60,70) 158 (55,192) 212 (51,214) 232 (59, 256) 0.29 0.10 
Lateral raise (kg) 43 (30, 65) 54 (27, 146) 63 (39, 163) 72 (48, 230) 0.11 0.05 62 (18, 70) 122 (22,146) 158(23, 163) 187 (32, 230) 0.11 0.05 
Triceps 
extension kg) 
56 (34, 65) 104 (24, 184) 181 (46, 230) 181 (46, 230) 0.11 0.10 29 (28, 66) 46 (24, 184) 79 (39, 180) 85 (46,230) 0.11 0.10 
Biceps curl (kg) 66 (57, 72) 108 (60, 210) 108 (86, 212) 107 (80, 210) 0.29 0.53 70 (53, 70) 180 (45,210) 212 (78,220) 222 (95, 242) 0.11 0.05 
External 
shoulder rotation 
(kg) 
66 (42, 72 ) 108 (45,190) 108 (79,198) 108 (39, 191) 0.29 0.53 70 (36, 70) 150 (45,164) 198 (62,220) 217 (95, 260) 0.11 0.05 
 #Friedman test for differences across weeks 3-8; †Wilcoxon test for difference between pre and post intervention (Week 3-4 Vs Week 7-8) performance, 
statistical significance P <0.05 
 
Table 5:7 The participants' exercise performance in terms of median (25th, 75th percentile) weight lifted at week 1-2, 3-4, 5-6 and 7-8 for different type of lower  
body  resistance training (n = 6) 
 Right leg Left leg 
 Week 1-2 Week 3-4 Week 5-6 Week 7-8 †P #P Week 1-2 Week 3-4 Week 5-6 Week 7-8 †P #P 
Seated knee 
extension 
24(23,30) 73 (63,93) 90 (45, 160) 90 (74, 222) 0.04 0.04 24 (22, 26)  74 (54, 105) 88 (44, 160) 90 (69, 222) 0.04 0.04 
IRQ 24(23,27) 72 (52, 103) 88 (43, 166) 90 (65, 222) 0.08 0.04 24 (22, 27) 72 (54, 107)  86 (42, 157) 90 (59, 222) 0.08 0.04 
Hip flexion 24 (23, 26) 72 (46, 89) 43 (36, 165)  64 (61, 244) 0.11 0.09 23 (20, 26)  75 (45, 98) 41 (36, 133) 70 (53, 202) 0.47 0.31 
Hip abduction 22 (21, 25) 72 (40, 98) 74 (38, 132) 123 (60, 232) 0.07 0.04 24 (21, 26) 59 (33, 98) 66 (37, 128) 64 (56, 191) 0.07 0.02 
IRQ, Inner range quads; #Friedman test for differences across weeks 3-8; †Wilcoxon test for difference between pre and post intervention (Week 3-4 Vs Week 
7-8) performance, statistical significance P <0.05
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For upper body exercise, the Friedman test showed that there was a significant increase in 
weight lifted across week 3-8 for lateral raise (both arms) and for biceps curl and external 
shoulder rotation on left arms only (p = 0.05). Participants showed no improvement in other 
upper body exercises (table 5:6).  
For the lower body, the weight lifted significantly increased across week 3 - 8 for all lower 
body exercises except for hip flexion (p=0.04) (table 5:7).  When weight lifted in week 3-4 was 
compared to week 7-8, there was a significant improvement in weight lifted for seated knee 
extension on both legs (p=0.04) and a trend towards significance for IRQ (p=0.08) and hip 
abduction of both legs (p=0.07). 
5.8.4 Pre and post exercise comparison on nutritional status, inflammation and quality 
of life  
For the exercise group, post intervention median BMI, FTI, HGS, Albumin, Haemoglobin, 
URR appeared to be lower than the baseline levels (ns) although there was a trend towards 
reduction in BMI (p=0.07). The post intervention median scores of physical function, mental 
health and general health components of quality of life were also lower than the baseline levels 
(ns). On the other hand, post intervention median C-RP, LTI, Waist circumference and score 
of social function quality of life were higher than baseline levels (ns). Only the increase in sit 
to stand measures was statistically significant (from a median (25th, 75th percentile) of 10.5 (3, 
13) to 11 (8, 15.5) p = 0.04) (table 5:8). There were limited data from the control group, no 
comparison analysis were performed. 
Repeat data was only available for one control participant.
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Table 5:8 Changes over time (8 week exercise intervention) in markers of nutritional status, inflammation and quality of life for intervention and †control group 
participants.  
 Baseline Post intervention 
    
Variable 
All 
(n = 9) 
Exercise group 
(n = 6)  
Control group 
(n = 3) 
All 
(n = 9) 
Exercise group 
(n = 6)  
Control group 
(n = 3) 
#P 
BMI (kg/m2) 30 (24, 32) 30 (24, 32) 29  26  (22, 31) 26 (22, 31) N.D 0.07 
HGS (kg) 24 (18, 38) 27 (18, 40) 23 26 (22, 32) 26 (22, 36) 22 0.92 
WC (cm) 100 (94, 110) 103 (100, 111) 89  100 (89,110) 103 (97, 112) 82 0.59 
Albumin (g/l) 35 (33, 40) 37 (33, 45) 33 , 35 35 (33, 38) 36 (33, 38) 32, 34 0.25 
Haemoglobin 
(g/l) 
108(102,121) 116(105, 125) 94, 107  111(103, 122) 112 (102, 121) 104, 111 0.60 
C-RP (mmol/l) 3.8 (1, 12) 11 (1, 14) 1, 1.9  4 (1.4, 11.7) 11 (2.5, 15.1) 1, 1.8 0.34 
Lean mass 
index (kg/m2) 
15 (11, 19) 17 (12, 20) 11 14 (11, 22) 16 (12, 22) 12 0.50 
Fat mass index 
(kg/m2) 
12 (4, 17) 15 (3, 18) 8  10 (6, 15) 10 (6, 16) 8 0.50 
Sit to Stand 
(counts) 
10 (4, 11) 10.5 (3, 13) 8 11 (8, 12) 11 (8, 16) 11 0.04 
URR (%) 78 (68, 82) 78 (69, 81) 33, 78 74 (68, 80) 77 (70, 80) 36, 72 0.72 
ERI 0.05 (0.03, 0.1) 0.04 (0.03,0.09) 0.1 0.05 (0.03, 0.1) 0.04 (0.03, 0.06) 0.1 0.85 
SGA 
A (n (%)) 
B (n (%)) 
 
7 (78%) 
 
6 (100) 
 
1 (33) 
 
6 (67) 
 
6 (100) 
N.D N.S 
2 (22%) 0 2 (67) 0 0 N.D N.S 
QoL 
Physical 
function (%) 
 
46 (36, 53) 
 
48 (39, 55) 
 
35, 39 
 
45 (39, 55) 
 
45 (39, 56) 
 
38, 46  
 
0.67 
Mental health 
(%) 
43 (36, 53) 48 (37, 54) 33, 38 44 (31, 55) 44 (32, 54) 27, 42 0.27 
Social health 
(%) 
32 (27, 47) 30 (26, 49) 32 37 (33, 42) 37 (36, 44) 27 0.25 
General health 
(%) 
38 (31, 56) 40 (31, 57) 38 36 (31, 40) 37 (30, 42) 36 0.60 
Data presented as median (25th, 75th percentile) except for control group (minimum, maximum); N.D = No data; N.S; No statistics computed; #Wilcoxon test for 
pre and post intervention comparison for intervention group
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5.8.5 Study feasibility and acceptability outcomes 
5.8.5.1 Patients’ perception of the exercise intervention programme - PPI 
HD patients (n = 19) provided feedback on the exercise intervention by reviewing the prepared 
demonstration video and responding to the interview questions (see Appendix 21). Figure 5:2 
shows responses to each standardised question.  
 
Figure 5:2 Patients response feedback to the seven questions pertaining the exercise 
intervention 
On the whole response were largely positive with 79% agreeing that they could complete the 
intradialytic resistance training with supervision, 63% felt they could independently complete 
the resistance training, 100% agreed the tutorial video was easy to understand and 63% did not 
believe ‘low-tech’ exercise would disrupt current treatment. However, 47% were unsure 
whether resistance training may cause pain/discomfort.  Overall 89% of participants believed 
intradialytic resistance training would be beneficial. 
Table 5:9 below gives examples of patients’ responses to and comments regarding the exercise 
programme. The responses have been grouped into themes with a total of five themes were 
identified:  logistical concerns, uncertainty, concerns about tiredness, the perceived simplicity 
of the exercise and the potential benefits of the exercise.  
Key: 
Qn 1 = I can perform the 
exercise with supervision 
and instructions. 
Qn 2 = I can easily carry 
out exercise independently. 
Qn 3 = The demonstration 
video is clear 
Qn 4 = Exercise video is 
helpful. 
Qn 5 = Exercise would not 
disrupt my dialysis. 
Qn 6 = I fear exercise 
would cause pain and 
discomfort. 
Qn 7 = I feel exercise 
would be beneficial. 
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Table 5:9 Thematic response of patients as identified through the interview 
Response Themes Supporting Quotes 
Logistics  “How are you going to manage it if say, there are six people doing it” 
 “I think it might set my machine off” 
 “I think you’ll find it hard to get people to do exercise on dialysis days” 
Uncertainty  “I would be interested in doing it” 
 “Depends on the days, maybe something not working” 
 “I would love to see for myself” 
 “No, just have to do it to find out” 
Fatigue  “If it was too strenuous then leave it off” 
 “Not at all, not on the day of dialysis” 
 “It’s a question of whether I will have the motivation, sometimes you just don’t 
care” 
 “I haven’t got much energy so can’t imagine me doing them to be honest” 
 “My concern is because I get tired”  
 “When I have the dialysis, it makes me so tired and weak but don’t know how 
others feel” 
Exercise 
Simplicity 
 “They are simple exercises and I don’t think they are very strenuous” 
 “Very clear and easy to understand” 
 “It (video) explains it well, probably because I have indulged in this sort of 
activity before” 
 “Got somebody there to show us, so alright” 
Potential Benefits  “Very good idea” 
 “I honestly think this is a good idea, cause since dialysis, you tend to notice 
muscle going down” 
 “It couldn’t be better” and “This has made my day” 
 “These are good” 
 “If I could do them then they are beneficial” 
 “I’ll try anything to get movement you know” 
 “Anything to do with exercise has got to be good” 
 
5.8.5.2 Patients’ perception of the exercise programme post intervention 
At the end of intervention period, exercise participants were provided with questionnaires and 
asked for their feedback.  The questions were designed to assess participants attitudes prior to 
and after intervention period. Table 5:10 shows a summary of individual participants’ 
responses. 
Generally, participants were moderately active (except one participant) even before the 
introduction of this programme. All six respondents provided positive feedback about the 
exercise. 
Among the control group, one participant out of three reported doing exercise (yoga) every day 
for 15 minutes and walking once-twice a day for 15-20 minutes.  
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Table 5:10 Post intervention feedback from exercise participants (n = 6) 
Interview theme Participant’s responses 
Types of exercise/physical 
activities prior to intervention 
NW06: Walking 
NW08: Walking and muscle training 
NW011: None 
NW 013:Very active before 2018 (walked 4miles/day), 
stopped exercise due to bodily pain 
NW 014: Very active due to nature of work,  
SDU 02: Cardio exercise 
Frequency of exercise/physical 
activities prior intervention 
NW06: Twice per week, 10 – 15 each 
NW08: 3 days per week, 20 – 25 each day 
NW011: none 
NW013: 4 miles/day 
NW014: works 8 -12 hrs, 6 – 7 days/week 
SDU 02: Exercise 4 times/week 
Attitudes towards 
exercise/physical activities after 
intervention 
NW06: Exercise is a good idea, I need to remain 
physically and mentally active  
NW08: It helped improved my mobility. I wish they 
would happen every week 
NW011: I like to exercise and would like for the exercise 
to continue.  
NW013: Very keen to exercise 
NW014: I am active enough, I don’t need more exercise 
programme 
SDU02: I enjoy exercise, it helps relieve boredom  
Opinion on the exercise 
intervention 
NW06: Beneficial, it was uplifting and drew me out of 
my shell as HD can make you feel withdrawn. I felt it 
improved my (dialysis) clearance. 
NW08: Beneficial, I loved it and wish were available 
more often 
NW011: Was beneficial, I enjoyed it 
NW013: Beneficial, it helped relieve pain and am 
increased my physical functioning 
NW014: Beneficial 
SDU02: Beneficial as it helped relieve boredom whilst 
on dialysis  
 
5.8.5.3 Completion rate for participant step count data 
Exercise group participants had 50% data completion rate for the walking programme (step 
counts from pedometer records). Out of six participants, 3 fully completed their records 
whereas two participants missed one time record and one participant missed two periods’ 
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records (see table 5:4). In two participants the pedometer stopped working and in one the 
stepcounter was lost and in all cases had to be replaced. 
There was 33% (n=1) data completion rate for the control group both exercise and outcome 
measures. 
5.8.5.4 Clinic personnel’s feedback on the exercise programme  
Clinics personnel who were directly involved with dialysis care were provided with a 
questionnaire designed to collect their opinion on the exercise programme. Five nurses agreed 
to provide feedback and figure 5:3 below provides a summary of their responses.  
The majority agreed that the exercise was easy and practical for patients, felt that patients 
engaged well and thought that the exercises were a good addition to the treatment. They also 
agreed that exercise provided positive experiences and outcomes for patients and supported the 
idea of integrating the programme into usual clinic care and also extending it to other CKD 
patient group. 
In addition, the majority reported that the programme did not increase their workload and was 
not a burden to staff members.  
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5.8.5.5 Resource implications of the exercise programme 
The cost of the exercise equipment per participant was £85, this included the cost for dumbbells 
(£30 a set), ankle weights (£20 a set) and pedometers (£35 each).  
 
 
Questions Key: 
Qn 1= Exercises were easy for patients 
Qn 2= Patients understood exercise benefits 
Qn 3 = Patients had good engagement in the intervention 
Qn 4 = Patients perceive exercise as good addition to the treatment 
Qn 5 = The exercise programme increased my workload 
Qn 6 = Exercise programme was a burden to other staff members 
Qn 7 = The intervention interfered with delivery of standard care 
Qn 8 = I feel exercise provided positive experience and outcome to patients 
Qn 9 = Exercises were practical and suitable for the patients 
Qn 10 = I would like for the exercise to be sustainable and integrated into usual care 
Qn 11 = I feel these exercise should be considered by other CKD patients 
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Figure 5:3 Post intervention feedback from clinic personnel (n = 5) 
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The programme also required the presence of a physiotherapist each session i.e 2 hours of 
physio time per session to supervise, assist and record outcome measures from participants. 
This is equivalent to 6 hours of physiotherapist time per participant per week. The cost of 1 
hour physio time equivalent in the present study was £20. A total of 48 hours per participant 
(8 weeks duration) of physio time was paid for in this study that involved 9 participants (6 in 
the exercise group), equating to an approximate staff cost of £960 per exercising participant. 
Additional research time was also incurred for assessment and analysis of study outcome 
measures e.g. BCM measurement, physical function tests, recording of biochemistry data.  
5.9  Discussion 
This study was conducted as a pilot study to investigate the feasibility of the previously 
described exercise intervention in the group of patients. Sixteen (16) participants from St. 
Georges’ and North Wandsworth dialysis units were eligible to take part in this study. Of these, 
10 participants consented to participate and were randomised into the exercise (n=7) and 
control (n=3) groups. Six (6) participants completed the four weeks of exercise after 1 
participant withdrew due to receiving a kidney transplant. 
The median age of participants in both groups were 51 yrs, which is slightly below the national 
level of 64 yrs40. Male participants outnumbered female (there was only one female participant) 
in this pilot study. This gender difference is not surprising as there were more male participants 
in the previous longitudinal study from which this cohort was obtained. Participants had a wide 
dialysis vintage ranging from 9 to 158 months (median = 27), but this did not differ between 
the two groups. Hypertension and Diabetes type II were the most frequently comorbidities in 
this cohort but obesity and polycystic kidney disease were also present. Hypertension and 
Diabetes are the common cause of CKD worldwide272,447 and in the UK, Diabetes type II is the 
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most prevalent cause40. It is therefore not uncommon to find the two conditions highly 
prevalent in this population group. 
Nutritional status of the participants  
The baseline nutritional status of exercise participants was satisfactory with reference to their 
median BMI and SGA. However, their median albumin level was slightly below the European 
best practise guideline on nutrition (EBPG)150. Although the median HGS levels of both men 
and female patients in the present study were above the suggestive cut off point (22.5kg and 
7kg for male and female respectively) for increased mortality among haemodialysis patients, 
the levels were certainly far below recommendations from European Working group on 
Sarcopenia. The working group recommends HGS level of 30kg and 20kg for male and female 
respectively for general elderly general population 320.  This suggest that there could be some 
degrees of muscle weakness/wasting making their overall nutritional status questionable. This 
once again raises the issue of the accuracy and sensitivity of BMI in identifying nutritional 
status of dialysis patients, considering the potentially parallel issues of obesity and sarcopenia 
as discussed in chapter 4. Equally, SGA is a subjective tool which visually looks for wasted 
muscles and asks the patient about recent activity level but does not objectively measure muscle 
strength. Participants’ median waist circumference (WC) was 100cm, a level at which other 
researchers have suggested is reflective of abdominal obesity448 and indeed, only two out of 
nine participants were in the low risk category. In a study by Postorino et al.449,450, WC of > 
95cm was also associated with an increased risk of cardiovascular disease in haemodialysis 
patients.  
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Participants’ dietary energy and protein intakes were below the recommended levels 131,135, 
potentially contributing to the sub-optimal albumin and muscle mass observed. However, this 
contradicts the SGA which graded most participants as adequately nourished. Whilst their 
nutritional status was not yet at a critical level, there is a risk of deterioration if their dietary 
intake is not improved. Nevertheless, two of participants reported that they were intentionally 
trying to reduce their body weight, and therefore there is a chance that they have reduced their 
calorie intake. This could explain why the overall nutrition status was graded as satisfactory 
despite inadequate protein and energy intake. It also possible that dietary intake was under 
reported.  Dietary intake was assessed through food diaries that involved patients recalling and 
recording types and quantity of food they consumed for the whole day. The limitation of food 
diaries as a food assessment method has been widely highlighted by other researchers451,452 an 
in chapter 6 of this work.  
It should also be noted that iron plays an important role (as a component of myoglobin) in 
muscle metabolism through supply of oxygen as explained in chapter 1. In addition to sub-
optimal nutrition, the muscle weakness observed could also be attributed to iron deficiency 
present in this cohort.    
Biochemistry profile of participants  
Although participants had satisfactory dialysis clearance, 4 out 9 participants were inflamed 
with raised C-RP throughout the study period. It is of great concern that these patients are 
inflamed despite the evidence of adequate dialysis clearance. There is evidence that choice of 
dialyser might influence the inflammatory response. In a randomized study of 18 haemodialysis 
patients, C-RP levels were found to elevate when patients were dialyzed with cuprophan as 
compared to when dialyzed with polyamide dialyzers453. This might also be the case for 
patients in the present study but information on types of dialyzers used by this cohort were 
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beyond the scope of this study. Elevated inflammatory markers are detrimental to these 
patients’ wellbeing as it increases the risk of developing cardiovascular disease, muscle wasting 
and anaemia as previously discussed in chapter 1, and consequently decreases their quality of 
life and survival.  It is therefore important that further clinical investigations are conducted in 
order to determine the reasons for persistent inflammation observed in some patients despite 
them having adequate dialysis.  
Haemoglobin levels of the participants were at the low end of the normal range stated in the 
UK Renal Association (UK RA) guideline of 100 – 120g/l179. This could be linked with 
inflammation and suboptimal dietary iron intake observed in this cohort. There is a close 
relationship between nutritional status, dietary intake (particularly protein foods which are also 
good source of iron) with haemoglobin levels in this population221. In the previous study 
(chapter 4), a significant association was observed between dietary iron and serum iron levels. 
The discussion on the relationship between nutritional status and anaemia is presented in 
chapter 1. Unfortunately, due to the small sample size, further statistical analysis to test if there 
is any association between dietary iron intake, nutritional status or inflammation status with 
the haemoglobin level could not be performed. This would have help to explain if there is any 
link between the dietary intake, nutritional status and inflammation in this cohort. 
Participants’ quality of life 
Participants’ quality of life, based on the scores of the four domains (general health, physical 
functioning, mental health and social functioning) of QoL, SF-36v2, OPTUM® were less than 
50% meaning that they were below the 50th percentile of general population (table 5.8). When 
comparing these findings to those from the DOPPS study (an international, prospective, 
observational study of haemodialysis practice patterns and associated outcomes), participants’ 
scores in the “general health” component were above that reported in the Europe cohort, but 
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comparable to the scores of Japan and USA cohorts of the DOPPS study. The scores of physical 
functioning component were comparable to the Europe cohort but slightly higher than that of 
USA and far below that of the Japan cohorts. The scores of social functional and mental health 
in the present study were below that of all three continents cohort of the DOPPS study454.  
Several factors have been identified to be associated with haemodialysis QoL including 
presence of comorbidities which were reported to reduce mental health score while increased 
dialysis blood flow, low calcium and creatinine levels and protein intake were associated with 
higher physical component score455.  Having three or more chronic diseases, more hospital 
admissions and a longer treatment duration in addition to demographic characteristics such as 
advanced age and female gender were also reported to negatively influence patients’ quality of 
life456. In the previous longitudinal study(chapter 4), reduced measure of muscle mass and the 
length of time since starting dialysis were found to be associated with reduced quality of life. 
In the present study, participants reported to have multiple co-morbidities including anaemia, 
bodily pain and reduced physical activities. All these tend to reduce patients’ quality of life and 
could therefore be considered and used to inform the provision of personalized care services to 
meet the needs of this vulnerable group. 434In addition to treatment and therapies used to 
alleviate disease associated symptoms and comorbidities, physical activities or exercises 
263,434,457 have shown the potential in improving quality of life. 
Response and outcome of exercise intervention 
The study did not set a target on number of steps to be performed but rather a target of exercise 
duration and frequency in a week. With regards to resistance training, participants trained at 
the intensity that matched their individual physical capacity and progressively increased. This 
allowed participants to work out according to their capacity. However, the study aimed to 
monitor participants’ performance and to study whether there were significant changes during 
the intervention period.   
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Among the participants of the intervention group, the lowest average step count/week was 
observed from the oldest participant (aged 90’s) whereas the highest count was from the 
youngest participant in the group (aged 30’s) (table 5:4). The performance of the older 
participant on both walking and resistance training were less than half of that of their younger 
counterpart. The young participant was able to reach the weekly walking target and exceeded 
this whereas the oldest participant was able to walk only for a day or two in a week and for less 
than 30 minutes per session. This was an expected difference due to the normal physiological 
differences and physical functioning capacity but highlights the heterogeneity within the 
haemodialysis population even within one unit and therefore the challenges of designing a 
suitable safe but challenging exercise protocol for this population, especially if there is a need 
or desire for this to be delivered with minimal staff input. The young participant reported 
having no challenges to physical functioning while the older participant had challenges to his 
mobility and physical functioning, possibly linked to having a fistula in both arms. The hand 
grip strength and sit-to-stand records further showed the differences in functionality between 
these two participants as the scores of the youngest participant were higher than that of the old 
participant. Poor physical condition and health related problems have also been reported to be 
the barrier to exercise in kidney disease patients in a study by Clarke et al.458 Recognising that 
there are a wide range of abilities among patients, a personalized assessment/evaluation 
(looking at individual changes over time) rather than the standardized or general group 
comparison might be useful. 
In the present study, it worth noting that participants were in different dialysis sessions and had 
different levels of physiotherapist contact. Two of the participants only received a small 
proportion of the intended sessions even so both participants showed increased amount of 
weight lifted over the few sessions they had. Whilst there are inadequate data in the current 
study to draw conclusions as to the impact of environment and support on adherence and 
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outcomes it does suggest a potential confounding effect that requires further investigation. 
Therefore, in addition to the physical differences at baseline, the differences in improvements 
in exercise performance could also be due to the differences in levels of (motivation and 
guidance) input from a physiotherapist and number of exercise sessions they participated in. It 
has been noted on other studies that motivation particularly from a physiotherapist and other 
health care professionals members of clinic care team is important for the success of exercise 
programmes458,459. It is therefore important that care professionals reduce the preconceptions 
about who can/cannot exercise and promote exercise to all patients.  
It is unfortunate that we had limited data on walking recorded from the control group. It was 
challenging to monitor participants in the control group as they lacked motivation and incentive 
to fully participate in the programme. This shows that for this type of research design, careful 
consideration is required in planning such that participants in the control group are offered 
incentives to participate fully in the programme. In the current study, the participants in the 
control group were offered a one to one discussion with the physiotherapist   after the study 
duration. Their poor engagement in the programme suggests that this was not enough incentive 
to motivate their participation. A close or regular contact and motivation from the 
physiotherapist would probably help to improve the compliance.  Alternatively, a before and 
after study design in which participants acts as their own controls would be ideal. In this design 
participants are followed up for a certain period before intervention (a control phase) and then 
participants commence the intervention as the whole group or divided into subgroup (in which 
case they would commence the intervention at different times,i.e immediate + delay). In the 
present work, the matched data could have been collected during the longitudinal study 
(presented in chapter 4), and these could have served as a non-exercise control such that each 
participant acts as own control. Such a design was adopted by Reboredo et al.270 in their study 
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of which they evaluate changes on physical functioning, blood pressure, quality of life, and 
laboratory data among hemodialysis patients before and after 12 week aerobic exercise. 
The current study found a significant improvement in exercise performance across the 
intervention period particularly for lower body exercises. There was 23% to 53% improvement 
in weight lifted by arms and 12% to 98% improvement in weight lifted by legs.  However, this 
improvement was not reflected in HGS as measures of physical strength. The median grip 
strength of the male (but not female) participants were below the gender specific cut of point 
set by the European working group on sarcopenia. Although sit to stand test showed significant 
improvement after exercise intervention, generally when compared to the ‘below average sit to 
stand score’ set by the National Centre for Injury Prevention and Control, the majority  of 
participants had a score below the average for their gender and age (where data were available).   
There was no significant changes in nutritional status, inflammation, haemoglobin or quality 
of life in those participants receiving the exercise intervention. It is likely that the intervention 
was too short or the exercise intensity was not high enough to produce significant changes. It 
is also possible that the markers used to asses these outcome measures were inadequate or not 
sensitive e.g muscle strength was assessed using handgrip strength and sit to stand tests only. 
Other functional tests like shuttle walk test or tests that target specific muscle groups may be 
more sensitive to improvements in function. C-RP was the only available marker of 
inflammation. It would have been more informative to include wide range of pro-inflammatory 
cytokines like IL-6 and Tumour necrosis factor (TNF-α) and more markers of iron metabolism 
(e.g transferrin receptor). Unfortunately these were not able to be analysed due to limited time 
and resources.  
Nevertheless, the observed improvement in exercise performance is very encouraging and it 
suggests that there is a potential benefit from this form of exercise on dialysis. It is likely that 
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significant changes in physical and physiological outcomes would have been observed had this 
study duration been extended. 
Although there is no standard guideline on exercise load or prescription for this population 
group, there has been a comparable exercise intervention on haemodialysis patients with a 
minimum of 10 weeks duration. The study compared aerobic plus resistance training with 
resistance training alone (12 participants in each group) all performed during dialysis 253. 
However, this study did not measure inflammatory markers or body composition therefore it 
is not known whether 10 weeks of low intensity exercise would result in beneficial changes to 
these markers.  
A study by Afshar et al.460,461 showed that intradialytic cycling using stationary bikes alone (n 
= 7) or high intensity resistance training (RPE, 15 – 17) conducted for 8 weeks could improve 
inflammation. However, these studies employed a more intensive exercise regime and so differ 
from the present study, which might explain why significant changes were not seen in 8 weeks. 
The small sample size might also be a reason behind the observed outcome as the study lacked 
statistical power. When sample size was calculated using haemoglobin concentration as a 
primary outcome, results showed that 26 or more subjects would be required for each group in 
order to detect the minimum 8.9g/l  haemoglobin concentration observed in a study by 
Roberedo et al.270, when comparing two groups (intervention and control), using 2 sided test 
with size 5% and power of 80%. Other studies have also employed longer durations that the 
present study, commonly 12 rather than 8 weeks. 
Reboredo et al.270 showed an improvement in haemoglobin levels of haemodialysis patients 
after twelve weeks of exercise intervention that combined aerobic (cycle ergometer) and 
resistance. Another twelve weeks intradialytic resistance training study by Cheema et al.462 was 
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also able to improve muscle attenuation, muscle strength, mid-thigh and mid-arm 
circumference, body weight, and C-reactive protein.  
Nevertheless, there was a significant improvement in Sit-to-Stand performance (a positive 
indicator of improved mobility) and the whole exercise programme was well received by those 
participants and clinic staff who took part in the evaluation. The finding of this study suggests 
that patients liked the idea of intradialytic exercise as they understand the benefits involved 
and thought it was a good distraction and use of time whilst on dialysis. This was also depicted 
in the small PPI study that was conducted to help develop the exercise programme and concurs 
with the findings of Heiwe et al.463 Although there were a few concerns regarding the logistics 
and safety of the intervention, the majority had positive perceptions regarding the planned 
programme.  
However, physical illness in particular joint pain was often reported and limited participants’ 
engagement in walking and lower body resistance training. This is consistent with the finding 
of Clarke et al458 who investigated the barriers to exercise in the non-dialysis patient and found 
that poor health in addition to fear to injury, lack of guidance and lack of facilities are the main 
barriers.  
Another reported barrier was a concern about the safety of resistance training whilst on dialysis, 
as participants feared it might cause injuries to their dialysis access site. This was also among 
the reasons for the majority of potential participants declining to take part in this pilot study. 
Conversely, some patients thought the advantages of exercise for their well-being outweighed 
the potential risks and were motivated to take part despite their physical limitations. Such 
patients offer the potential of being good promotors of exercise programmes if involved and 
would be vital to the success of any roll out of an exercise intervention going forward since 
those who participated in the programme were overwhelmingly positive. The importance of 
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patient and public involvement (PPI) in various stages of research including study design, 
implementation and dissemination has received increasing recognition464,465. Through PPI, 
there is a potential to increase participant recruitment rate and improve their retention and 
therefore ultimately increase the success rate of trails466,467 and maximise the outputs from the 
funding and time committed to such research. 
Anecdotally, there was also a notable peer influence on the participation in the study. The 
research team witnessed first-hand how one patient with a negative attitude toward exercise 
could easily influence others and change their decision regarding taking part.  
Another reported barrier to participation was poor mental health with some participants 
reporting symptoms of depression and lacking motivation to engage in any activities. 
Depression and anxiety are common problems for patients with renal failure due to the disease 
symptom burden and other life style challenges that comes with the illness468. According to 
Johnson and Dwyer469, over 70% of haemodialysis patients exhibit symptoms of depression 
and anxiety and yet the majority are still likely to go unnoticed. In the present study cohort, the 
score on the mental health component of the quality of life index was indeed below the 50th 
percentile of the general population. Unfortunately, at the time of this study the renal unit had 
no psychologist dedicated to these patients highlighting the need for more mental health care 
provision. Regular physical activities have been reported to help relieve the symptoms of 
depression and anxiety and to improve quality of life in dialysis patients 470,471. Promotion and 
motivation of patients’ involvement in regular exercise, among other benefits could help 
alleviate symptoms of depression and so this may be a more powerful motivator of participation 
than emphasising the physical health benefits. 
Lack of encouragement from clinic staff due to their high workload could also contribute to 
low motivation. There was a noticeable difference in average weekly steps between participants 
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that had more contacts with the physiotherapist (NW13, NW14 and SDU02) compared to those 
who had less contact (NW06, NW08, NW11).  Similarly other studies 472,473 have shown a 
decrease in motivation when supervision is inadequate. This suggests that a high level of 
support, monitoring, adjustment and motivation is required to improve patients’ participation 
in exercise activities. Even what seems on paper to be a relatively low complexity exercise 
programme like walking requires significant physiotherapist’s input. This has cost implications 
and highlights the need for having a physiotherapist in clinic as part of routine clinic care 
service. 
These factors observed to influence patients’ engagement in the present study are not unique 
and have been widely reported by other studies 459,474-476 that have evaluated the barriers to 
exercise among dialysis patients. 
This study protocol was designed with the aim of offering a safe but inexpensive exercise 
programme as an alternative to the commonly and widely used bicycle-based programmes 
which have significant cost and space implications, especially in low resource settings.  This 
study showed that despite its simplicity, there is still a considerable cost associated with the 
programme in particular the cost for physiotherapist salary to personalise the exercise 
prescription and ensure patients were safely exercising during their sessions. It was noted that 
in order for the patients to adhere to the exercise programme they needed regular contact with 
the physiotherapist who would encourage them and provide guidance. It was also noted that it 
is unlikely for patients to undertake the intradialytic resistance training independently.  
Some Renal units utilise physiotherapy assistants to run established intradialytic exercise 
programme (personal communication with Dr. S. Greenwood) and it could be possible that 
having a physiotherapist assistant to supervise the current exercise intervention (after initial 
178 
 
assessment and exercise prescription by the qualified physiotherapist) rather than 
physiotherapist would reduce the costs of running the intervention 
5.10  Study limitations  
There were several limitations to this study, some of which (including those related to outcome 
measures used) have already been mentioned in the discussion section above and on previous 
chapters.  
Participant recruitment rate was low (62%) hence only a small sample size was achieved.  This 
was largely contributed by a small number of eligible participants that were available for 
inclusion into the study (those recruited to and completing the previous longitudinal study). 
However, as mentioned in chapter 4, the longitudinal study also had a sub optimal low 
recruitment rate (47 out of intended 116 patients) and even fewer completed the four month 
follow up (41 participants). Patients reported unfavourable experiences with another anaemia 
study (the PIVOTAL study)190 that was conducted earlier at the clinic and therefore became 
reluctant to take part in the present study. Had there been no time or finanial constraints, more 
clinics would have been considered and involved into the trial to increase recruitment 
opportunities and hence sample size. 
There were considerable delays in achieving ethical approval for the study and local clinical 
buy-in due to concern of the staff regarding additional workload.  
It was challenging to gain support from clinical staff and equally challenging to recruits and 
retain participants into the study. 
In addition, securing a suitable physiotherapist with the necessary flexibility to accommodate 
the study sessions was more difficult than anticipated and represented the largest financial 
commitment within the project.  
179 
 
Because of lack of funding, it was not possible to hire a full time physiotherapist to oversee the 
whole programme and instead the programme utilized different exercise therapists (including 
trainees) who worked on a part time basis limiting the number of sessions that could be offered.  
Although there was a standard operating procedure in place for the exercise programme, there 
may have been individual variations and the conformity to the operating procedure in the 
administration and reporting of the exercise outcome. Due to the combination of these time and 
budgetary constraints the original proposed sample size was not achieved and the duration of 
the study had to be reduced to ensure that all patients could be followed up within the time 
available. These changes to the original study protocol will have undoubtedly limited the ability 
of the study to achieve clinically or statistically significant results but equally highlight the 
challenges of conducting ‘real-world’ research in a clinical setting.  
Other limitations are associated with the study design. It was evident that dividing such a small 
sample into control and exercise group was not the best approach as this not only that it reduced 
the sample per group but also reduced motivation within the control group and their subsequent 
response rate. As presented in the discussion section, we could have overcome this, had the 
longitudinal study been considered as a non-exercise control period such that each participant 
acted as their own control (as in a before and after study design). Pre-intervention step counts 
were not assessed and as such limited the evaluation of the exercise intervention on that 
outcome measure. Again, such data could have been collected during the non-exercise period 
and to serve as a baseline measure for comparison with post exercise outcome measures.  
There were also limitations and challenges in monitoring adherence to the walking program. 
As explained in the methodology section, participants were given pedometers, instructed to 
wear then throughout their waking period and to walk for a minimum of 30 minutes a day. 
However, there was no certain way of assessing adherence to wearing the pedometer (other 
than participants’ self-reports). It was therefore difficult to interpret whether the low step 
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counts observed reflected the true level of exercise performed or there was variability in 
wearing the pedometer.  
This pilot study has proved that a duration of 8 weeks of low intensity exercise is insufficient 
to achieve changes in body composition and as such objectives IV and V of this study could 
not be accomplished. 
5.11  Conclusion 
Participants’ nutritional status was satisfactory but their energy and protein intakes were sub-
optimal. Muscle functioning (measured by hand grip strength and sit to stand test) was poor 
and quality of life (measured by SF-36v2 questionnaire) was lower than that of the general 
population and a comparable cohort of dialysis patients.  
The exercise intervention could not bring desirable changes in body composition, inflammation 
or haemoglobin status of participants. However, the increase in weight lifted in each session 
from 3/4th week to the final 7th/8th week showed up to 98% improvements (i.e double the 
amount lifted in the early stage of the intervention). 
The exercise intervention was acceptable but challenging to implement because, despite 
utilizing inexpensive equipment, in order for the programme to succeed, it requires investment 
from a full time physiotherapist or physiotherapy assistant to motivate and supervise patients, 
expertise that is currently not available in the St.George’s nephrology service.  
5.12  Recommendations 
1. It is our recommendation that all renal units should consider including the exercise 
professionals within the standard clinic care service to promote the role of exercise in  
improving patients’ physical and mental health. 
2. We also recommend for renal units to consider including psychological health care as part 
of clinical services to dialysis patients overcoming depression and sense of hopelessness. 
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3. We recommend for continuation of this study and extend it to other dialysis unit (this will 
help to increase sample size), offer more incentives or involvement to the control group (to 
improve their cooperation) and increase duration of the intervention for proper evaluation 
of this form of exercise protocol.  
4. For research to be promoted as part of usual function of renal units reflecting on its potential 
benefit to patients and staff through informing on good practice. They should also consider 
internal and external research collaborations/partnership and encourage multidisciplinary 
research groups. 
5. Direct involvement of patients in research activities (patient lead research) from planning 
to execution stage, not only that it will help to improve the methodology but will help to 
bridge the gap between researchers and patients and gain their trust and cooperation. E.g in 
the present study, it would have helped to have patients who are exercise champions to 
encourage and support other patients throughout the intervention. 
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 CHAPTER 6  
6. GENERAL DISCUSSION AND CONCLUDING REMARKS 
6.1. Summary of thesis findings 
End stage renal disease (ESRD) patients are highly uremic86 and often experience other 
comorbidities e.g. protein energy wasting (PEW)93, inflammation and anaemia87,88  
The condition increases social burden due to the increase in care demand and this significantly 
disrupts family and social life. The range of life time treatment and therapies that an individual 
with end stage renal disease undergoes are very costly, posing an economic burden to families 
and society as a whole. The burden is particularly overwhelming in developing countries, 
including those of sub-Saharan region, due to limited resources (expertise in renal care and 
finances) for the treatments, often leading to suboptimal care and increased mortality risk.11  
Nutrition plays an important role in the management of ESRD. Unfortunately, whilst the 
discipline of nutrition and dietetics is widely developed and specialized in developed countries 
like the UK, this is not the case in developing countries of the sub-Saharan region including 
Tanzania. The region has limited nephrology services in general, not to mention few 
professionals working in renal nutrition/dietetics.  
Acknowledging the gap in the renal nutritional services in the region and the high risk of 
malnutrition and its association with poor treatment outcome, the first stage of this research 
work investigated cross-sectionally, the nutritional status of ESRD patients on haemodialysis 
in Tanzania (a country in sub-Saharan Africa). A similar study was also conducted in the UK 
(specifically within a single hospital in the South East UK), which was deemed to represent 
‘best practice’ for comparison purposes. The detailed findings and discussion of this work are 
presented in Chapter 2. In summary, this first study showed that UK haemodialysis patients 
had better nutritional status, electrolyte control and dialysis clearance compared to their 
183 
 
Tanzanian counterparts. The striking finding was that haemoglobin levels in the Tanzanian 
cohort were significantly lower than the recommendations and certainly lower than that of their 
UK counterparts, despite them being on anaemia management therapies. Their median (25th, 
75th) Hb levels were 82g/l (76, 106) and the majority (75%) had haemoglobin levels below the 
renal care guideline which calls for Hb to be maintained within the range of 100 – 200g/l for 
dialysis patients on erythropoietin (EPO) treatment.  
Anaemia is not uncommon in ESRD patients due to insufficient EPO production from the failed 
kidneys87, however, it is expected that the use of injectable EPO and intravenous iron would 
help to correct anaemia in this group281. Nevertheless, hypo-responsiveness to EPO is also a 
common problem, affecting about 10% of haemodialysis patients193. It was therefore a concern 
that EPO hypo-responsiveness might be the reason for the suboptimal haemoglobin levels 
among Tanzanian HD patients. There are known contributory factors for anaemia or EPO 
hypo-responsiveness such as sub-optimal dosage or non-compliance with EPO therapy (due to 
financial constraints), iron deficiency, malnutrition200,   and inflammation308, but these could 
not be studied in the first cross-sectional study due to the limited data collected.   
Therefore, the follow up study to stage 1 involved a more in-depth cross-sectional study that 
measured a broader range of these known factors (i.e. dietary intake, nutritional status/body 
composition, inflammatory markers and iron markers) and studied their contribution to the 
haemoglobin status of Tanzanian HD patients. It was important to conduct further 
investigations and attempt to explain the reasons for suboptimal Hb levels because of the 
negative health implications of anaemia for these patients as discussed in Chapter 1 as well as 
the more general negative implications of a patient group receiving sub-optimal treatment. In 
particular, anaemia management therapies (EPO and IV iron) are expensive, and so improving 
patients’ response to them will also likely help lower the doses required to achieve the desired 
clinical outcomes and ultimately reduce the costs associated with treatment.  
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The follow up study involved adult HD patients with Hb concentrations less than 100g/l who 
were on EPO treatment at one major dialysis unit in Tanzania.  Data were collected on EPO 
and iron therapy, dietary intake, nutritional status, inflammatory markers, dialysis adequacy 
and iron metabolism. The detailed findings and discussion of this work are presented in Chapter 
3. In summary, results showed that participants had inadequate dietary protein and energy 
intakes compared to the recommended  ≥1.2g/kg/day and ≥ 35kcal/kg/day respectively 131,135. 
Their median (25th, 75th percentiles) energy intake was 24.4kcal/kg/day (18, 31) and protein 
was 0.6g/kg/day (0.5, 0.9). Their diets were predominantly starch-based and lacking in protein, 
fruits and vegetables. Their low energy intakes were a cause for concern as these patients are 
already prone to protein energy wasting due to their disease status making optimal protein and 
energy intakes essential. Whilst starchy foods are the main staples and fairly inexpensive in 
Tanzania, protein, particularly animal protein, can be expensive and therefore unaffordable for 
low income or financially challenged individuals and families. With these patients already 
facing financial pressures due to high treatment costs, it is likely that they have reduced access 
to adequate food. The observed inadequacy of dietary intakes could also be a reflection of poor 
appetite that is commonly reported by CKD patients as their disease condition progresses346. 
The altered sense of taste, coupled with strict dietary restrictions and the inability of patients 
to prepare their meals due to fatigue have all been shown to compromise dietary intakes in 
these patients 333,347 and may be the case for these Tanzanian patients.  Moreover, it was 
recognised that there are no renal dietitians or renal trained nutritionists in Tanzania, severely 
limiting their access to appropriate dietary advice and monitoring. There are also no local 
guidelines for renal diets and this is likely to make it more difficult to provide standard nutrition 
care to these patients.  
The findings of this second Tanzanian study also suggested some degree of muscle wasting as 
hand grip strength (HGS) and albumin levels of these participants were below the 
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recommended ranges320. This is likely to be a direct consequence of the inadequate dietary 
intakes already discussed as there were also close links between HGS and protein and energy 
intakes. Participants generally had high C-RP levels (a marker of inflammation) and this was 
found to be negatively associated with the albumin status, suggesting that the inadequate 
nutritional status of these patients could be a consequence of both dietary inadequacy and 
inflammation. 
Alongside their low haemoglobin concentration, participants in the second study were observed 
to have a notable iron deficiency. Significant and positive relationships between haemoglobin 
concentration and most of the studied nutritional indices were identified (e.g albumin, muscle 
mass, BMI, HGS and fat tissue index (FTI)). Similarly, serum iron was found to be associated 
with FTI and HGS. Also, Erythropoietin resistance index (ERI) was negatively associated with 
BMI, muscle mass and HGS. Further analysis showed that muscle mass was the main predictor 
of both haemoglobin and EPO resistance. The findings suggest that the nutritional status and/ 
or body composition of Tanzanian patients receiving HD is positively impacting on anaemia 
status and/or response to EPO.  
The modifying effects of nutritional status and body composition on EPO response have been 
proposed in other studies12,13,222. An improved EPO response was found in patients with both 
high fat and muscle mass13,222 and with an increase in BMI12, although the mechanisms behind 
these observed relationships are still subject to debate. Some authors suggest that the protective 
effect of increased body fat, lean mass or BMI might simply be an indication of the survival 
advantage conferred by better nutritional status and/or the reduced uraemic distribution volume 
(consequently, reduced inflammatory syndrome) in patients with larger body size13,222. 
However, one author suggested that the benefit is actually associated with body fat and 
suggested the relationship is linked with the reduced haemodilution (due to lower water content 
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in fat) and increased levels of leptin hormone228 which correlates positively with 
obesity/adiposity408. 
Leptin hormone is secreted by the adipose tissue and its primary function is regulation of 
appetite401 and energy expenditure402. However, the hormone has also been suggested to have 
an haematopoietic role by stimulating proliferation of haematopoietic stem cells228,364,370 and 
therefore, in the presence of EPO, leptin could potentially increase erythropoiesis and hence 
haemoglobin concentration. A significant positive association was observed previously 
between leptin hormone and haemoglobin concentration.365  
However, these studies have their own limitations, for example the use of nutritional indices 
derived from mathematical modelling rather than direct measures (as discussed in chapter 3) 
to study the association. The link between obesity/fat adiposity and increased oxidative stress 
and inflammatory response is well known and leptin has been cited as a promoting factor in 
that relationship477. It was therefore not expected to find the positive association between body 
fat and Hb and/or EPO response.    
The study presented in chapter 4 was therefore conducted to explore further the mechanism 
behind the observed relationship between nutritional status, body composition and anaemia 
status among dialysis patients on EPO treatment. It was hypothesized that Hb concentration 
would increase with the increase in muscle mass and/or body fat, such that patients with good 
muscle mass and/or higher body fat would have a better chance of achieving their Hb targets 
compared to those with low muscle mass and/or body fat. This part of the research was 
conducted in the UK because of the limited research equipment including laboratory facilities 
in Tanzania. To gain more understanding on the topic, the study was conducted longitudinally 
(over four months) and it involved additional markers of nutritional status, body composition, 
leptin hormone and iron status and metabolism which had not been assessed in chapter 3. Also, 
in this study, body composition was assessed using a Body Composition Monitor (BCM) 
187 
 
(Fresenius Medical Care AG & Co, Germany) which has been validated for use in 
haemodialysis patients as opposed to a portable conventional bio-impedance machine that was 
used in Tanzanian cross-sectional study. This work is presented in detail in chapter 4. 
Like the previous Tanzanian cohort, inadequate dietary energy and protein intakes were 
observed in the UK HD patients. The albumin and HGS status of these patients were also sub-
optimal. Although the overall haemoglobin levels in this UK cohort were satisfactory, half of 
the cohort had sub-optimal haemoglobin levels which did not increase throughout the 4 months 
despite active treatment. However, unlike the Tanzanian cohort, a lower proportion of patients 
(38%) in the UK cohort had concurrent inflammation. There was a negative relationship 
between inflammation and lean tissue index (LTI) and also a positive relationship between LTI 
and Quality of Life (QoL). This reflects the increased risk of impaired QoL in these inflamed 
individuals. 
Although there was no relationship between baseline nutrition status (apart from dietary iron 
which positively correlated with iron levels), body composition or inflammation with iron 
markers; longitudinally, Hb concentration appeared to be positively associated with body fat. 
Other markers such as EPO resistance index, transferrin receptor or ferritin appeared to be 
independent of body composition, nutritional status or inflammation when analysed cross-
sectionally or over time. This was unexpected as it contrasted with the findings from the 
previous cross-sectional study. However, the baseline haemoglobin concentrations of 
participants in the Tanzanian cohort were much lower than those of the UK cohort, which might 
explain the lack of association seen here.  It is likely that the previously observed association 
between body composition and EPO response index exists for more severely anaemic cases.  
Another interesting observation made in chapter 4 was the association between leptin hormone 
and haemoglobin concentration which appeared to concur with other researchers on the who 
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have proposed a role for the hormone in erythropoiesis 225-227,370 as previously discussed. 
However, we could not draw definitive conclusions regarding this mechanism because leptin 
hormone did not correlate with any other haematopoietic markers like sTfR, whose positive 
association would have confirmed an increase in erythropoiesis with the increase in leptin. 
Similarly, one would expect to see the decrease in ERI with an increase in leptin hormone 
which was not identified in this cohort. The involvement of leptin and body fat in erythropoiesis 
is therefore still an area requiring further investigation to establish a causal relationship. It 
would be ideal to measure different types of adiposity, e.g. subcutaneous versus visceral fat, 
and to investigate whether these would have the same impact on leptin hormone production 
and erythropoiesis (as they are known to have different implication in metabolic syndrome). 
Although there was no direct relationship between markers of inflammation and those of iron 
status or metabolism, there was a negative correlation between serum transferrin receptor 
(sTfR) and hepcidin-25. Hepcidin-25 is a hormone which regulates intestinal absorption of iron 
and its release from the reticuloendothelial cells166,409. Upregulation of hepcidin-25 reduces 
iron availability for red blood cell production412, which could explain the observed relationship 
with sTfR (reflecting a reduction in iron availability/uptake413) in the present study and is 
consistent with the findings  of Drakou et al414 from a prospective study of pre-dialysis patients.   
Following the findings of an influence of body composition (body fat and muscle mass) on 
haemoglobin levels and EPO response, the study presented in Chapter 5 was conducted to 
investigate and test the hypothesis that body composition can be modified through exercise, 
and to investigate whether this modification would be sufficient to drive improvements in 
patients’ Hb levels. Rather than replicating previous studies that have used intra-dialytic 
cycling this protocol was designed with low resource settings in mind and as such involved 
exercise of low intensity, requiring only minimal equipment and combining both aerobic 
(walking) and resistance training. Whilst this approach had logistical merit its efficacy or 
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feasibility were unknown and so a pilot and feasibility study was set up in an attempt to 
maximise the value of the research undertaken within the limited budget and time available. 
This type of exercise programme was found to be feasible for dialysing adults with ESRD.  
However, despite its simplicity, investment in physiotherapy services were still required for it 
to succeed. Patients needed regular contact with the physiotherapist for motivation and 
supervision (for intradialytic exercises), suggesting that a truly ‘no cost’ exercise intervention 
in this population is not possible. However, the investigated exercise programme retains 
potential and certainly enabled costs associated with traditional inter-dialytic exercise to be 
reduced, if not removed altogether, such that it only required relatively inexpensive equipment 
as opposed to expensive stationary bikes (which also require physiotherapy supervision). The 
intervention did not bring significant changes in body composition, dialysis clearance or 
inflammation status but was undoubtedly affected by the small sample size and short duration. 
However, there was a noticeable improvement in exercise performance and lower body 
strength in those who did engage and it was evident that patients involved had low baseline 
levels of physical functioning and so could benefit from regular physical activities.  
6.2 Critical evaluation of the programme: strengths, limitations and review of 
study design 
6.2.1 Strength of the thesis 
This programme of work has added to the literature surrounding the management of ESRD 
patients. It has highlighted the regional differences (UK versus Tanzania) in patient care as 
influenced by resource availability, with better care and treatment outcome observed in the 
high resource setting (UK). It has also shown that anaemia management of HD patients requires 
multidisciplinary approaches, with nutrition playing as significant role as the pharmacological 
approach. With the needs of lower resource ESRD populations in mind, this thesis has provided 
evidence for the potential feasibility and benefits of an exercise protocol involving resistance 
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and walking (aerobic) among HD patients. The protocol was adopted with consideration of the 
known limitations of the renal care services in sub-Saharan Africa and the needs and desires of 
the patients themselves through PPI work but testing in this setting is now required, informed 
by the UK pilot. 
Another strength of this work is the use of multiplex analysis techniques in the laboratory. This 
is a new technique applied to analyse sets of biomarkers as opposed to single analytes, thereby 
minimizing sample use and costs. However, this approach was not without challenges with 
multiple standards used and some parameters giving readings that were out of range, 
compromising the reliability of results.  
6.2.2 Limitations of the thesis 
Despite its potential contribution, this program does not lack limitations. Study specific 
limitations and weaknesses have already been discussed in individual chapters. In this section, 
limitations and/or weaknesses of the program in general will be discussed.  
The whole project aimed to investigate how nutrition in general could modify/influence 
patients’ response to EPO treatment. The first two sub-studies (presented in chapters 2 and 3) 
of this work set a direction suggesting the associations between muscle and body fat with Hb 
concentration and ERI (an index of EPO resistance) required investigation. These were cross-
sectional studies and had limited data available and variables which could be studied. The two 
subsequent studies (presented in chapters 4 and 5) were designed to investigate this in greater 
detail and to try ad address the limitations already identified in this project, and the wider field. 
However, these studies also had some limitations which had implications for achievement of 
the study aims.  
A major limitation was on the study design itself for the final trial. The study included patients 
who were receiving EPO treatment and who had Hb concentrations which were below the 
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recommended range (< 100g/l).  Because of this, there was no reference cohort. It was realised 
that, to definitively explain the modifying role of nutrition on EPO response, the study needed 
a cohort of patients whose Hb levels were within the recommended range, who could serve as 
a reference cohort for comparison with those with sub-optimal Hb levels. Because of this 
limitation, the study could not achieve its main aim of providing a a robust explanation of the 
modification effect of body composition on EPO responses.  
Another significant limitation to the study was the failure to achieve the target sample size . 
This reduced statistical power of the studies limiting significance of the findings. It was 
challenging to get patients with low Hb to volunteer to take part in the research activities, 
particularly in the exercise intervention as some reported that “they see no benefit of involving 
in research” and others simply thought “it was too much to take on alongside their treatment 
or health challenges”. Their negative attitude was also affected by peer influence and 
experience of the recently completed PIVOTAL study. The PIVOTAL trial was also an 
anaemia related study hence the present study was deemed by some patients to be an 
unnecessary repetition of research. It is anticipated that the under-recruitment issues were also 
exacerbated by the narrow inclusion criteria. With hindsight, including patients with an Hb 
concentration within range would have helped to increase the sample size.  
It was evident that subject randomisation in this project was not the best approach, particularly 
given the low subject numbers which resulted in very small numbers in the allocated subgroups 
and the low engagement of the control group. Future studies could overcome this challenge by 
employing a different study design such that each participant is assessed for all desirable 
outcome measures (including step counts) for a period of time before the intervention 
commences and in that way acts as their own control. This was possible considering that there 
was a period of longitudinal observation before the exercise intervention. Although the original 
aim of conducting a longitudinal observational study prior to the exercise intervention was to 
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obtain baseline (before intervention) data, the outcome measures were not carefully selected as 
exercise related measures were missed. Because of this the longitudinal observational study 
could not serve as a baseline to the exercise study. 
Inadequate dietary intake was reported across all studies in the present work, but to a large 
extent, this was not reflected in the nutritional status. We therefore believe that this could be 
due to the inherent limitation of the dietary assessment methods used. FFQs, food diaries and 
multiple 24 past recall methods are all subject to recall and recording bias. Although in the 
current study foods were recorded for three days of the week (in an attempt to represent the 
usual weekly dietary intake), the accuracy of recalling the food types and estimation of portion 
size and recording is still subject to many human errors. This method can also pose a response 
burden and this may alter dietary behaviour, e.g previous studies have found that some 
respondents may alter their dietary intake intentionally or unintentionally (both the type and 
amount eaten) to reduce the respondent  burden or portray a more optimal diet451. This was also 
the case in the present study as some respondents reported only one day’s intake and claimed 
the other two days intake were the same as the first reported.  Nutrient analysis can also be 
complex due to different recipes and mixed dishes increasing the likelihood of errors in dietary 
assessment. In the present cohort, the respondents were of mixed ethnic groups and culture, 
and there were indeed varied types of food recorded whose recipes were not accommodated in 
the food composition database/analysis software used. Moreover, in most cases, participants’ 
food was prepared as family meals and they could not adequately describe food 
recipes/ingredients incorporated in dishes. The situation was more challenging in the analysis 
of the dietary intake of the Tanzanian patients due to a lack of standard portion sizes and the 
lack of availability of specific dietary analysis software that would accommodate local food.  
Manual analysis was performed using a paper-based local Tanzanian food composition table 
increasing the likelihood of errors. There are a number of new dietary assessment techniques 
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that utilize technology that could possibly reduce the error of the conventional methods478 e.g, 
digital images for food identification and portion size estimation using the mobile phone 
camera to produce real-time data479-484.  Although most of these are still in development and 
require validation, they have the potential to improve dietary assessment in the near future. 
These technologies might also be expensive particularly for large scale epidemiological 
studies, but once acquired they will help to reduce both researcher and respondent burden and 
increase the accuracy of dietary assessment.  
Another general limitation across the programme of work was related to the nature of the study 
setting and the participants involved. Because the study was conducted in a clinical setting 
during dialysis visits, research activities were to be aligned and frequently adjusted such that 
the clinics activities and individual patient’s schedules were not compromised. Most often this 
caused inconsistencies in the timing of measurements and consequently on the accuracy of the 
outcomes measured. For example, for almost all outcome measures, the timing of a 
measurement (how far before or after the dialysis treatment) will significantly alter the results. 
In the present study, we would particularly acknowledge the limitation in the accuracy of waist 
circumference and HGS measures and sit to stand tests as these were taken at varied times 
(before or after dialysis) depending on patient convenience. To gain full control of research 
activities, we believe it is important for the study to be designed such that there is minimal 
influence or interference between research and clinic activities. In this instance, conducting 
research activities on non-dialysis days or out of dialysis clinics could have helped. However, 
there would be some ethical issues to consider with regards to the research burden to 
participants (e.g. the additional time spent for research activities considering the time they 
already spend for dialysis treatment). The current study received positive ethics opinion 
considering that there would be no extra time imposed to patients. 
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There were also challenges and limitations in the measures of body composition used. The 
measurement taken using bio-impedance technology only provided estimates or surrogate 
measures rather that direct quantities (as provided by imaging tools like DEXA and CT scans). 
We could not perform direct measures of muscles, body fat or fluid due to resource constraints 
(time and finance). It is likely that the lack of clear association seen between body composition 
and anaemia markers in the present study was due in part to the inaccurate measures of body 
composition.  
Because of all the aforementioned limitations to the study, regrettably it could not provide 
certain answers to the original research questions. Section 6.5 provides a detailed account of 
important amendment needed to the study to answer these research questions.  
6.3 Concluding remarks 
Inadequate nutrition is a common problem for adults receiving haemodialysis for ESRD in both 
Tanzania and the UK. In both countries inadequate protein and energy intakes are commonly 
seen resulting in an overall suboptimal nutritional status, in particular a degree of muscle 
wasting.  UK haemodialysis patients had better dialysis clearance and they also had improved 
status in relation to inflammation and bone minerals compared to Tanzanian patients, 
potentially reflecting the higher quality dialysis care received.  
Anaemia was highly prevalent in Tanzania HD patients on EPO treatment compared to UK 
counterparts, coexisting with iron deficiency and inflammation.  There was a close relationship 
between nutritional status (albumin, BMI, muscle mass and body fat), in particular muscle mass 
and body fat which appeared to positively associated with Hb concentration and EPO response. 
This relationship was stronger in the Tanzanian cohort likely reflecting their more severe 
anaemia. 
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A flexible exercise programme that includes walking and intradialytic resistance training is 
practical, however it is not cost neutral since the presence of a physiotherapist was required for 
supervision and motivation. HD patients have low mobility and physical functioning and would 
benefit from motivation and support from clinic personnel and peers to engage in physical 
activities.  
Eight weeks of walking plus intradialytic resistance training did not bring significant changes 
in body composition, inflammation, dialysis adequacy or anaemia status but improved exercise 
performance and lower body strength. Longer studies in a larger sample are warranted to 
confirm the impact of such an intervention on both mental and physical health and the 
feasibility of providing support through peer supporters as well as or instead of health 
professionals. 
6.4 General recommendations 
Given the influence of nutrition status and body composition on haemoglobin status and EPO 
response, nutrition must be considered along with other pharmacological therapies used for 
anaemia management, extending beyond ensuring adequate iron intake to maximising the 
whole diet including energy intake and macronutrient balance. Patients require adequate 
dietary intakes plus regular physical activity to help them maintain their lean body mass.  
Renal nutrition services should be integrated into renal care services in Tanzania. Even the 
most basic nutritional parameters were not being assessed on a routine basis. The hospital 
should invest in renal nutritional training to upskill the available staff and allow them to 
maximise their contacts with patients and ensure a more holistic, whole body approach to their 
management, with anticipated benefits for patients and their families and for the limited health 
care budgets through therapy optimisation 
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Greater use of iron supplementation alongside EPO therapy is recommended within the dialysis 
care services in Tanzania to tackle the problem of iron deficiency. Equally, dietary iron can be 
increased through promotion of adequate intake of protein rich foods. 
All renal units should consider including routine physiotherapy/ exercise therapy services as 
part of their standard usual care for dialysis or ESRD patients.  
All opportunities to increase patients’ physical activity levels (through lifestyle as well as 
leisure activity) should be taken.  The use of group exercise sessions at clinics or gyms/clubs 
should be explored due to the potential for creating supportive and more sustainable ESRD 
exercise communities.  
6.5 Study design review  
Introduction of the study 
Anaemia is common among ESRD patients. There is a suggestion that body fat and/or muscle 
modifies how a patient responds to EPO therapy, such that there are better responses among 
patients with high muscle mass and/or body fat. However, there are contradictory results as to 
whether it is muscle or body fat that confers the greater benefit and what would be the 
mechanism for the suggested associations.  Research evidence is also mounting with regards 
to the benefit of exercise among haemodialysis patients including improving body 
composition, dialysis clearance and haemoglobin status and these have been well described in 
the introduction section of this thesis (section 1.5.1). 
The aim of the present thesis was to investigate the link between body composition (body fat 
and muscles mass) and EPO response (as reflected by the haemoglobin concentration). It also 
intended to investigate if body exercise can modify the association, presumably through 
modification of body composition and/or dialysis clearance and inflammation.  
Revision: Hypothesis and study objectives are both revised and stated as below:  
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Hypothesis of the study 
i. Patients with higher muscle and higher body fat mass will have better EPO response 
(reflected by levels of haemoglobin concentration) than those with lower muscle mass 
and body fat. 
ii. There will be an improvement in muscle mass, dialysis clearance and haemoglobin 
concentration after an exercise intervention when compared to a control period prior to 
intervention. 
iii. The exercise program involving walking and intradialytic exercise will be practical, 
acceptable and will lead to improvement in physical functioning and quality of life   
 
Objectives of the Study 
i. To investigate the relationship between body composition (muscle and body fat) and 
haemoglobin concentration before and after exercise intervention. 
ii. To study the impact of exercise intervention on dialysis clearance, physical functioning 
and quality of life.  
iii. To investigate the practicality and acceptability of an exercise intervention involving 
walking and resistance training among HD patients and care professions. 
Methodology 
Building on the experiences and challenges of the previous studies several changes are 
suggested to the study design, exercise intervention and evaluation. 
Study design 
I suggest the adoption of quasi-experimental study design rather than a randomised control 
design. Patients will be observed for a period of time (the original four month duration is 
retained) and assessed on all outcome measures of interest. These will serve as baseline 
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measurements and allow participants to act as their own controls. The intervention will then be 
offered to all participants for an equal period of time (4 months) and throughout this period a 
similar set of outcome measures will be assessed. In this design, pre-intervention measurements 
(single time point and changes over time) will be used as reference data and compared with 
measures during and post intervention (and with changes over the intervention period). By 
adopting this study design, I believe that the intervention will be more socially acceptable to 
the participants whilst also removing the   ethical concerns associated with withholding a 
potentially beneficial intervention from the control group. 
Study participants: Inclusion and exclusion criteria 
As previously stated, the study will include adult HD patients (≥ 18 years) who are on anaemia 
management therapy (i.e EPO). The haemoglobin level criteria that were previously considered 
(< 100g/l) will be removed. This is to provide a broader range of participants for comparison 
based on haemoglobin levels. It will also help to increase number of potential participants for 
recruitment to attain the desired sample size.  
Participants who lack capacity, command of English, those with anaemia of non-renal 
aetiology and those that are contraindicated for exercise will be excluded from the beginning 
of the study.  
Study Intervention 
The study intervention will be walking (as a form of aerobic exercise) and resistance training 
and as such remains unchanged from the previous intervention. However, I propose several 
changes in the intervention delivery protocol as described below.  
Walking 
Participants will be advised to walk for a minimum of 30 minutes as previously but to walk on 
non-dialysis days. This is because experience showed that patients are less likely to engage in 
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exercise after dialysis due to tiredness. They will also be individually prescribed with the 
walking pace, this will be reviewed and adjusted to maintain the 12 – 14 (somewhat difficult) 
rate of perceived exertion (RPE).  To monitor their exercise, they will be provided with and 
accelerometer pedometer and requested to wear them whenever they are walking. 
Accelerometer pedometers have an added advantage of being able to record speed, distance 
and force/energy spent on activity in addition to the time and step counts that the standard 
pedometer used in the present study was able to record.  
Intradialytic resistance training  
The protocol for resistance training will be retained as there were no problems encountered 
with regards to this.  Following initial assessment, individual prescription of exercise will be 
made to achieve exercise at a level of RPE 12 – 14 on the borg scale. The exercise will be 
performed whilst on dialysis during the second hour. The exercise duration and number of sets/ 
repetitions for each exercise will be determined by the physiotherapist after initial assessment.  
The typical program will be implemented using free-weight dumbbells for upper body 
exercises (shoulder press, lateral raise, triceps extension, biceps curl and external shoulder 
rotation) and weighted ankle cuffs for lower body exercises (seated knee extension, hip flexion, 
hip abduction and inner range quad exercises). 
Monitoring and supervision of exercise program 
The completed study showed that close supervision is required for this intervention to be 
successful. I propose the following changes in the monitoring and supervision process: 
i. Participants to be signed up to a mobile phone message reminder service such that every 
morning they receive a reminder of the exercise program of the day. 
ii. Participants to be in contact with the exercise supervisory team whenever they go for 
dialysis. To ensure that there are no missing contacts due to limited physiotherapist 
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access, it is practical for exercise coaches or assistant therapist to be trained and work 
under supervision of the physiotherapist. During clinic appointments, in addition to 
supervising the resistance training, the exercise supervisors will retrieve and record data 
from the pedometers, will check for exercise compliance and any adverse effects. Any 
concerns will be discussed and resolved as required. 
iii. An accredited physiotherapist will remain responsible for reviewing and describing the 
exercise program at monthly intervals or to individual participant when indicated due 
to health reasons. 
Outcome measures 
The outcome measures have been reviewed with some measures omitted (e.g anthropometric 
measures and subjective global assessment) to reduce response burden and allow resources to 
be directed to those that are necessary to answer the primary research questions. 
The following outcomes will be measured: 
Primary outcome: Haemoglobin concentration 
Secondary outcomes: Muscle mass, body fat mass (subcutaneous and visceral fat 
distribution), hand grip strength, inflammatory markers (serum C-RP, IL-6 and IL-10), iron 
metabolism markers (serum hepcidin-25, soluble transferrin receptor, transferrin saturation 
percentage, serum iron), kidney function biochemistry (serum creatinine and urea); dietary 
intake (including any food supplement). 
Other outcome measures: 
 Physical functioning (sit to stand test, shuttle walk test, changes in exercise 
performance), Quality of life (using standard validated questionnaire) 
 Exercise acceptability questionnaire  
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 Adverse effects (hospitalization, cardiovascular morbidity and mortality, critical limb 
ischaemia) 
 Cost effectiveness of the exercise intervention. There will be a need to assess whether 
this intervention is cost effective.  This will be done by comparing the cost incurred to 
administer the intervention with the cost incurred by those who do not exercise  for 
example comparing the costs incurred in the control and intervention period and 
extrapolating these to longer term care (e.g. hospital admissions, medication and iron 
therapies). This element of the project would require the input of a Health Economist, 
conferring up front costs at the research stage which we would hope to recoup if the 
intervention were deemed cost effective and rolled out to a larger sample. 
Note: I suggest a revision in the measurements and laboratory techniques as follows: 
1. Body composition to be assessed after dialysis and using Dual-energy X-ray 
absorptiometry (DEXA) rather than a body composition monitor to give more detailed 
description of muscle and body fat. This will require for the machine to be on site and to 
be supported by radiation trained individuals.  
2. To correct for errors in laboratory analysis that resulted from using the Multiplex 
Immunoassay system, the analysis will be revised to employ more sensitive tests, e.g 
enzyme-linked immunosorbent assay (ELISA) technique for the measurement of serum 
IL-6, IL-10, soluble transferrin receptor and iron. 
3. To allow all research measurements to be performed accurately, there will be a need for 
patients to remain after their dialysis treatment for approximately 30 minutes. This will 
have implication for both time and finances (transportation costs) and there will be a need 
for participants to be compensated for this.  
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Study end point 
To meet the academic timeline, the study will be terminated after four month of intervention 
period + assessment. However, the study may be terminated early for individual participants 
when an adverse health effect is experienced. 
Data analysis 
Data analysis will be revised in accordance to the hypothesis stated and the new study design. 
6.6  Implementation of Exercise intervention in Tanzania  
If the present exercise intervention is proven to be beneficial in improving EPO responses, this 
will in turn help to reduce treatment costs. These are costs associated with anaemia therapies 
(dose of therapies required to achieve clinical targets will be lowered) and hospital admission. 
If patients’ physical functioning and quality of life are both improved, this will also help to 
reduce dependence rate and care burden of patients. Carers will have more time for other 
developmental activities and the quality of life of the patients and their wider family would be 
expected to improve.  
This intervention is desirable for patients care in Tanzania considering the high prevalence of 
renal anaemia and high relative cost associated with treatment. It will be of interest to the clinics 
and the government in general to reduce treatment costs and improve patients’ treatment 
outcome. However, there will be a need for training physiotherapist and exercise assistants to 
successfully incorporate exercise into usual clinic care.  
Exercise is increasingly being adopted in Tanzania as a lifestyle among young population group 
due to concerns of their body weight and image. However, it is not a common practice for 
elderly and ill people to engage in exercise. They largely live sedentary life styles and prefer 
using aid even in daily household activities and mobility (minimal walking).  
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The implementation of a similar intervention in a Tanzanian clinic setting will therefore largely 
depend on the cost effectiveness analysis. A longer and larger study preferably conducted in 
Tanzania might help provide more evidence before it is adopted in usual clinic care.  
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Appendix 6: Participant information sheet for Tanzania cross-sectional study 2 
 
INFORMATION SHEET  
(version 1, 10/03/2016) 
PROJECT TITLE: Low haemoglobin status in Tanzania haemodialysis patients on ESA treatment:   
                             Contributory factors and their association with patients’ haematological response to    
                             dietary iron and oral iron supplementation.  
Introduction 
I am Tanzanian nutritionist and assistant lecturer from the University of Dodoma currently 
undertaking a PhD in Nutritional sciences (renal nutrition) at the University of Surrey, UK. IAs part of 
my research I am currently conducting a a study on iron deficiency anaemia and its management 
among Tanzania haemodialysis patients. 
I would like to invite you to take part in this research project. Before you decide you need to 
understand why the research is being done and what it will involve for you. Please take the time to 
read the following information carefully. Talk to others about the study if you wish. 
What is the purpose of the study? 
Patients with kidney failure have poor red blood production because they don't make enough of an 
important hormone called Erythropoietin (EPO). This hormone is usually produced in the kidney, but 
when the kidney fails there is less hormone and therefore not enough red blood cells are produced 
leading to anaemia.  
To help with this problem, patients are treated with a synthetic form of EPO and iron to help them 
with red blood cell production. However, for several reasons, patients might still fail to achieve a 
desirable level of iron. This is often the case in Tanzania, where the majority of haemodialysis patients 
have low haemoglobin (a measure of iron status) (< 9g/dl) despite being on EPO treatment. 
This research study aims to find out what factors may lead to these persistent low iron levels in 
Tanzanian HD patients who are on EPO treatment. It also intends to determine whether oral iron 
supplements (which are a relatively cheap treatment option compared to IV iron) and dietary iron can 
increase iron levels enough.  
Why have I been invited to take part in the study? 
Because you have Hb concentration below the healthy level despite being treated with EPO. 
Do I have to take part? 
No, you do not have to participate. There will be no adverse consequences in terms of your care or 
treatment if you choose not to take part. Your participation is voluntarily. You can withdraw at any 
time without giving a reason.  
What will my involvement require? 
You will be asked to:  
1. Consume one iron supplement tablets three times a day for eight weeks. A weekly dose will 
be provided to you free of charge every week when you attend dialysis session.  
2. You will be asked how often you take your supplements and how you feel since starting to 
consume then. This will be done every week when you attend dialysis session. 
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3. You will be given advice on type of foods rich in iron and those which inhibit and/or facilitate 
iron absorption and asked to try and include iron sources more often in your diet. This will be 
done monthly for four months 
4. During a short chat with a researcher you will be asked to recall all foods and drinks consumed 
in the past 24 hours. This will done monthly for five months 
5. Your height will be measured at your first appointment and then your body composition 
(amount of fat and muscle) will be measured routinely using a BIA machine – you will stand 
on this in light clothing. This will done monthly for five months. 
6. Your clinical records/notes will be consulted for type of EPO and iron you are using, dose and 
frequency. This will done monthly for five months 
7. Your blood test results will be collected from routine tests already done at your clinics.  If not 
available, your usual blood sample routinely collected at the clinics will be sent to another lab 
for analysis. NO extra blood samples are required, NEITHER will you incur charges for any extra 
tests that were not in your routine clinical assessment.  This will also be done monthly for five 
months 
 
What will I have to do? 
If you would like to take part please go through the consent form and ask any questions you have 
Once you are happy that you understand the study and are willing to participate please sign the 
consent form.  
You will then be enrolled to the study and take part as previously prescribed.  
What are the possible disadvantages or risks of taking part? 
The risk is minimal, you may experience stomach discomfort when taking the supplement. The renal 
physician or nephrologist will be regulating the dose and help with management of all side effects as 
desirable. 
What are the possible benefits of taking part? 
If the supplement is properly consumed as directed and dietary advice followed, there is a possibility 
of improving your iron status.  
What happens when the research study stops? 
As a participant you will be provided with the summary of the study findings and recommendations 
will be made to allow you to continue to improve your iron status.    
What if there is a problem? 
Any complaint or concern about any aspect of the study will be addressed. You can contact directly 
the principal investigator (Ms. Nyangi Gityamwi), renal unit nephrologist/physician or the head of 
renal unit. More contact information (including phone numbers) of the mentioned will be proved to 
all participants at the beginning of the study.  
Will my taking part in the study be kept confidential? 
Yes. All of the information you give will be anonymised, your clinical ID numbers will be used instead 
of names so that those reading reports from the research will not know who has contributed to it.  
Data will be stored securely in accordance with the Data Protection Act 1998. Only the principal 
investigator and unit personnel involved in the study will have access to data. 
Contact details of researcher and supervisor? 
The study is conducted by: 
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Ms. Nyangi A. Gityamwi, a PhD researcher  
School of Biosciences and Medicine 
University of Surrey  
GU2 7XH 
Guildford, UK 
Supervisors:  
1. Dr. Kathryn Hart  
Lecturer in Nutrition & Dietetics  
Faculty of Health and Medical Sciences  
AY Block (40AY03)  
Surrey University  
Guildford  
GU2 7XH 
2. Dr. Barbara Engel 
Senior Teaching Fellow in Nutrition & Dietetics  
Faculty of Health and Medical Sciences  
AY Block (33AY03)  
Surrey University  
Guildford  
GU2 7XH 
Who is organising and funding the research? 
The research is organised above mentioned researcher with assistance from supervisors. 
It is funded as a part of PhD programmeme by Commonwealth scholarship commission, UK.  
The supplement have been provided as support from DenkPharma, Germany 
Who has reviewed the project? 
This study has been reviewed and received an ethical approval by the Muhimbili National Hospital’s 
Institutional Ethics Review Board (MNH-IRB)  
 
The study has also been reviewed and received a Favourable Ethical Opinion (FEO) from the Faculty 
of Health and Medical Sciences Ethics Committee, at the University of Surrey. 
 
 
Thank you for taking the time to read this Information Sheet. 
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Appendix 7: Consent form for Tanzania cross-sectional study 2  
 
CONSENT FORM 
[version 1, date 10/03/16]  
 
 Study title: Low haemoglobin status in Tanzania haemodialysis patients on ESA treatment:     
                      Contributory factors and their association with patients’ haematological response to  
                      dietary iron and oral iron supplementation        
 
  Please initial each box                           
 
 I have read and understood the Information Sheet provided (version 1, date 10/03/16).  I have 
been given a full explanation by the investigators of the nature, purpose, location and likely 
duration of the study, and of what I will be expected to do.   
 I have been advised about any discomfort/possible ill-effects on my health and well-being 
which may result.  I have been given the opportunity to ask questions on all aspects of the 
study and have understood the advice and information given as a result.                                                                                                             
 I agree to comply with the requirements of the study as outlined to me to the best of my 
abilities. I shall inform the investigators immediately if I have any concerns / suffer any 
deterioration of any kind in my health or well-being / experience any unexpected or unusual 
symptoms 
 I understand insurance is in place which covers harm that is likely to result from my 
participation in this study as detailed in the participant information sheet                                                                                                 
 I agree for my anonymised data and/or samples to be used for this study / future research that 
will have received all relevant legal, professional and ethical approvals. 
 I understand that all project data will be held for at least 6 years and all research data for at 
least 10 years in accordance with University policy and that my personal data is held and 
processed in the strictest confidence, and in accordance with the 321 Data Protection Act (1998). 
 I authorise my doctor to disclose details of my relevant medical or drug history, in confidence. 
 I agree for the researchers to contact me to provide me with a study results summary. 
 I agree for the researchers to contact me about future studies. 
 I understand that relevant sections of my medical notes and all data collected during the study, 
may be looked at for monitoring and auditing purposes by authorised individuals from 
Muhimbili national hospital, University of Surrey, University of Dodoma and other regulatory 
authorities where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 I agree for my personal data and/or unidentifiable samples to be transferred to University of 
Surrey, UK  I understand that my personal data will  be held under the data proctection laws of 
UK. 
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 I understand that I am free to withdraw from the study at any time without needing to justify 
my decision, without prejudice and without my legal rights and medical care being affected.  
 
 I understand that I can request for my data to be withdrawn until the point at which the date 
is published and that following my request all data already collected from me will be destroyed  
 If I withdraw I allow the researchers to use my personal data, in addition to anonymous data, 
already collected as outlined in the participant information sheet and this consent form 
 I confirm that I have read and understood the above and freely consent to participating in this 
study.  I have been given adequate time to consider my participation. 
 
 
 
Name of participant (BLOCK CAPITALS)    ......................................................  
 
Signed  ......................................................  
 
Date  ......................................................  
 
 
  
                                                          
 
Name of researcher/person taking consent  …….............................................. 
(BLOCK CAPITALS)   
  
Signed   .................................................... 
 
Date  ………………………………………………..                              
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Appendix 8: Data Collection Proforma for Tz cross-sectional study 2 
           DATA COLLECTION PROFORMA 
1. Demographic characteristics 
Clinic name……………… Patient’s clinical ID……………. Comorbidities (if any) 
 ……………………. 
 ……………………. 
 ……………………. 
Gender (tick the correct) 
 Female  
 Male 
Age:…………………….. 
Dialysis start date (dd/mm/yr) 
…………………………………… 
2. ESAS and iron information  
ESAs  
Type (name)  
Dosage and frequency prescribed  
Dose coverage  
Reason(s) for sub-optimal coverage if any i. ………………………………………… 
ii. ………………………………………… 
iii. ………………………………………… 
IRON 
Type (name)  
Dosage and frequency prescribed  
Dose coverage  
Reason(s) for sub-optimal coverage if any i. ………………………………………… 
ii. ………………………………………… 
iii. ………………………………………… 
Adverse health effect(s) of oral iron if any 
(tick all apply) 
i. Constipation 
ii. Stool discolouration 
iii. Nausea 
iv. Stomach discomfort 
v. Others (specify) 
…………………………................................ 
……………………………………………… 
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PATIENT’S ID: ………………………………………… 
 
3. Body composition 
Body weight (kg)  
Body height/ stature (cm)   
Body fat (%)  
Muscle mass (%)  
Body fluid (%)  
BMI (kg/m2)  
 
4. Blood biochemistries2 
Serum Creatinine (µmol/l)  
Blood urea (mmol/l)  
 Pre-dialysis sample   
 Post-dialysis sample  
Serum albumin (g/l)  
Adjusted Calcium (mmol/l)  
Phosphate (mmol/l)  
Potassium (mmol/l)  
Sodium (mmol/l)  
Serum C-reactive protein (C-RP) (mg/l)  
Serum iPTH (pmol/l)  
Haemoglobin concentration (g/l)  
Serum Ferritin (ng/l)  
TSAT (%)   
  
  
  
                                                          
2 It is desirable that all biochemical and haematological tests performed on a sample obtained before a mid-
week HD session. Mactier et al., 2011. Renal Association Clinical Practice Guideline on Haemodialysis (Guideline 
6.1) Nephron Clin Pract 2011;118 (suppl 1):c241–c286 Renal Association Clinical Practice Guideline on 
Haemodialysis (Guideline 6.1) 
                                                                                                 
 
 
Appendix 9: Dietary record sheet for Tz cross-sectional study 2 
MULTIPLE 24 PASS RECALL (MPR) TEMPLATE3 
Patient ID: ………………………………                                                         Day and Date of food intake (e.g Monday (dd/mm/yy)): …………………………………… 
Interviewer initials: ……………………..                                                    Date of interview (dd/mm/yy): ……………………………………………………. 
 
Quick list of foods 
Time 
e.g 1300hr 
Occasion 
e.g lunch 
Description of food, drink and ingredients amount and cooking 
method 
How much of this food 
did you eat? 
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
                                                          
3 The MPR tool is adapted with modification from the United State Development of Agriculture(USDA) 
                                                                                                 
 
 
Appendix 10: The adapted Iron Food frequency questionnaire  
  
 IRON FOOD FREQUENCY QUESTIONNAIRE 
When answering this questionnaire consider your intake of food over the past month. To help you do this, please think of an event in your life that happened 
one months ago and think about your eating pattern since that date. 
Example: 
Consider if you have sugar in all your drinks during the day as well as added to other food items and indicate how many times in a day you are consuming 
sugar [e.g 2 cups of tea with sugar, burns with sugar for snacks, 1 glass of fruit juice with sugar, result into choosing the category (4 plus times a day)] 
Consider if you have maize meal and indicate how many times you are consuming maize [e.g eating porridge made of maize flour for breakfast, ugali for 
lunch and kande for dinner result into choosing category (2 to 3 per day)] 
Consider if you have meat (beef) and indicate how many times you are consuming [Eg eating meat pilau every Sunday, minced meat samosa every Monday; 
will result into choosing category (2 to 3 per week)] 
In the past month, I have eaten this food……………………. 
Food 
item 
Never 
eaten 
Less than once a 
month 
1 to 3 times a 
month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once per 
day 
2 to 3 times 
per day 
4 plus times 
per day 
Sugar         √ 
Maize        √  
Beef     √     
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MEAT AND POULTRY (NYAMA NA KUKU) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than once 
a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus times 
per day 
Beef  
(Nyama ya Ng’ombe) 
         
Goat 
(Nyama ya mbuzi) 
         
Pork 
(Nyama ya nguruwe) 
         
Lamb 
(Nyama ya kondoo) 
         
Game meat (eg venison) 
(Nyama ya pori) 
         
Chicken 
(Nyama ya kuku) 
         
Duck 
(Nyama ya bata) 
         
Sausages (beef) 
(Soseji ya ngombe) 
         
Sausages (chicken) 
(Soseji ya kuku) 
         
Liver(Beef, lamb,goat)  
(Maini ya ngombe, 
kondoo, mbuzi) 
         
Liver (Chicken, duck) 
(Maini ya kuku, bata) 
         
Kidney (beef, pork) 
(Figo ya ngombe, mbuzi, 
kondoo) 
         
Intestines (beef, goat, 
lamb) 
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(Utumbo wa ngombe, 
mbuzi, kondoo) 
 
FISH AND SEA FOODS (SAMAKI) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus times 
per day 
Fish (eg salmon, catfish, 
perch, tilapia,tuna) 
(Samaki sato, sangara, 
kambale, nk) 
         
Anchovy (dagaa)          
Squid, Octopus 
(Kamba, pweza) 
         
Prawns, Shrimps, Crabs 
(Kaa) 
         
 
EGGS (MAYAI) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus times 
per day 
Eggs (boiled, fried, 
scrambled, poached) 
(Mayai ya kuchemsha, 
kukaaga) 
         
Egg based dishes (eg 
omelettes, egg curry) 
Mayai kwenye chakula 
kama mkate nk 
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DIARY PRODUCTS (BIDHAA ZA MAZIWA) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a 
month 
1 to 3 times 
a month 
Once 
per 
week 
2 to 3 
times per 
week 
4 to 6 
times per 
week 
Once 
per day 
2 to 3 
times per 
day 
4 plus 
times per 
day 
Fresh cow’s milk as drink 
(Maziwa fresh ya ng’ombe) 
         
Fresh cow’s milk added to drinks 
(eg tea, coffee ) 
(Chai, kahawa ya maziwa ya 
ng’ombe) 
         
Fresh milk added to foods (maziwa 
ya ng’ombe kwenye chakula) 
         
Goat’s milk as a drink (maziwa ya 
mbuzi) 
         
Goat’s milk added to drinks eg 
coffee, tea (chai, kahawa ya 
maziwa ya mbuzi) 
         
Goat’s milk added to foods 
(maziwa ya mbuzi kwenye chakula) 
         
Yoghurt, cultured milk (maziwa 
mtindi, yogat) 
         
Soy milk as a drink (maziwa ya 
soya) 
         
Soy milk added to drinks eg coffee, 
tea 
(chai, kahawa ya maziwa ya soya) 
         
Coconut milk (tui la nazi)          
Ice cream           
Cheese (jibini)          
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LEGUMES AND NUTS (KUNDE NA KARANGA) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a 
month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 
times per 
day 
4 plus 
times per 
day 
Soybeans (e.g in porridge)          
Kidney beans (maharage 
mekundu, jeshi) 
         
Lentils (dengu)          
Peas (njegere, 
choroko,kunde,mbaazi) 
         
Peanuts, peanuts butter (Karanga, 
siagi ya karanga) 
         
Cashew nuts (korosho)          
Sesame seeds (ufuta)          
Almonds (kungu)          
 
ROOTS AND TUBERS (MIZIZI) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a 
month 
1 to 3 
times a 
month 
Once 
per 
week 
2 to 3 
times per 
week 
4 to 6 
times per 
week 
Once 
per 
day 
2 to 3 
times 
per day 
4 plus 
times 
per day 
Cassava (ugali wa muhogo, muhogo wa 
kuchemsh/kukaanga/kuchoma) 
         
Irish/ round potatoes (viazi mbatata e.g vya 
mchuzi, chips, crisps vimechanganywa na vyakula 
vingine) 
         
Sweet potatoes (viazi vitamu vya kukaanga, 
kuchemsha, crisps ) 
         
Yams (magimbi)          
Plantains (ndizi za kupika, kuchemsha, mtori 
kuchoma, kukaanga, crisps) 
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CEREALS AND GRAINS PRODUCTS (MBEGU NA NAFAKA) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a 
month 
1 to 3 
times a 
month 
Once 
per 
week 
2 to 3 
times per 
week 
4 to 6 
times per 
week 
Once 
per 
day 
2 to 3 
times 
per day 
4 plus 
times per 
day 
Whole Maize (e.g ugali wa dona, mahindi 
choma/chemsha, uji wa dona) 
         
Polished/refined maize (eg ugali sembe, uji 
sembe, kande) 
         
Soghum meals (eg ugali, uji wa mtama)          
Millet meals (eg ugali, porridge wa ulezi)          
Brown Rice (wali wa brown)          
Polished/white rise (wali mweupe, vitumbua, 
mkate wa kumimina, uji wa mchele) 
         
White bread and burns (mkate, chapatti, skonzi, 
donats, maandazi n.k vya unga mweupe) 
         
Brown bread and burns (mkate, chapatti, 
skonzi, donats, maandazi n.k vya unga wa ata) 
         
Iron fortifies wheat flour in breads and burns 
(mkate, chapatti, skonzi, donats, maandazi vya 
unga ulioongezewa madini ya chuma) 
         
Macaroon, spaghetti (tambi, makaroni)           
Cakes (all types excluding chocolate and fruit 
cakes) 
(Keki aina zote isipokua za chokoleti) 
         
Chocolate cakes 
(Cake za chokoleti) 
         
Biscuits plain (Biskuti nyeupe)          
Chocolate biscuits (Biskuti za chokoleti)          
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VEGETABLES (MBOGA ZA MAJANI) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus times 
per day 
Green beans (maharage 
mabichi) 
         
Red cabbage (kabichi 
nyekundu) 
         
White cabbage(kabichi 
nyeupe) 
         
Carrots (karoti)          
Mushrooms (uyoga)          
Cucumber, zucchini 
(tango) 
         
Onion (kitunguu)          
Tomatoes (nyanya)          
Spinach (spinachi)          
Chinese (chinizi)          
Amaranthus (mchicha)          
Sweet potato leaves 
(matembele) 
         
Cassava leaves (kisamvu)          
Pumpkin leaves (majani 
ya maboga) 
         
Okra (bamia)          
Wild vegetables 
(mgagani, mnafu) 
         
Radish plant (figiri)          
Egg plant (biringanya, 
nyanya chungu) 
         
Green papers (pilipili 
hoho) 
         
Hare lettuce (mchunga)          
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FRUITS (MATUNDA) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus 
times per 
day 
Apples (epo)          
Bananas(ndizi mbivu)          
Citrus fruits(chungwa, 
chenza, limao, ndimu) 
         
Mangoes (maembe)          
Grapes (zabibu)          
Watermelon (tikiti)          
Avocados, Olive (parachichi, 
zaituni) 
         
Pears (peasi)          
Pineapples (nanasi)          
Plum,peaches (tunda damu, 
pichi) 
         
Pawpaw (papai)          
Guava (pera)          
Prunes, dates (tende)          
Soursop (stafeli)          
Tangerine (chenza)          
Tamarind (ukwaju)          
Orange (chungwa)          
Lemon, lime (ndimu, limao)          
Baobab (ubuyu)          
Passion fruit (pesheni)          
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BEVERAGES(VINYWAJI) 
In the past month, I have eaten this food……………………. 
Food item Never 
eaten 
Less than 
once a month 
1 to 3 times 
a month 
Once per 
week 
2 to 3 times 
per week 
4 to 6 times 
per week 
Once 
per day 
2 to 3 times 
per day 
4 plus times 
per day 
Beer          
Red wine          
White wine          
Spirits e.g whisky          
Black Tea (chai)          
Chocolate, milo, cocoa 
drink  
         
Coffee (kahawa)          
Herbal tea ()          
Fruit juices (Juice za 
matunda halisi) 
         
Energy drinks (e.g 
redbull, malta) 
         
Coke, Pepsi          
Other carbonated drinks 
(e.g sprite,fanta) 
Soda nyinginezo e.g 
sprite  
         
                                                                                                 
 
 
Appendix 11: NHS-REC & HRA ethical approval 
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Appendix 12: SGA questionnaire 
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Appendix 13: Hepcidine-25 ELISA assay manual from CUSABAO© 
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Appendix 14: Luminex bio-plex immunoassay system manual  
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Appendix 15: Quality of life questionnaire (SF-36v2™ OPTUM® PRO CoRE) 
 
Your Health and Well-Being 
 
 
This survey asks for your views about your health.  This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
Thank you for completing this survey! 
 
For each of the following questions, please tick the one box that best describes 
your answer. 
 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
    
   1    2    3    4    5 
 
2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
    
   1    2    3    4    5 
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3. The following questions are about activities you might do during a 
typical day.  Does your health now limit you in these activities?  If so, 
how much?  
 
 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports ......................  1 .............  2 .............  3 
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf.............................  1 .............  2 .............  3 
 c Lifting or carrying groceries ....................................................  1 .............  2 .............  3 
 d Climbing several flights of stairs .............................................  1 .............  2 .............  3 
 e Climbing one flight of stairs ....................................................  1 .............  2 .............  3 
 f Bending, kneeling, or stooping ................................................  1 .............  2 .............  3 
 g Walking more than a mile ........................................................  1 .............  2 .............  3 
 h Walking several hundred yards ...............................................  1 .............  2 .............  3 
 i Walking one hundred yards .....................................................  1 .............  2 .............  3 
 j Bathing or dressing yourself ....................................................  1 .............  2 .............  3 
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4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
 a Cut down on the amount of  
  time you spent on work or  
  other activities ..................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less than you  
  would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Were limited in the kind of  
  work or other activities ....................  1 ..............  2 ..............  3 ..............  4 .............  5 
 d Had difficulty performing the 
  work or other activities (for  
  example, it took extra effort) ...........  1 ..............  2 ..............  3 ..............  4 .............  5 
 
 
5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or 
anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
 a Cut down on the amount of  
  time you spent on work or  
  other activities ..................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 b Accomplished less than you  
  would like ........................................  1 ..............  2 ..............  3 ..............  4 .............  5 
 c Did work or other activities 
  less carefully than usual ...................  1 ..............  2 ..............  3 ..............  4 .............  5 
 
 
 295 
 
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
    
   1    2    3    4    5 
 
 
 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
     
   1    2    3    4    5    6 
 
 
 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
    
   1    2    3    4    5 
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9. These questions are about how you feel and how things have been with 
you during the past 4 weeks.  For each question, please give the one 
answer that comes closest to the way you have been feeling.  How much 
of the time during the past 4 weeks… 
 
 
10. During the past 4 weeks, how much of the time has your physical health 
or emotional problems interfered with your social activities (like 
visiting with friends, relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
    
   1    2    3    4    5 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
 a Did you feel full of life? ..................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Have you been very nervous? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  
cheer you up? ...................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Have you felt calm and   
peaceful? ..........................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 e Did you have a lot of energy? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Have you felt downhearted   
and low? ...........................................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 g Did you feel worn out? ....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Have you been happy? .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Did you feel tired? ...........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
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11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
     
 a I seem to get ill more 
easily than other people ..................  1 ..............  2 .............  3...............  4 ..............  5 
 b I am as healthy as  
anybody I know ..............................  1 ..............  2 .............  3...............  4 ..............  5 
 c I expect my health to  
get worse .........................................  1 ..............  2 .............  3...............  4 ..............  5 
 d My health is excellent .....................  1 ..............  2 .............  3...............  4 ..............  5 
 
 
 
 
 
 
 
Thank you for completing these questions! 
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Appendix 16: Rate of Perceived Exertion (RPE): Borg scale 
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Appendix 17 : Information sheets for UK longitudinal study 
 
Participants’ Information Sheet for Observation study 
 
PROJECT TITLE: Investigation of changes in body composition, inflammation and responses to anaemia 
treatment, before and after exercise intervention among haemodialysis patients 
 
Introduction 
We are a team of investigators from St. George’s University NHS hospital and the University of Surrey here in 
the UK. The team includes renal dietitians, nutritionists, doctors, nurses and physiotherapists that are closely 
involved with usual care or research activities in patients with kidney disease.   
We would like to invite you to take part in this research project. Before you decide you need to understand 
why the research is being done and what it will involve for you. Please take the time to read the following 
information carefully. Talk to others about the study if you wish. 
What is the purpose of the study? 
Patients with kidney failure have poor red blood cell production because they don't make enough of an 
important hormone called Erythropoietin (EPO). This hormone is usually produced in the kidney, but when the 
kidney function decreases there is less hormone and therefore not enough red blood cells are produced 
leading to anaemia.  
To help with this problem, patients are treated with a man-made form of EPO and iron to help them with red 
blood cell production. However, for several reasons, patients might still be anaemic and this can significantly 
affect their health and quality of life. There is a suggestion that how much fat or muscle a patient has may be 
important but it is still unclear of what is the best body composition for dialysis patients is and how this can 
be best achieved. This research study aims to investigate how body composition and nutritional status 
influence how you respond to anaemia treatment. In addition, other markers of your health status and muscle 
strength will also be observed as these could also have an influence. 
 
Why have I been invited to take part in the study? 
Because you are a dialysis patients and your Haemoglobin concentration (a marker in the blood of your iron 
levels) is below the normal level and you are currently receiving anaemia treatment. 
Do I have to take part? 
No, you do not have to participate. Your participation is voluntarily and you can withdraw at any time without 
giving a reason. There will be no adverse consequences in terms of your care or treatment if you choose not 
to take part. There may not be a direct benefit in your response to anaemia treatment as a result of your 
participation in the study. 
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What will my involvement require? 
If you are happy and decide that you would take part in this study, we will ask you to sign a consent form and 
enrol you into the study. We will then collect some information about your health status and medication from 
the clinic files, then you will go through some body measurements, interviews, physical fitness tests and 
additional blood tests for 2 to 4 months as explained in table 1.  
Table 1: Study activities for participants  
Activities Timing including minutes of 
participant’s time 
Your upper body muscular strength will be measured using a hand grip 
dynamometer  (piece of equipment that you squeeze) 
Once every month  
(2 minutes whilst waiting dialysis) 
Your lower body muscular strength  will be measured  by:  
 30 seconds the sit and stand test  
Once every month  
(1 minute whilst waiting dialysis) 
Your waist circumference will be measured Once every month  
(2 minutes after dialysis) 
Your body composition (fat and muscle) measured using Bio-impedance 
machine (BCM machine) and ViScan.   
Once every month  
(5 minutes immediately prior to dialysis) 
A researcher will use your information and measurements to assess your 
nutritional status (Subjective Global Assessment questionnaire) 
At the beginning and the end of the 
study (10 minutes whilst on dialysis) 
Results from your routine blood tests will be obtained from your clinic notes  Once every month - does not affect 
participant’s time 
Additional 5 mls (1 teaspoon) of blood will be taken during  your usual pre-
dialysis blood draw (no extra needles) for additional tests (hepcidin and 
leptin hormone, IL-6, IL-10, transferrin receptor, ferritin, iron and % 
transferrin saturation) 
Once every month for study duration 
(just before dialysed) 
You will be provided with a food diary, and asked to record all food and 
drinks consumed on three days of the week (dialysis, weekend and weekday 
non-dialysis days) at each recording point 
Record at home 
We will ask you some questions to assess your quality of life with the help 
of a questionnaire at the beginning and end of the study 
Whilst on dialysis, 10 minutes 
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What are the possible disadvantages or risks of taking part? 
The body composition monitoring machine (Fresenius BCM) is safe to use with no radiation involved, and it is usually 
used in your routine care to measure your muscles, fat and body fluid. ViScan is similarly safe, it has been modified 
to measure fat around your abdomen (stomach).  
If I participate, how will it affect the length of my clinic appointments? 
There will be no additional visits to the clinic and all study measurements will be performed during your normal visit 
to the dialysis clinic. Most measurements will be taken whilst you are waiting for dialysis, and these all together will 
take no more than 10 minutes. We will also measure your body weight after dialysis the same way you do as part of 
your routine care.  It is therefore our hope that, this study will not prolong your stay at the clinic.   
What happens to the blood sample collected? 
Blood samples collected will be assigned with study identification numbers, initially processed at your dialysis clinic 
then sent to the laboratory at University of Surrey for further analysis of tests previously mentioned. The anonymised 
samples will be stored within the same laboratories for the duration of the study then disposed at the end of the 
study period in accordance with the Human Tissue act 2004 Codes of Practice. 
What happens when the research study stops? 
As a participant you will be provided with the summary of the study findings.  
Will the data collected be kept confidential during and after the study? 
Yes. All of the information you give will be anonymised, you will be assigned with study identification numbers and 
those will be used instead of names during data collection and storage. Non-identifiable data will be stored in 
computers that are password protected throughout the study period in accordance with the Data Protection Act 
1998. Only members of research team involved in the study and direct care team will have access to data. This data 
will be analysed to provide a meaningful information about your health status. The results will be presented a group 
level so that no individual can be identified from them. After the study, anonymised data will be stored for 10 years 
after completion of the study in accordance to St.George’s University Hospital NHS Trust archive policy.
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You can find out more about how we use your information 
https://www.stgeorges.nhs.uk/education-and-research/research/research-privacy-notice/  
Who is organising and funding the research? 
The research is organised by the above mentioned team (and listed below).  It is partly funded as a 
part of PhD training programmeme by the Commonwealth scholarship commission, UK.  
It is also part funded by St. Georges’ Kidney Patients Association  
Who has reviewed the project? 
The study has been reviewed by the St George’s Joint Research and Enterprise Services. 
It has also been reviewed and received a Favourable Ethical Opinion from the NHS Research ethics 
committee and Human Research Authority.  
 
What if there is a problem? 
Any complaint or concern about any aspect of the study will be addressed. You can contact your usual 
care team directly and/or any member of research team. Contact information (including phone 
numbers) of the team are at the end of this letter.  
The NHS complaints mechanisms are also available to you. 
St George’s Patient Advice and Liaison Service (PALS) are on Tel: 020 8725 3492 or 
020 8725 1609. 
If you are still not satisfied with the response, you may contact: 
The Joint Research and Enterprise Service at St George’s: 020 8725 4986. 
 
 
Contact details of Principal investigator  
The study is conducted by: 
Helena Jackson 
Department of Nutrition and Dietetics                                             
St. George’s University Hospital NHS Foundation Trust 
E-mail:Helena.jackson@stgoeorges.nhs.uk  
Phone:  020 8672 1255 Bleep 6009  
    
303 
 
Other members of research team are: 
 Name Title & 
Discipline 
Institution Contact 
1 Dr. Debasish 
Banerjee  
Consultant 
Nephrologist  
St George's 
University Hospitals 
NHS Foundation 
Trust 
Debasish.Banerjee@stgeorges.nhs.uk 
Phone: 02087251673  
2 Nikki Webster Physiotherapist St George's 
University Hospitals 
NHS Foundation 
Trust 
Nikki.Webster@stgeorges.nhs.uk 
Phone: 020 8725 2399 (bleep 6248) 
3 Dr. Kathryn 
Hart 
Research 
dietitian 
Surrey University k.hart@surrey.ac.uk 
Phone:  
4 Dr. Barbara 
Engel 
Renal dietitian Surrey University/ 
St George's 
University Hospitals 
NHS Foundation 
Trust 
b.engel@surrey.ac.uk 
Phone: 01483 686397 
 
 
5 Nyangi 
Gityamwi 
Nutrition 
scientist/ 
PhD researcher 
Surrey University n.gityamwi@surrey.ac.uk 
Mobile: 07459002077 
6 Joe 
Wainwright 
Exercise 
Physiologist 
Surrey University J.Wainwright@surrey.ac.uk 
Mobile: 07740973151 
7 Jisha Mathew Anaemia 
Specialist 
Nurse 
St George's 
University Hospitals 
NHS Foundation 
Trust 
Jisha.Mathew@stgeorges.nhs.uk 
Phone: 020 8725 1738 
8 Fiona Sinclair Lead Dialysis 
Nurse 
St George's 
University Hospitals 
NHS Foundation 
Trust 
Fiona.Sinclair@stgeorges.nhs.uk 
 
 
Thank you for taking the time to read this Information Sheet 
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Appendix 18 : Information sheet for Exercise study 
 
Participants’ Information Sheet - Pilot study 
PROJECT TITLE: Investigation of changes in body composition, inflammation and responses to anaemia treatment, 
before and after exercise intervention among haemodialysis patients 
Introduction 
We are a team of investigators from St. George’s University NHS hospital and the University of Surrey here in the UK. 
The team includes renal dietitians, nutritionists, doctors, nurses and physiotherapists that are closely involved with 
usual care or research activities in patients with kidney disease.   
We would like to invite you to take part in this research project. Before you decide you need to understand why the 
research is being done and what it will involve for you. Please take the time to read the following information 
carefully. Talk to others about the study if you wish. 
What is the purpose of the study? 
This study is the part of the continuing research study that assess how body composition and other markers of health 
status influence patients’ respond to anaemia management treatments. There is a suggestion that how much fat or 
muscle a patient has may be important but it is still unclear of what the best body composition for dialysis patients 
is and how this can be best achieved. Exercise studies already carried out (mostly using bikes), have suggested that 
exercise could be beneficial in improving body composition and health. But these bikes are expensive and impractical 
for patients to use in their own homes. 
This research study therefore aims to find out if a flexible inexpensive exercise programme like walking could be a 
suitable alternative and whether patients are able to keep to it. It will also see if adding resistance (muscle) training 
to it has added benefits, and whether this combination can create a better body composition in dialysis patients that 
will help them to get the most out of their iron treatments. The findings from this study are essential to improve how 
we support and treat people on dialysis to increase wellbeing and quality of life, make the most of the medications 
they are taking, improve their health and reduce costs. 
Why have I been invited to take part in the study? 
Because you are a dialysis patients and your Haemoglobin concentration (a marker in the blood of your iron levels) 
is below the normal level and you are currently receiving anaemia treatment. In addition, your health records indicate 
that it is safe for you to exercise.  
Do I have to take part? 
No, you do not have to participate. Your participation is voluntarily and you can withdraw at any time without giving 
a reason. There will be no adverse consequences in terms of your care or treatment if you choose not to take part. 
There may not be a direct benefit in your response to anaemia treatment as a result of your participation in the 
study. 
What will my involvement require? 
If you are happy and decide that you would take part in this study, we will ask you to sign a consent form and enrol 
you into the study. You will be randomly allocated to either a group that will exercise (walking + muscle training 
whilst on dialysis) OR to a group that will continue with usual care (you won’t be asked to do anything different). If 
you are in a usual care group, you will still have a chance to participate in the exercise after four months if you wish. 
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We will then collect some information about your health status and medication form 
the clinic files, then you will go through some body measurements, physical fitness tests and additional blood tests 
for up to 4 months. 
Table 1: Study activities for participants  
Activities Timing including minutes of 
participant’s time 
Your upper body muscular strength will be measured using a hand grip 
dynamometer  (piece of equipment that you squeeze) 
Once every month  
(2 minute whilst waiting dialysis) 
Your lower body muscular strength  will be measured  by:  
 30 seconds the sit and stand test 
Once every month  
(1 minute whilst waiting dialysis) 
Your waist circumference and skinfold thickness will be measured  Once every month  
(2 minutes after dialysis) 
Your body composition (fat and muscles) measured using Bio-impedance 
machine (BCM machine) and ViScan.   
Once every month  
(5 minutes immediately prior to dialysis) 
A researcher will use your information and measurements to assess your 
nutritional status (Subjective Global Assessment questionnaire) 
Before and after exercise intervention 
(10 minutes whilst on dialysis) 
Results from your routine blood tests will be obtained from your clinic notes  Once every month - does not affect 
participant’s time 
Additional 5 mls (1 teaspoon) of blood will be taken during  your usual pre-
dialysis blood draw (no extra needles) for additional tests (hepcidin and 
leptin hormone, IL-6, IL-10, transferrin saturation, ferritin, % transferrin 
saturation) 
Once every month for study duration 
(just before dialysed) 
You will be provided with a food diary, and asked to record all food and 
drinks consumed on three days of the week (dialysis, weekend and weekday 
non-dialysis days) at each recording point 
Record at home 
We will ask you some questions to assess your quality of life with the help 
of a questionnaire at the beginning and end of the study 
Whilst on dialysis, 10 minutes 
You will have a test of your heart health (Electrocardiograph test) at the 
beginning and end of the study 
Whilst on dialysis – takes less than 5 
minutes to attach electrodes and detach 
them 
If you are in the exercise group, you will be guided to perform a set of 
resistance exercises using thick resistance bands, dumbbells and ankle 
weights depending on your strength capacity whist on dialysis. 
3 times every week  
(30 minutes whilst on dialysis + 15 
minutes before dialysis for exercising 
your fistula arm)   
If you are in the exercise group, You will also be advised on the walking 
programme, be provided with a pedometer and requested to wear it all the 
time when walking to record your daily step count. 
5 times every week (depending on your 
capacity to walk, this can be done at your 
preferred time) 
If you are in the exercise group, We will also ask you to record your 
performance and comment in the exercise log book how you feel when 
exercising and your general opinion about the programme. 
Whenever exercising throughout the 
study period 
 
 
 
What are the possible disadvantages or risks of taking part? 
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The risk associated with the exercise programme is minimal, you may experience minimal 
muscle cramps or tiredness in the muscles involved in exercise. The person supervising the exercise will monitor your 
progress and adapt the exercises according to your individual capacity.  
The measurements taken have no risks. The body composition monitoring machine (Fresenius BCM) is safe to use 
with no radiation involved, and it is usually used in your routine care to measure your muscles, fat and body fluid. 
ViScan is similarly safe, it has been modified to measure fat around your abdomen (stomach).  
The Electrocardiogram (ECG) test (test for heart health) is also safe and painless. No electricity is put into your body, 
the electrodes placed on your skin detect the electric signals released by your heart. You might only feel slight 
discomfort when electrodes are removed from your skin-similar to removing a sticking plaster. 
If I participate, how will it affect the length of my clinic appointments? 
There will be no additional visits to the clinic and all study measurements will be performed during your normal visit 
to the dialysis clinic. You will exercise your muscles whilst on dialysis (for approximately 30 minutes) and some 
measurements, interviews and exercise of the fistula arm will be performed whilst you are waiting for dialysis (for 
approximately 30 minutes). A few other measurements will need to be performed after you have dialysed and are 
free of excess fluid. These will be performed immediately after dialysis and will take not more than 15 minutes). It is 
therefore our anticipation that, the exercise programme will not prolong your stay at the clinic for more than 15 
minutes.  
What will happen to the control group? 
If you are assigned into a control group, at the end of the study, if interested, you will also get an opportunity to 
engage in the similar set of exercises as the intervention group. You will be provided with exercise equipment, initial 
guidance from exercise therapist and a video of the exercise programme for you to follow with minimal supervision.     
What happens to the blood sample collected? 
Blood samples collected will be assigned with study identification numbers, initially processed at your dialysis clinic 
then sent to the laboratory at University of Surrey for further analysis of tests previously mentioned. The anonymised 
samples will be stored within the same laboratories for the duration of the study then disposed at the end of the 
study period in accordance with the Human Tissue act 2004 Codes of Practice. 
What happens when the research study stops? 
As a participant you will be provided with the summary of the study findings and if interested you will have the 
opportunity of continuing, unsupervised with the exercise programme.  
Will the data collected be kept confidential during and after the study? 
Yes. All of the information you give will be anonymised, you will be assigned with study identification numbers and 
those will be used instead of names during data collection and storage. Non-identifiable data will be stored in 
computers that are password protected throughout the study period in accordance with the Data Protection Act 
1998. Only members of research team involved in the study and direct care team will have access to data. This data 
will be analysed to provide a meaningful information about your health status and the changes that exercise 
programme will bring to your health. The results will be presented a group level so that no individual can be identified 
from them. After the study, anonymised data will be stored for 10 years after completion of the study in accordance 
to St.George’s University Hospital NHS Trust archive policy.  
You can find out more about how we use your information 
https://www.stgeorges.nhs.uk/education-and-research/research/research-privacy-notice/ 
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Who is organising and funding the research? 
The research is organised by the above mentioned team (and listed below).  It is partly funded as a part of PhD 
training programmeme by the Commonwealth scholarship commission, UK.  
It is also part funded by St. Georges’ Kidney Patients Association  
Who has reviewed the project? 
The study has been reviewed by St George’s Joint Research and Enterprise Services. It has also been reviewed and 
received a Favourable Ethical Opinion from the NHS Research ethics committee and Human Research Authority.  
What if there is a problem? 
Any complaint or concern about any aspect of the study will be addressed. You can contact your usual care team 
directly and/or any member of research team. Contact information (including phone numbers) of the team are at 
the end of this letter.  
The NHS complaints mechanisms are also available to you. 
St George’s Patient Advice and Liaison Service (PALS) are on Tel: 020 8725 3492 or 
020 8725 1609. 
If you are still not satisfied with the response, you may contact: 
The Joint Research and Enterprise Service at St George’s: 020 8725 4986. 
 
Contact details of Principal investigator  
The study is conducted by: 
Helena Jackson 
Department of Nutrition and Dietetics                                             
St. George’s University Hospital NHS Foundation Trust 
E-mail:Helena.jackson@stgoeorges.nhs.uk  
Phone:  020 8672 1255 Bleep 6009  
 
 
 
 
 
Other members of research team are: 
 Name Title & Discipline Institution Contact 
1 Dr. Debasish 
Banerjee  
Consultant 
Nephrologist  
St George's University 
Hospitals NHS Foundation 
Trust 
Debasish.Banerjee@stgeorges.nhs.uk 
Phone: 02087251673  
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2 Nikki Webster Physiotherapist St George's University 
Hospitals NHS Foundation 
Trust 
Nikki.Webster@stgeorges.nhs.uk 
Phone: 020 8725 2399 (bleep 6248) 
3 Dr. Kathryn Hart Research dietitian Surrey University k.hart@surrey.ac.uk 
Phone:  
4 Dr. Barbara Engel Renal dietitian Surrey University/ St 
George's University 
Hospitals NHS Foundation 
Trust 
b.engel@surrey.ac.uk 
Phone: 01483 686397 
 
 
5 Nyangi Gityamwi Nutrition 
scientist/ 
PhD researcher 
Surrey University n.gityamwi@surrey.ac.uk 
Mobile: 07459002077 
6 Joe Wainwright Exercise 
Physiologist 
Surrey University J.Wainwright@surrey.ac.uk 
Mobile: 07740973151 
7 Jisha Mathew Anaemia 
Specialist Nurse 
St George's University 
Hospitals NHS Foundation 
Trust 
Jisha.Mathew@stgeorges.nhs.uk 
Phone: 020 8725 1738 
8 Fiona Sinclair Lead Dialysis 
Nurse 
St George's University 
Hospitals NHS Foundation 
Trust 
Fiona.Sinclair@stgeorges.nhs.uk 
 
 
 
 
 
Thank you for taking the time to read this Information Sheet 
 
 
309 
 
Appendix 19: Consent form for UK longitudinal study 
   
REC Reference Number: 18/LO/0443     IRAS ID: 229786 
SPONSOR ID: 18.0016 
Patient Identification Number for this trial: ______________________________                                                                   
 
CONSENT FORM (version 2, 01/04/2018) 
 
TITLE: INVESTIGATION OF CHANGES IN BODY COMPOSITION AND RESPONSES TO ANAEMIA 
TREATMENT, BEFORE AND AFTER EXERCISE INTERVENTION AMONG HAEMODIALYSIS 
PATIENTS 
Name of Researcher: Helena Jackson        
                                                                                                                       Please initial each box 
 
1. I confirm that I have read and understand the information sheet dated _________ 
version______ or the above study and have had the opportunity to consider the 
information, ask questions and have these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
3. I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from St George’s University 
Hospitals NHS Foundation Trust (SGHT) and/or University of Surrey, the NHS Trust or from 
regulatory authorities where it is relevant to my taking part in research. I give permission 
for these individuals to have access to my records. 
4. I agree to take part in the above study.  
 
5. I agree to my anonymised data and/or results being used for future research 
   
6. I agree to my samples being used as described in the information sheet 
 
9. I agree to my GP being informed of my involvement 
 
10. I agree to be contacted later about exercise intervention if I am eligible 
 
 
______________________      ________________ ____________________ 
Name of Patient                               Date                                               Signature  
 
 
________________________          ________________      ____________________ 
Name of person taking consent             Date  Signature 
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Appendix 20: Consent form for Exercise study 
   
REC Reference Number: 18/LO/0443     IRAS ID: 229786 
SPONSOR ID: 18.0016 
Patient Identification Number for this trial: ______________________________                                                                   
 
CONSENT FORM (version 2b, 08/06/2018) 
 
TITLE: INVESTIGATION OF CHANGES IN BODY COMPOSITION AND RESPONSES TO ANAEMIA 
TREATMENT, BEFORE AND AFTER EXERCISE INTERVENTION AMONG HAEMODIALYSIS 
PATIENTS 
Name of Researcher: Helena Jackson        
                                                                                                                       Please initial each box 
 
2. I confirm that I have read and understand the information sheet dated _________ 
version______ for the above study and have had the opportunity to consider the 
information, ask questions and have these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
3. I understand that relevant sections of any of my medical notes and data collected 
during the study may be looked at by responsible individuals from St George’s University 
Hospitals NHS Foundation Trust (SGHT) and/or University of Surrey, the NHS Trust or from 
regulatory authorities where it is relevant to my taking part in research. I give permission 
for these individuals to have access to my records. 
4. I agree to take part in the above study.  
 
5. I agree to my anonymised data and/or results being used for future research 
   
6. I agree to my samples being used as described in the information sheet 
 
9. I agree to my GP being informed of my involvement 
 
 
 
 
______________________                         ________________                _______________                
    Name of Patient                                                   Date                                          Signature  
 
 
________________________                          ________________              _______________ 
Name of person taking consent                                Date                  Signature
 
 
311 
 
Appendix 21: Exercise feedback form –PPI 
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Appendix 22: Exercise log book 
 
 
EXERCISE LOG 
WALKING AND RESISTANCE TRAINING 
 
 
 
 
STUDY PARTICIPANT ID 
 
……………………………………………………… 
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                        WALKING (please enter this from patients log)   
 Daily Step 
count 
Notes/comments (How do you feel?) 
Prescribed 
plan 
 NB Aiming for at least 30 minutes a day 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5   
Day 6 
optional 
  
Day 7 
optional 
  
 
                       RESISTANCE 
 Exercise Weight/ 
colour of 
band 
No. of 
reps 
No. of 
sets 
Notes/comments 
(How do you feel?) 
Prescribed 
workout 
(copy from 
baseline or 
from last 
day of 
previous 
week) 
shoulder press     
 
lateral raise     
 
triceps extension     
 
biceps curl     
 
external shoulder 
rotation 
    
 
seated knee 
extension 
    
 Inner Range Quad 
IRQ 
    
 
hip flexion     
 
hip abduction     
 
     
 
Day 1 
 
shoulder press     
 
lateral raise     
 
triceps extension     
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biceps curl     
 
external shoulder 
rotation 
    
seated knee 
extension 
    
 Inner Range Quad 
IRQ 
    
 
hip flexion     
 
hip abduction     
 
     
 
Day 2 shoulder press     
 
lateral raise     
 
triceps extension     
 
biceps curl     
 
external shoulder 
rotation 
    
seated knee 
extension 
    
Inner Range Quad 
IRQ 
    
 
hip flexion     
 
hip abduction     
 
     
 
Day 3 shoulder press     
 
lateral raise     
 
triceps extension     
 
biceps curl     
 
external shoulder 
rotation 
    
seated knee 
extension 
    
 Inner Range Quad 
IRQ 
    
 
hip flexion     
 
hip abduction     
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Appendix 23: Standard operating procedures for exercise 
 
         Standard Operating Procedures: Ex-BodyComp-Hb- Pilot study 
 Muscle conditioning 
Equipment  Ankle weights and hand dumb-bells, BORG RPE scale 
Absolute 
contra-
indications 
to exercise 
training 
Signs and symptoms of acute infections, such as malaise, fever, 
atypical fatigue, severe headaches/dizziness, chest pain, nausea, 
diarrhoea, flu like symptoms 
 
Excessive intradialytic weight gain that severely impacts on resting BP 
and HR indices|: BP >160/100 and HR > 100bpm and signs of 
peripheral oedema 
 
Patient missed previous dialysis session 
 
Erratic fluctuating BP and HR 
 
Blood glucose outside exercise recommended range: 5.5-11 mmol/l. if 
glucose > 12 to 13 mmol/l exercise should be abandoned 
Exercise 
training 
conditions 
Dialysis room temperature 18-21 oC  
 
Pre 
exercise 
training 
health 
Ask patients how they feel and if there have been any changes in 
themselves since the last time 
 
Assess and record BP and HR. if these indices are outside normal 
range for this patient but do not exceed contra-indicated ranges 
(above) then evaluate reasons why and apply professional judgement 
and evaluation of risk/benefit ratio 
 
Postpone / stop exercise if patients experience symptoms of deep 
vein thrombosis such as unusual swelling, redness and pain in the 
lower legs 
 
Check glucose if patient is diabetic 
Exercise 
training set 
up 
To be offered three times a week (however if patient feels this is too 
much – can reduce to twice a week) 
 
Advise and encourage good posture in seated position with legs 
supported by couch or cushions or sitting over edge of couch. The 
parts of body not exercising should be kept as still as possible 
Procedures Exercise patients 3 times a week, during  HD, after at least 60 minutes 
of dialysis has elapsed but not more than 120 minutes. 
 
If the patient has a fistula in their arm (or leg) do not exercise the limb 
with the fistula 
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 Start without any weights ( 5 reps as warm up).  
 
Progress to a complete set of 8 – 12 repetitions at an RPE of 12-14 
 
Keep to maximum of 2 sets in first two weeks 
 
Progress to maximum of 4 sets (maximum of 40 minutes exercise) 
 
Progress weights by 0.5kg at a time 
 
Following completion of the programme, 5 minutes stretching 
exercises should be performed as a cool down 
 
Instructions 
to patients 
during the 
procedure 
Patients should be shown how to avoid eliciting a Valsalva manoeuvre 
response during muscular conditioning exercises, via correct breathing 
patterns 
Assessment 
outcome 
recording 
procedures 
Following completion of the session, please record: 
Which exercises have been completed 
No of sets and repetitions of each exercise 
Weight used 
Pre session and post session RPE 
Average session RPE 
If programme not completed, reason why 
Record any adverse events and immediately report to Helena Jackson 
Health and 
safety 
checks 
during the 
training 
Ensure lower limbs are free from femoral lines and skin intact and free 
from complications where weights are to be used 
 
Ensure vital signs are stable 
 
Chatting with patients during exercise is advised in order to assess 
effort, responsiveness and if they follow verbal information. If they 
seem confused, or not fully responsive stop the exercise and evaluate 
Health and 
safety 
checks 
after the 
training  
3 minutes after the training, check the BP and HR again to ensure they 
have returned to safe baseline levels and are not experiencing any 
symptoms of hypo/hyperglycaemia if diabetic 
Immediate 
life support 
procedures 
If you suspect the development of any adverse effects of exercise 
raise the alarm with dialysis unit staff, remove the exercise equipment 
away from the patient and follow dialysis unit life support procedures. 
Record any events in the exercise training diary for that patient and 
inform the PI (Helena Jackson) and Clinic Manger Ana Borba. 
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Date:   
Please complete before dialysis 
Signs and symptoms of acute infections Yes   / No   please delate as appropriate  
Excessive intradialytic weight gain Fluid gain =          BP =                           HR = 
 
Patient missed previous dialysis session 
 
Yes   / No   please delate as appropriate 
Blood glucose; please record if diabetic  
Exercise can start after an hour of dialysis 
(warm up can start before then) 
Time started dialysis 
 
Time started exercise 
Please complete 3-5  minutes after exercise 
session 
BP =                           HR = 
 
Date:   
Please complete before dialysis 
Signs and symptoms of acute infections Yes   / No   please delate as appropriate  
Excessive intradialytic weight gain Fluid gain =          BP =                           HR = 
 
Patient missed previous dialysis session 
 
Yes   / No   please delate as appropriate 
Blood glucose; please record if diabetic  
Exercise can start after an hour of dialysis 
(warm up can start before then) 
Time started dialysis 
 
Time started exercise 
Please complete 3-5  minutes after exercise 
session 
BP =                           HR = 
    
Date:   
Please complete before dialysis 
Signs and symptoms of acute infections Yes   / No   please delate as appropriate  
Excessive intradialytic weight gain Fluid gain =          BP =                           HR = 
 
Patient missed previous dialysis session 
 
Yes   / No   please delate as appropriate 
Blood glucose; please record if diabetic  
Exercise can start after an hour of dialysis 
(warm up can start before then) 
Time started dialysis 
 
Time started exercise 
Please complete 3-5  minutes after exercise 
session 
BP =                           HR = 
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Appendix 24: Food diary 
 
 
 
 
 
Date: DECEMBER  2018 
 
Dear 
You will find a food record diary on the back of this letter. Please use it to record your intake of all 
food and drink over three days. This will give us the information we need to review your diet. 
Please DO: 
 Try to record what you eat as you eat it throughout the day, rather than trying to remember 
everything at the end of the day. 
 Record the amounts of food eaten in as much detail as possible. Use weights on the side of 
packets or the number of teaspoons/tablespoons to help you. 
e.g. Breakfast:  4tbsp cornflakes with 1/4pt full-cream milk 
2 slices thick-cut brown bread, thickly spread with butter and 2tsp jam 
 Include all snacks, even a single biscuit or few crisps 
 Include all fluids, even sips of water 
 Include any nutritional supplements, such as Fortisip, Complan, multivitamins or minerals, 
whether prescribed or ones you have bought yourself. 
 Contact us with any questions or problems you may have about the food diary or any aspect of 
your diet. 
 
Thank you, 
 
The Renal Dietitians: 
Anamaria Cucliciu 
Barbara Engel -  
Helena Jackson 
Jade Russell 
Victoria Turner 
 
Researcher: 
Nyangi Gityamwi  
Mobile: 07459002077 
Grosvenor Wing 2nd Floor 
St George’s Hospital  
Blackshaw Road  
London  
SW17 0QT 
Renal Dietetic Service 
Direct Telephone Line 
(020) 8725 2145 
Renal Services – Food Diary 
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                            STUDY ID: ……………………………        Unit No:…………………………………….. 
MEAL DAY 1       (Date:                                                            )       Dialysis day 
Breakfast  
 
 
Mid-morning snack  
Midday Meal  
 
Afternoon Snack  
Evening Meal  
 
Evening/ Bedtime 
Snack 
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                            STUDY ID: ……………………………        Unit No:………………………… 
MEAL DAY  2  (Date:                                                                         )       Non-dialysis day 
Breakfast  
 
 
Mid-morning snack  
Midday Meal  
 
Afternoon Snack  
Evening Meal  
 
 
 
Evening/ Bedtime 
Snack 
 
 
 
 
 
 
 
321 
 
                            STUDY ID: ……………………………        Unit No:…………………………………….. 
MEAL DAY 3 (                                                                                          )  Weekend day 
Breakfast  
 
 
Mid-morning snack  
Midday Meal  
Afternoon Snack  
Evening Meal  
Evening/ Bedtime 
Snack 
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Appendix 25: Post intervention feedback form – Patients 
 
POST INTERVENTION FEEDBACK FORM 
                      Intervention group 
 
1) Prior to this study, how 
many times did you take part 
in any physical 
activity/exercise per week? 
 
 
 
 
 
 
 
 
 
 
 
2) What form(s) of physical 
activity/exercise did you take 
part in prior to this study? 
 
(Please give details of any 
activities/exercises e.g. walking / 
swimming / gym) 
 
 
 
 
 
 
 
 
3) Please describe your 
attitude(s) to physical 
activity/exercise. 
 
Has your attitude to physical 
activity/exercise changed 
during this study? 
 
(E.g. I enjoy exercise, I know 
exercising is good for me, I 
don’t enjoy exercising, I take 
part to stay healthy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
4) Do you feel the exercise 
programme in this study was 
beneficial? 
 
If so, please provide brief 
details 
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                Control group 
 
1) How many times do you take part in any 
physical activity/exercise per week? 
 
 
 
 
 
 
 
 
 
2) What form(s) of physical 
activity/exercise do you take part in? 
 
(Please give details of any 
activities/exercises e.g. walking / swimming 
/ gym) 
 
 
 
 
 
 
 
 
 
3) Please describe your attitude(s) to 
physical activity/exercise.  
 
(E.g. I enjoy exercise, I know exercising 
is good for me, I don’t enjoy exercising, 
I take part to stay healthy) 
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Appendix 26: Post intervention feedback form – Clinic personnel 
 
CLINIC PERSONNEL QUESTIONNAIRE 
 PROJECT TITLE: INVESTIGATION OF CHANGES IN BODY COMPOSITION AND RESPONSES TO ANAEMIA 
TREATMENT, BEFORE AND AFTER EXERCISE INTERVENTION 
AMONG HAEMODIALYSIS PATIENTS 
                              Date: ……………………………………………….             Unit/Clinic:………………………………………………………… 
The purpose of this questionnaire is to gain insight into your views as a clinic care staff providing direct 
care for the patients’ who have participated in the exercise during dialysis intervention. 
 
 
 
 
 
 
                     Please tick the appropriate box: 
 Strongly 
Disagree 
Disagree Agree Strongly 
Agree 
1) The exercises were easy for patients 
to follow 
    
2) Patients’ understood the benefits of 
the exercise 
    
4) Patients’ engagement in the 
intervention was good 
    
5) Patients’ overall perception was that 
the exercises were a good addition to 
treatment 
    
6) The exercise programme increased 
my workload  
    
7) The exercise programme was a  
burden to other staff members 
    
8) The intervention interfered with the 
delivery of standard care 
    
9) I feel the exercise provided positive 
experience and outcomes for patients  
    
Please provide a brief summary of your involvement with dialysis patients: 
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 Strongly 
Disagree 
Disagree Agree Strongly 
Agree 
10) I feel that the exercises provided 
were practical and suitable for these 
patients 
    
11) I would like for the programme to be 
sustainable and integrated into clinical 
practices 
    
12) Overall I feel that these exercises 
should be considered for other CKD 
patients 
    
 
 
 
 
 
Are there any concerns that you have regarding this exercise-intervention? 
Any other comments regarding the intervention? What would like to see changed or added? 
